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Abstract 
Ovarian cancer has the highest mortality rate of all gynaecological cancers and is the 
fifth most common cancer to occur in women in the UK. Amongst various imaging 
modalities, ultrasound is considered the main modality for ovarian cancer triage.  As 
with other imaging modalities, the main issue is that the interpretation of ultrasound 
images is subjective and observer dependent. Texture analysis has been shown to 
have potential in the objective assessment of ovarian cancer in a preliminary study. 
Another form of texture analysis is Acoustic Structure Quantification (ASQ), which 
has been documented to have a number of successful uses in liver diseases. However, it 
has not been applied to ovarian lesions. Therefore, the aim of this study was to assess 
prospectively the diagnostic performance of texture analysis methods such as GLCM, 
Wavelet, and ASQ in discriminating between benign and malignant adnexal masses 
and between different types of benign masses and compare it to widely used scoring 
models. 
Prior to applying ASQ to ovarian images, its reliability and repeatability were first 
evaluated. This includes random variation caused by the ultrasound system and the 
operator during image acquisition.  A tissue-equivalent phantom was used in these tests. 
It was found that the ASQ feature demonstrated excellent repeatability for ASQ 
software, with all transducers showing less than 0.4% variance from the mean: thus, 
ASQ software is able to produce reliable ASQ output measures. When testing the 
factors that may influence the performance of the ASQ analysis, the results revealed 
that three factors do not influence the mean of the output curve: the ROI size, depth 
and gain setting. However, focal position has a significant effect on the mean of the 
output curve.  Transducer frequency does not affect the output curve except when 
using high frequencies such as 8 MHz. Other tests were done to determine the 
appropriate parameters in the software to be used on images of ovarian masses. 
Firstly, ASQ was applied to 45 pelvic masses. The preliminary results showed no 
significant difference between benign and malignant masses using the ASQ 
technique: therefore, the study was terminated due to failure to discriminate the 
benign from the malignant masses using ASQ. 
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Secondly, two types of textural features were investigated in this study: grey-level co-
occurrence matrix (GLCM) and wavelet, as recommended by a preliminary study. A 
sample of 169 masses was collected from participants, of which 140 were benign and 
29 were malignant by histology. In addition to texture features, other widely used 
scoring models were applied on the same images for comparison, namely RMI, PMI 
and ADNEX. 
The results revealed excellent discriminatory ability in both GLCM and wavelet 
between malignant and cystic masses and between benign and cystic masses, with 
AUC of .994 and .895 for GLCM and .894 and .814 for wavelet respectively, as well 
as between normal and malignant tissue, with p >.05 and p=.004 in both GLCM and 
wavelet respectively. 
Results also showed that GLCM outperformed RMI and ADNEX in distinguishing 
between benign and malignant masses, even when dividing the study population into 
pre- and postmenopausal groups. In addition, GLCM has the advantage of being 
objective and not operator dependent. Receiver operating characteristic (ROC) curve 
analysis was carried out to determine the discriminatory ability of textural features, 
which was found to be satisfactory. 
The principal conclusion was that GLCM and wavelet features can potentially be used 
as computer aided diagnosis (CAD) tools to help clinicians in the diagnosis of ovarian 
cancer. 
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1. Introduction  
Ovarian cancer is the second most common gynaecological malignancy; however, it 
remains the leading cause of death among these diseases (Givens et al., 2009). In spite 
of the diagnostic and therapeutic advances in the care of women with ovarian cancer, 
the overall five-year survival rate remains unchanged. The reason for this is that most 
cases are diagnosed in the late stages of the disease, when the five-year survival rates 
falls below 20% (Dutta et al., 2010a).  
CA125 is a commonly used tumour marker to assess ovarian cancer. However, the 
usefulness of this marker is limited due to lack of sensitivity, as it is elevated in only 
50% of patients with stage 1 cancer (Ronco et al., 2011) and has poor specificity 
because it is elevated in numerous benign conditions such as endometriosis, 
adenomyosis and pelvic inflammatory disease, as well as several non-gynaecological 
conditions such as diverticulitis, liver and heart failure, and in cancer of the pancreas, 
breast, bladder and liver (Ronco et al., 2011).  
Researchers have combined ultrasound with CA125 to increase the sensitivity and 
specificity of differentiating between benign and malignant masses. As a result, the 
Risk of Malignancy Index (RMI) was created (Jacobs et al., 1990). It became 
recommended by the Royal College of Obstetricians and Gynaecologists. However, it 
has a sensitivity of 89% and a specificity of 73% (RCOG, 2003). 
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A study in 2005 concluded that ultrasound has a high false-positive rate in the 
differential diagnosis of adnexal malignancies, even with using several scoring 
systems (Guerriero et al., 2005). 
Other researchers have used Doppler to differentiate between benign and malignant 
ovarian masses to improve the specificity of ultrasound. Unfortunately, according to 
most of these studies, this approach does not add significant useful information, with 
a reported accuracy of only 35%- 88% (Kinkel et al., 2000, Gentry-Maharaj and 
Menon, 2012).  
Others have tested the usefulness of using four markers as a combined test for early-
stage ovarian cancer detection and showed a sensitivity and specificity of 91.3% and 
88.5% respectively (Gentry-Maharaj and Menon, 2012). These panels, nevertheless, 
have yet to be validated widely in clinical trials. 
Other preoperative methods to differentiate benign from malignant ovarian masses 
have been developed and tested recently, such as ultrasound contrast agents (Fleischer 
et al., 2012, Dutta et al., 2010a), 3D imaging (Huchon et al., 2012) and using CT 
(Palma et al., 2012) or MRI imaging. However, they all have limitations, including 
limited availability, high cost, difficulty with the identification of small tumour 
deposits, cancer extension and the distinction between benign and pathological lesions 
(Iyer and Lee, 2010, Dutta et al., 2010a). 
In recent years, objective diagnostic methods have been proposed to overcome the 
limitations of subjectivity and operator dependence. However, there is no reliable 
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technique available at present. Hence, a new objective method is desired to address 
the above-mentioned issues which will contribute in patient management. 
Texture analysis is a technique for evaluating the structure within an image. In digital 
imaging, texture analysis is the analysis of the distribution of grey level values across 
the pixels of a given region of interest. The variation in intensity reflects some 
physical variation in the underlying structure, as explained by (Szczypiński et al., 
2009); moreover, the image texture of medical images describes the internal structure 
of human tissue or organs. It can also describe pathological changes (Xian, 2010). The 
texture analysis of ultrasound images relies on the principle that, when disease occurs 
and starts to affect the structure of the tissue, the tissue should reflect a different 
ultrasound signal, which will in turn cause the texture feature to give a different value 
to normal tissue (Morris, 1988) 
Texture analysis techniques have been successfully applied to various types of tissues 
and organs (Michail et al., 2007, Giger et al., 2008), including the carotid artery 
(Coleman et al., 2005), breast (Alacam et al., 2003, Chen et al., 2002, Huang et al., 
2008, Ramaraj and Raghavan, 2011), heart (Vince et al., 2000), thyroid gland 
(Smutek et al., 2003), prostate (Basset et al., 1993), pancreas (Das et al., 2008) and 
liver (Lee et al., 2003, Xian, 2010, Vicas et al., 2011, Kumar et al., 2012). However, it 
has not yet been widely tested on ovarian tissue. 
A preliminary study has demonstrated the usefulness of texture analysis in 
differentiating ovarian lesions (Hamid et al., 2011). Therefore, objective 
differentiation between benign and malignant ovarian tissue through texture analysis 
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on a larger sample would be beneficial by validating the accuracy of the method and 
therefore decreasing the rate of unnecessary surgery. 
This is a prospective cross-sectional study of patients with adnexal masses to validate 
texture analysis as a method of objectively differentiating ovarian lesions to overcome 
the subjectivity and operator-dependent limitations of Ultrasound.  
 
1.1. Research hypothesis 
Based on recent developments in ultrasound imaging, computer technology and 
extensive research on texture analysis with a focus on medical images, it is 
hypothesized that the texture analysis technique can be used to characterize and 
quantify ovarian tissue based on B-mode image texture. 
The motivation for this technique is clear: since the output of texture analysis of an 
image can be expressed numerically, it provides a quantitative means of image 
description, which could help in reducing subjectivity. This technique would also 
overcome the reproducibility issue encountered as a result of the subjective 
interpretation of the image. Combining human skills with results from computers to 
aid diagnosis is expected to improve the overall diagnosis of ovarian masses.  
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1.2. Aims and objectives 
 
Study aims: To assess prospectively the diagnostic performance of texture analysis 
on grey-scale transvaginal ultrasound images in discriminating between benign and 
malignant adnexal tumours and to compare it to other widely used scoring systems. 
The primary end-point is the accuracy of diagnosing ovarian cancer when compared 
with histology. 
The secondary end-point is an attempt to correctly classify the pathology and compare 
the sensitivities and specificities of GLCM and Wavelet tissue characterization 
techniques compared with other widely used diagnostic models. 
 
1.2.1. Objectives:  
In achieving the above aim, the following objectives have been set: 
- To estimate the accuracy of texture analysis in differentiating ovarian lesions 
against histology results. 
- To compare texture analysis performance with other widely used scoring 
systems. 
- To improve the sensitivity and specificity of transvaginal ultrasound in the 
diagnosis of ovarian lesions through objective assessment of the ultrasound 
images. 
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1.3. Thesis structure 
 
This study is divided into two parts. The first part focuses on Acoustic Structural 
Quantification (ASQ). This part can be further divided into four main sections: 
section A will include a definition of the new term followed by background 
information and the phantom study in which repeatability and reproducibility will be 
tested; then, section B will study Influence factors such as ROI size, ROI depth, 
Focus, Gain setting, and frequency on ASQ. Then, in section C, the influence of pre-
defined image parameters on ASQ output will be discussed. Lastly, section D will 
demonstrate the application of ASQ on images of benign and malignant masses.  
 
The second part focuses on texture features and consists of materials and methods 
used in the study, results and figures, a discussion of the main results and then the 
conclusion of the study. 
 
This thesis is structured into six main chapters: 
Chapter 1:  this chapter gives an overview of the whole thesis. 
Chapter 2: this chapter critically evaluates current ultrasonic techniques used to 
diagnose ovarian cancer and related issues. Alternative techniques are also reviewed 
in this chapter. 
Chapter 3: this chapter introduces the utilization of ASQ technique for  identification 
of ovarian cancer tissues. 
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Chapter 4:  this chapter focuses firstly features on explaining two of texture analysis 
methods, namely GLCM and wavelet, then applies these methods to ultrasound 
images of ovarian masses. 
Chapter 5: this chapter contains the general discussion of the study results of both 
ASQ and texture analysis in ovarian cancer early diagnosis. 
Chapter 6:  this chapter provides a summary and conclusion of the study and mentions 
its limitations, as well as recommending possible future work. 
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2. Literature Review 
2.1. Background 
Ovarian cancer is the second most common gynaecological malignancy in the 
developed countries and is the fifth leading cause of death due to cancer among 
women (McDonald et al., 2010, Enakpene et al., 2009, Leitzmann et al., 2009, Jemal 
et al., 2009, Ulusoy et al., 2007, Goff et al., 2007, Varras, 2004, Morgante et al., 
1999). Globally, the average lifetime risk of ovarian cancer is about 1 in 70 women, 
and cancer is seen very rarely before the age of 40 (Loubeyre et al., 2012). 
About 21,290 new cases of ovarian cancer are expected in 2015. Moreover, an 
estimated 14,180 deaths are expected in the USA in 2015. It causes more deaths than 
any other cancer of the female reproductive system. The majority of cases (63%) are 
diagnosed in the late stages, with a five-year survival rate of 27%, in comparison with 
a 72% survival rate when detected in the early stages (American Cancer Society, 
2015). In the European Union, an estimated 44,149 new cases were diagnosed and 
29,770 deaths from ovarian cancer occurred in 2012 (International Agency for 
Research on Cancer, 2012). 
In the United Kingdom, just over 7,000 new ovarian cancer cases are diagnosed every 
year (Cancer Research, 2012). According to Cancer Research UK, of all women 
diagnosed with ovarian cancer, 40% will live at least five years after diagnosis: the 
30% diagnosed with stage I cancer will have a 90% five-year survival rate, while the 
15% diagnosed with late stage cancer will have only a 6% 5-year survival rate 
(Cancer Research, 2012). Ovarian cancer becomes more common with increasing age. 
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Three-quarters of new ovarian cancer cases in the UK are diagnosed in women aged 
55 and over. 
 As can be seen from the above, early diagnosis is a vital factor for prognosis. 
Ultrasound is considered the main imaging modality for ovarian cancer triage (Kinkel 
et al., 2000). However, there is concern about the reproducibility of the diagnosis, 
mainly due to the subjective nature of the interpretation of the images and its 
dependency on the experience of the observer. Other methods of diagnosis are tumour 
marker analysis as well as other imaging modalities such as magnetic resonance 
imaging (MRI) and computed tomography (CT). 
2.1.1. Ovarian cancer  
Normally, normal cells grow and divide to form new cells. When uncontrolled and 
abnormal growth and division of the cells occurs, it causes cancer. A mass of tissue of 
these extra cells will form and is called tumour, which can be benign (non-cancerous) 
or malignant (cancerous). Benign tumours do not invade the tissues around them and 
do not spread to other parts of the body (metastasis). Malignant tumours, however, 
have the ability to invade and destroy other tissues surrounding them. Cancer cells are 
able to metastasise via the blood stream or the lymph system and spread to other parts 
of the body. Ovarian cancer refers to cancer of the ovaries (the female reproductive 
organs). 
2.1.1.1. Ovaries: location and appearance 
 The ovaries are a pair of oval-shaped organs that normally measure 2-4 cm in 
diameter and are located in the pelvis, on each side of the uterus. Two individual 
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functions of the ovaries are: (i) to produce eggs, and (ii) to produce the female 
hormones (oestrogen and progesterone). (See figure 1) 
 
Figure 1: Female Reproductive system 
 
Generally, uterine location influences the position of the ovaries. Normal ovaries are 
usually identified laterally or posterolaterally to the uterus. In cases of retroverted 
uterus, the ovaries tend to be located laterally and superiorly, near the fundus. 
Because of their variable position, superiorly or extremely laterally placed ovaries 
may not be visualised using the Transvaginal approach because they are out of the 
field of view.  
The ovaries are ellipsoid in shape, with their craniocaudal axes paralleling the internal 
iliac vessels, which lie posteriorly and serve as a helpful reference. 
On sonography, the normal ovary has a relatively homogenous echo texture with a 
central more echogenic medulla; well-defined, small anechoic or cystic follicles may 
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be seen peripherally to the cortex. The appearance of the ovaries changes with age 
and with the phase of the menstrual cycle (Rumack, 2005, 2011). 
Because of variability in shape, ovarian volume has been considered the best method 
for determining ovarian size. Volume measurement is based on the formula for the 
prolate ellipse (see equation 1). 
(width × height  × thickness × 0.523) or (d1 ×d2 × d3 ×0.532)                      
Equation 1: Ovarian volume  
Adult measurement of the ovary can be as large as 22 cm
3
. Following menopause, the 
ovary decreases in size with increased age. Due to its smaller size and lack of 
follicles, the postmenopausal ovary may be difficult to visualise sonographically. 
Mean ovarian volume ranges from 1.2 cm
3
 to 5.8 cm
3
. Ovarian volume > 8 cm
3
. is 
definitely considered abnormal (Rumack, 2005). Ovarian  masses can  be classified as 
simple cysts, complex cysts, or solid masses. Simple cysts are typically unilocular of 
any size, echo free and thin-walled. Thin septa (<3mm) may be present. The 
probability that a simple cyst will be malignant in a peri- or postmenopausal woman is 
exceptionally low (<1%) (Ekerhovd et al., 2001, Sharma et al., Published Online 
2011). Complex cysts have echogenic content, papillary formation, thick inner septa 
(>3mm), thick walls and might contain solid components. Even though most complex 
cysts are benign when examined histologically, there are no imaging features that can 
differentiate benign from malignant tissue in these lesions. The presence of a solid 
intracystic area increases the likelihood of malignancy. Solid masses usually raise the 
suspicion of malignancy, particularly when extra-pelvic ascites are present 
(Woodward et al., 2004). 
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Generally, ovarian cancer can develop at any age, yet it is most likely to occur in 
older age, between 40 and 65 years (Crum, 2004, Loubeyre et al., 2012). Serous 
adenoma, mucinous adenoma and Brenner tumours are all examples of benign ovarian 
tumours, whereas serous adenocarcinomas and mucinous adenocarcinomas are 
examples of malignant ovarian tumours which originate from epithelial cells. 
According to (Jeong et al., 2000), epithelial cell origin tumours account for 85% of all 
ovarian cancer cases. Commonly, epithelial tumours occur in peri-menopausal and 
post-menopausal women, with a mean age of 55 years (Russell, 1994). 
2.1.1.2. Ovarian cancer: types 
Ovarian cancer is grouped into three major types according to the tissue of the ovary 
it originated from: (i) epithelial tissue, (ii) germ cell and (iii) sex cord-stromal cell. 
The most common type is epithelial, accounting for 85% of cases. Epithelial tumours 
are rare before puberty. Their frequency increases with age and reaches a maximum at 
60 years of age (Jeong et al., 2000). Germ cell tumours are less common, accounting 
for 5-10% of cases. They usually affect younger women, where the peak incidence is 
in the early 20s. Sex cord-stromal tumours are rare, accounting for only less than 5% 
of the total cases. They can be found in all age groups. Sex cord-stromal tumours 
originate in the connective cells that hold the ovaries together and produce female 
hormones. 
2.1.1.3. Ovarian Cancer: Staging 
Staging describes the extent or spread of cancer to other parts of the body at the time 
of diagnosis. Proper staging is essential in determining the type of therapy, such as 
surgery and chemotherapy planning, and in predicting the survival rate. Several 
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different staging systems are used to classify tumours. The TNM staging system 
developed by the International Union Against Cancer (UICC) and the American Joint 
Committee on Cancer (AJCC) evaluates tumours in three ways: the extent of the 
primary tumour (T), the presence or absence of regional lymph node involvement (N) 
and the presence or absence of distant metastases (M). After the T, N and M 
categories are assigned, they can be further grouped into stages I, II, III or IV, with 
stage I being early and stage IV being advanced disease according to the FIGO 
staging system developed by the International Federation of Gynecology and 
Obstetrics (Fischerova, 2011).  
The document that explains the FIGO ovarian cancer staging is available online at: 
(http://www.figo.org/files/figo-corp/docs/staging_booklet.pdf).  Briefly, the four 
stages of ovarian cancer are as follows and the illustrations are given in figure 2(a) to 
2(d): 
Stage 1: the cancer is limited to one or both ovaries and has not spread to other 
organs.  
Stage 2: the cancer can be found outside of the ovary, but has not spread further than 
the pelvic region (uterus, bladder, lower intestine). 
Stage 3: the cancer is limited to the peritoneal cavity. 
Stage 4: the cancer has spread beyond the abdomen to areas such as the liver, lungs 
and brain. 
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(a) 
 
(b) 
 
(c) 
 
 
(d) 
Figure 2:(a) to 2(d) illustrate the extent of the spread for stage 1 to stage 4 of ovarian cancer (adopted from: 
http://www.cancerresearchuk.org/cancer-help/type/ovarian cancer/treatment/stages-of-cancer ) 
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2.1.1.4. Risk Factors 
Although extensive research has been carried out, the aetiology of ovarian cancer is 
poorly understood. Nevertheless, the two most prominent factors associated with the 
risk of developing ovarian cancer are the increase in age and the presence of certain 
gene mutations. 
Several factors, such as oral contraceptive use, parity and breastfeeding are believed 
to be associated with decreased risk (Permuth-Wey and Sellers, 2009). Body mass 
index (BMI), height, family history of ovarian cancer and prolonged use of 
postmenopausal hormonal therapy (HRT) are associated with increased risk of 
ovarian cancer (Givens et al., 2009, Permuth-Wey and Sellers, 2009, Schouten et al., 
2008, McBee et al., 2007, Olsen et al., 2007, Engeland et al., 2003).  
2.1.1.4.1. Age 
Incidence of ovarian cancer increases with age, with a median age at diagnosis of 63 
years. Over 80% of cases occur after the age of 45 years. Okugawa and colleagues 
studied the relationship between age, histological type and the size of ovarian tumours 
and found that tumours in older patients are more likely to be malignant (Okugawa et 
al., 2001). Moreover, McBee and colleagues considered patient age as the most 
important predictor of whether a mass is likely to be malignant or benign (McBee et 
al., 2007). In addition, more than one-third of cases of ovarian cancer occur in women 
older than 65 years of age (McBee et al., 2007, Varras, 2004).  In women under the 
age of 45 years, the risk that an ovarian mass will be a primary malignancy is only 
one in fifteen (Varras, 2004).  It has been reported that the risk of ovarian cancer 
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increases progressively with age, with a higher risk after the menopause (Givens et 
al., 2009). 
2.1.1.4.2. Family History 
One of the most significant risk factors for ovarian cancer is a family history of breast, 
colon or ovarian cancer, especially if multiple first degree relatives (mother or sister) 
are diagnosed with ovarian cancer. Similarly, women with a previous personal history 
of breast cancer have double the risk of ovarian cancer, and the risk is increased 
nearly four-fold for women diagnosed with breast cancer before the age of 40 
(Permuth-Wey and Sellers, 2009, Givens et al., 2009).  
2.1.1.4.3. Height 
When taking the height of women into account as a risk factor, Schouten et al, ( 2008) 
found in their review of twelve prospective cohort studies from North America and 
Europe that height was not associated with an increased risk of cancer in 
postmenopausal women.  Conversely, a Norwegian cohort of 1.1 million women with 
7,882 cases of ovarian cancer reported a positive association between taller women 
(more than 1.75 m) and ovarian cancer compared with women between 1.60 and 1.64 
m in height (Engeland et al., 2003), and a recent Dutch study had similar results, 
finding a positive association in postmenopausal women between height and risk of 
ovarian cancer (Schouten et al., 2008).  
Gunnell conducted a study explaining that height on its own does not cause cancer but 
possibly acts as an indicator for some other exposure factors such as genetics, energy 
intake in early life and exposure to sex and growth hormones (Gunnell, 2001). This 
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concurred with Engeland and colleagues (2003), who demonstrated that height may 
be a sign that early life situations are interrelated with the risk of cancer.  
2.1.1.4.4. Body Mass Index (BMI) 
Studies that observe a relationship between current BMI and ovarian cancer risk in 
postmenopausal women are questionable. A meta-analysis in 2007 reported a 16% 
increase in risk for overweight women with BMI 25-29.9 kg/m
2
 and a 30% increased 
risk for obese women with BMI ≥30 kg/m2 in comparison to normal weight women 
with BMI 18.5-24.9 kg/m
2
 (Olsen et al., 2007).  
The majority of studies have found no relationship between current BMI and 
increased risk of ovarian cancer in postmenopausal women. However, they showed a 
positive correlation of early adulthood high BMI (age 18-20 years) and increased risk 
of ovarian cancer. Their findings suggested that long term, consistent excess weight 
represents a major risk factor for ovarian cancer, especially with no family history of 
ovarian cancer, whereas high BMI with positive family history of ovarian cancer will 
not increase the risk (Leitzmann et al., 2009, Olsen et al., 2008, Lubin et al., 2003, 
Engeland et al., 2003, Rodriguez et al., 2002). This was supported by others, who 
concluded that being overweight or obese in premenopausal years (<50 years) of age 
is associated with an increased risk of ovarian cancer when women become 
postmenopausal (Permuth-Wey and Sellers, 2009). One noteworthy limitation from 
the Leitzmann et al. (2009) study was the limited ethnic/racial diversity of participants 
(Leitzmann et al., 2009). Other studies disagreed with this and concluded that there is 
no association between BMI in early adolescence and the risk of cancer (Permuth-
Wey and Sellers, 2009, Schouten et al., 2008).  
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2.1.1.4.5. Hysterectomy 
Numerous studies have investigated whether hysterectomy or other procedures have 
an effect on the risk of ovarian cancer (Rosenblatt and Thomas, 1996, Green et al., 
1997, Kreiger et al., 1997, Miracle-McMahill et al., 1997, Risch et al., 1994, 
Hankinson et al., 1993). All of them have identified a reduced risk of ovarian cancer 
associated with either hysterectomy or tubal ligation (without oophorectomy). 
Furthermore, tubal ligation has a protective effect on ovarian cancer with an estimated 
reduced risk of between 18% and 70%. Although it is undetermined how these 
procedures reduce the risk of cancer, it has been proposed that the risk of ovarian 
cancer may decrease due to the decrease in blood flow to the ovaries (Permuth-Wey 
and Sellers, 2009).  
2.1.1.4.6. Use of Hormone Replacement Therapy (HRT) 
Hormones such as oestrogens and progesterone are believed to be involved in 
promoting ovarian carcinogenesis (Permuth-Wey and Sellers, 2009).  
A recent study showed an increased risk of ovarian cancer among HRT users. It was 
reported that the risk increased by 30% regardless of duration of use, route of 
administration or type of hormone used, even with a short duration of use (0-4 years) 
(Mørch et al., 2009). In 2009, Permuth-Wey and Sellers illustrated that both current 
and past users of HRT of five or more years had a significantly higher risk compared 
with women who had never used any type of HRT. They concluded that the 
considerable increase in the risk of ovarian cancer was associated with duration rather 
than with status of use. They supported their findings with the UK Million Women 
study results, which found that the incidence of ovarian cancer increased in current 
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HRT users with (prolonged) duration of use but did not differ significantly by type of 
hormone used and that past users were not at increased risk, since the risk diminished 
two years after discontinuing the treatment (Permuth-Wey and Sellers, 2009). Others 
(Greiser et al., 2007) found similar results when available studies were reviewed and 
further determined that the risk is greater in European studies than in North American 
studies.  
Other factors that are alleged to decrease the risk are: 
Parity: the risk of ovarian cancer is lower in women who have children compared to 
women who have never had children (Modan et al., 2001). 
Breastfeeding also reduces the risk of ovarian cancer in women who breastfed, 
compared to those who have never breastfed (Luan et al., 2013). 
Infertility: null gravid women who have been attempting to get pregnant for more than 
five years have an increased risk compared to women who have been trying to 
conceive for less than a year (Rossing et al., 2013). 
Oral contraceptives usage reduces the risk of ovarian cancer. (Modan et al., 2001) 
Web reference: http://info.cancerresearchuk.org/cancerstats/types/ovary/riskfactors/  
2.1.1.5. Symptoms  
According to (Chan and Selman, 2006), the symptoms of ovarian cancer are non-
specific. However, Goff and colleagues studied the possibility of early detection of 
ovarian cancer through the development of an ovarian cancer symptom index. They 
suggested, from their results, that specific symptoms such as abdominal/pelvic pain, 
increased abdominal size/bloating, or difficulty eating/feeling full quickly that are 
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experienced >12 times per month over a one-year duration should raise the suspicion 
of ovarian cancer (Goff et al., 2007).  This is consistent with a study by Smith et al.  
(2005), who added urinary urgency or frequency to the symptom profile. Other 
studies agreed, such as (Vine et al., 2003) and (Olson et al., 2001), as quoted by 
(Cancer Research, 2012). These studies are in agreement with another (Hamilton et 
al., 2009) which suggested that ovarian cancer should not be called the silent killer 
any longer because of the symptoms mentioned in previous studies. Moreover, their 
study found that there were only minor differences in documented symptoms between 
cases with early and later stages of the disease. 
In another review (McBee et al., 2007) which studied ovarian masses that require 
intervention, it was pointed out that the best predictors of malignant tumours are a 
combination of factors that include patient age, family history, menopausal status, 
symptoms, findings on clinical examination, ultrasound imaging findings and serum 
CA125 level. They listed the symptoms that suggest malignancy in women with 
pelvic mass as abdominal pain/bloating, abnormal vaginal bleeding or discharge, 
change in consistency of stool, decreased appetite, frequent urination, increased 
abdominal girth, nausea or vomiting and significant weight loss. They added that 
other clues could be found on physical examination, such as ascites or upper 
abdominal mass, a mass that is large, firm, irregular or fixed and nodularity on rectal 
examination.  
Evidence shows that to differentiate between women who are experiencing symptoms 
related to ovarian cancer and women who are not, the frequency, persistency, severity 
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and new onset of these symptoms might help (Bankhead et al., 2008, Goff et al., 
2007).   
Other than that, loss of appetite, nausea, lower back pain and shortness of breath may 
also be an indication of ovarian cancer. Nevertheless, it is important to emphasis that 
these symptoms could be due to other diseases. 
In a more recent study in 2012, the author discussed the possibility and the feasibility 
of using computer assisted diagnosis (CAD) to identify the symptoms of ovarian 
cancer by creating a predictive algorithm (Hamilton, 2012). 
2.1.2. Methods of Preoperative Evaluation 
Ovarian cancer is diagnosed at an advanced stage in most patients due to the non-
specific nature of the symptoms and signs of this disease. Several methods have been 
used for the preoperative evaluation of adnexal masses, such as gynaecologic 
examination, blood tests for serum levels of CA-125 (Van Calster et al., 2007), 
imaging procedures such as subjective evaluation of grey-scale and Doppler 
ultrasound findings by an experienced examiner (pattern recognition), CT/ MRI, 
laparoscopy and laparotomy, as well as patient characteristics such as menopausal 
status or age.  
The only way to confirm the diagnosis is to remove a tissue sample form the mass and 
examine it under a microscope: this is called histology (Marshall, 2008, American 
Cancer Society, 2015). 
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Before ultrasound became extensively available, the discovery of a palpable ovary or 
pelvic mass in a postmenopausal woman was considered an indication for surgery 
(Valentin, 2000). Therefore, it is of great importance that the imaging modality has a 
high sensitivity as well as reliable characterization of the lesions to allow accurate and 
consistent diagnosis. This is particularly vital since the symptoms of ovarian cancer 
are non-specific, and the patient management and treatment depend on tumour 
staging. 
2.1.2.1. Tumour markers 
Tumour markers are substances either produced or released by tumour cells or host 
cells, which point out that a tumour is present if identified in serum or other biological 
fluids. Preferably, a marker should be high in both sensitivity and specificity. They 
have the advantage of being non-invasive, quick, widely available and relatively 
cheap (Agarwal et al., 2011, Hellstrom and Hellstrom, 2008). 
2.1.2.1.1. Serum CA125 
CA stands for cancer antigen. CA 125 is a protein that is a so-called tumor marker or 
biomarker, which is a substance that is found in greater concentration in tumor cells 
than in other cells of the body. In particular, CA 125 is present in greater 
concentration in ovarian cancer cells than in other cells. It was first identified in the 
early 1980s. CA 125 is often measured as a blood test (Dong et al., 2008). 
Although CA125 is the most well-known and commonly used serum tumour marker 
in Gynaecology (Moore and MacLaughlan, 2010, McBee et al., 2007, Gadducci et al., 
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2004), the role of this biomarker in particular in the diagnosis of ovarian cancer is 
controversial. 
The usefulness of this marker is limited due to lack of sensitivity, as it is elevated in 
only 50% of patients with stage 1 cancer (Ronco et al., 2011) and in 75-90% of 
patients with advanced disease (Moss et al., 2005), as well as having poor specificity 
because it is elevated in numerous benign conditions such as endometriosis, 
adenomyosis and pelvic inflammatory disease as well as several non-gynaecological 
conditions such as diverticulitis, liver and heart failure, pancreatic cancer, and breast, 
bladder and liver cancer (Duffy et al., 2005, Ronco et al., 2011). 
Two studies based on the International Ovarian Tumour Analysis (IOTA) data by 
(Timmerman et al., 2007) and (Van Calster et al., 2007) examined the importance of 
CA125 in comparison with ultrasound, clinical information, and pattern recognition 
respectively. The first study suggested that when combining ultrasound with certain 
clinical information, the addition of serum CA125 level does not improve the 
preoperative classification of a mass or redirect management in either premenopausal 
or postmenopausal women.  
The other study found that pattern recognition by an experienced examiner was 
superior to measuring the level of serum CA125 in differentiating between benign and 
malignant adnexal masses. However, the later study revealed a bias because serum 
CA125 was more likely to be measured in women with suspected malignant masses 
only; moreover, 24% of benign cases did not have a serum CA125 done and were 
diagnosed confidently through pattern recognition alone. These results were agreed in 
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a later study that found that Transvaginal ultrasound done by an expert examiner is 
superior to CA125 analysis in diagnosing ovarian cancer (Alcázar and Guerriero, 
2011). 
Hartman and colleagues carried out a study to assess ultrasound criteria and CA125 as 
predictive variables of ovarian cancer. They described their work as the first study to 
attempt to reproduce the simple rule established by (Timmerman et al., 2008) and 
apply them outside the European centres of the IOTA. They concluded that the simple 
rules allow the correct classification of ovarian masses and added that CA125 
measurement can slightly improve the specificity of ultrasound examination when the 
scan is suggestive of malignancy; however, CA125 measurement should not be used 
alone in diagnosing ovarian tumours (Hartman et al., 2012). 
Moreover, a study commenced by (Givens et al., 2009) suggested that CA125 levels 
should be checked for postmenopausal women with adnexal masses to guide 
treatment options, but should not be used as a screening tool or when a mass is not 
identified. This result was supported later by the recent IOTA recommendation in 
2013 for clinical practice, where measurements of serum CA125 were not necessary 
for the characterization of ovarian pathology in premenopausal women. It also 
showed that measurements of serum CA125 are unlikely to improve the performance 
of experienced ultrasound examiners decision, even in the postmenopausal group 
(Kaijser et al., 2013). 
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2.1.2.1.2. Other Biomarkers 
In a recent study, six different serum markers were tested for their elevation in 
patients with ovarian cancer. This study suggested that human epididymis protein 4 
(HE4) is the best marker for use as a secondary screening test. The HE4 had a higher 
sensitivity in all stages of type 2 ovarian cancer and a lower sensitivity in early stages 
of type 1, including stage 1 and 2, when compared with Transvaginal ultrasound. 
However, these results need to be further validated and confirmed by an independent 
group that the measurement of HE4 outperforms Transvaginal ultrasound as a 
screening test (Urban et al., 2011). Similarly, a study done by Agarwal and 
colleagues, focusing on potential markers for detecting ovarian cancer, found that 
HE4 had a high sensitivity and specificity of 90% and 77.6% respectively. Moreover, 
it possessed the highest sensitivity in detecting stage 1 ovarian cancer, as well as 
fewer false positive results, especially in non-malignant ovarian diseases (Agarwal et 
al., 2011). 
Studies focusing on the potential use of HE4 as a biomarker of ovarian cancer suggest 
that it is elevated in over 50% of ovarian cancer patients with low CA125. In addition, 
HE4 has a greater sensitivity than CA125 in early stage ovarian cancer, as well as 
greater specificity in comparison with benign ovarian masses (Moore and 
MacLaughlan, 2010). Based on these findings, a scoring model was developed by 
Steven Skates and colleagues, called the Risk of Ovarian Malignancy Algorithm 
(ROMA), which uses measurements of CA125 and HE4, combined with menopausal 
status, in order to assign high or low risk of malignancy in women with pelvic mass 
(Moore and MacLaughlan, 2010).  
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Following this, in 2012, a study was commenced to compare CA125, HE4, ROMA 
and RMI in the classification of ovarian masses.  The four methods demonstrated 
similar levels of accuracy in their ability to differentiate adnexal masses, with RMI 
having the lowest sensitivity and HE4 the best overall sensitivity for evaluation of 
malignant tumours (Anton et al., 2012). (RMI will be explained in section 2.1.2.2.1.3. 
Risk of Malignancy Index, later in this chapter) 
More recently, ROMA was evaluated in a prospective, multicentre trial involving 472 
patients and provided a sensitivity of 93.8% and specificity of 74.9%. It performed 
well in premenopausal women, with a sensitivity of 100% and specificity of 74.2%. In 
addition, the study demonstrated a clear benefit of ROMA to ovarian cancer patients 
in terms of mortality and morbidity (Nolen and Lokshin, 2013).  
Another study focused on soluble mesothelin-related proteins (SMRP) and HE4. The 
results showed a comparable sensitivity of HE4 with CA125 but with higher 
specificity. Furthermore, the authors concluded that measuring SMRP and HE4 in 
serum could be useful for patients with ovarian cancer, as they complement CA125 
for diagnosing and monitoring patients. Nevertheless, the need for prospective studies 
to establish the clinical relevance of these findings is obvious (Hellstrom and 
Hellstrom, 2008).  
Another biomarker, called human Kallilrein 10 (hK10), was evaluated for ovarian 
cancer diagnosis and prognosis by (Luo et al., 2003). In this study, it was 
demonstrated that hK10 could identify a significant number of patients who were 
missed when using CA125 analysis alone. Moreover, when combining hK10 with 
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CA125, the achieved sensitivity was 73%, which is superior to hK10 (55%) or CA125 
(60%) alone with the same specificity of 90%. Thus, CA125 and hK10 can be 
combined to increase the diagnostic sensitivity of each of the biomarkers alone (Luo 
et al., 2003). Similarly, another study found that hK10 can be utilized in many 
malignancies but lacks sufficient specificity or sensitivity to be clinically useful when 
used alone (Dutta et al., 2010b). 
Despite recent advances in ovarian cancer biomarkers research, no simple blood test 
with the required sensitivity and specificity has yet been clinically validated (Dutta et 
al., 2010b). This could be explained by the complexity and heterogeneity of ovarian 
cancer. In other words, it is doubtful that a single biomarker will be able to detect all 
subtypes and stages of the disease with high specificity and sensitivity (Gagnon and 
Ye, 2008). 
2.1.2.2. Ultrasound 
Ultrasonography is, at present, the most widely used diagnostic imaging technique for 
the differential diagnosis of adnexal masses. It has been used in medical imaging for 
over half a century (Hangiandreou, 2003), and it is commonly considered as the 
preferred imaging modality in the study of the female pelvis (Derchi et al., 2001). It is 
a non-invasive procedure, with relatively low cost, and is well accepted by most 
women. Visualization of normal ovarian function and ovarian masses has improved 
since the introduction of the transvaginal transducer (Twickler and Moschos, 2010).   
Ultrasound is currently one of the most significant, extensively used, and valuable 
imaging modalities in medicine (Hangiandreou, 2003). According to Kinkel et al. 
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(2000), it is the imaging modality of choice in the evaluation of suspected adnexal 
masses; in addition, ultrasound is the main triage method for ovarian cancer prior to 
treatment. This was supported by a later study by Togashi (Togashi, 2003).  
The main downside of ultrasound is that the accuracy of ultrasound scanning is 
greatly dependent on three variables: operator, equipment and patient. To become an 
ultrasound expert in gynaecology requires extensive practical proficiency, which is 
not acquired easily by every person. To examine patients effectively, a high-end 
ultrasound machine equipped with sensitive Doppler and endocavitary and trans-
abdominal probes are needed. Another significant variable in the accuracy of 
ultrasound is the patient. Although there has been considerable improvement in 
scanning technology, there are nevertheless limitations in some cases such as obese 
patients and postoperative adherent intestinal loops causing acoustic shadowing 
(Fischerova, 2011). 
B-Mode or brightness mode is a two-dimensional ultrasound image display composed 
of bright dots representing the ultrasound echoes. The brightness of each dot is 
determined by the amplitude of the returned echo signal (Rumack, 2005). 
Doppler ultrasound is used to detect the motion of blood. It is based on the concept of 
Doppler shift, which is the change in frequency for a reflector moving relative to the 
source. When reflector is moving toward the transducer waves are closer together 
gives high frequency higher than the transmitted one. The difference between the 
transmitted and the received frequency is called Doppler shift (Horskin, 2010). 
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Ultrasound-based assessment for ovarian mass characterizations can be divided into 
the following techniques: morphologic information, which is based on B-mode 
images, and blood flow information, which is based on Doppler imaging. 
The level of performance of ultrasound examination in ovarian cancer diagnosis has 
been studied and reported to have a wide range. Kinkel et al. (2000), for example, 
reported that the accuracy of ultrasound is 65%- 94% for B-mode ultrasound and 
35%- 88% for colour Doppler flow imaging.  On the other hand, the Royal College of 
Obstetricians and Gynaecologists (RCOG), in its document “Guideline No. 34: 
ovarian cysts in postmenopausal women”, referred to sensitivity of 89% and 
specificity of 73% of ultrasound performance when using a morphology index in 
(DePriest et al., 1994) study (RCOG, 2003) 
(Kinkel et al., 2000) assert that although extensive studies have been done on 
ultrasound techniques and they have been found to be the best means of lesion 
characterization, this approach remains inconclusive. Nevertheless, it has been 
demonstrated that ultrasound techniques that combine grey-scale ultrasound 
morphology assessments with tumour vascularity imaging information (colour 
Doppler flow imaging) in a diagnostic system are significantly better in ovarian lesion 
characterization compared to using power Doppler, colour Doppler flow imaging, or 
grey-scale ultrasound morphologic imaging alone (Kinkel et al., 2000, Togashi, 
2003). 
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2.1.2.2.1. B-mode (brightness-mode) Ultrasound: (see figure 3) 
B-mode ultrasound uses morphological features to diagnose ovarian cancer. These 
features include cystic and solid tumour structure, the presence of septation and 
papillarities. Aletti et al. (2007) proposed that the presence of complex ovarian mass 
with both cystic and solid components and septation are highly suggestive of ovarian 
cancer. Other researchers (Twickler and Moschos, 2010) have found that the 
increased size of the mass is a significant factor in predicting malignancy. More 
recently, Valentin and colleagues confirmed in their study that unilocular adnexal 
cysts with papillation are more difficult to classify as benign or malignant using 
subjective assessment even when an experienced ultrasound examiner performs the 
scan (Valentin et al., 2013). 
 
Figure 3: examples of B-mode images of ovarian tumours. 
 
Although ultrasound findings are an excellent method for discriminating between 
benign and malignant adnexal tumours (Ameye et al., 2009), one of the main 
problems with this approach is that it is highly operator and equipment dependent and 
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therefore subjective (Wang et al., 2002, Shung, 2006). Therefore, the general concern 
in gynaecological ultrasound is the lack of standardized terms and procedures in the 
interpretations of the images (Timmerman, 2000). In order to provide a more 
standardized terminology and procedure, a group of investigators from the 
International Ovarian Tumour Analysis (IOTA) group has produced a paper entitled 
“Terms, definitions and measurements to describe the sonographic features of 
adnexal tumours: a consensus opinion from the International Ovarian Tumour Group 
analysis (IOTA) group” (Timmerman, 2000). Several scoring systems were 
developed to overcome the operator-dependent limitations and to increase the test 
performance, as well as allowing more dependable assessment of inter-observer and 
intra-observer variability and the comparison of results from different centres 
(Alcázar et al., 2003).  According to Van Holsbeke et al. (2009), the main benefit of 
using scoring systems is to provide a helpful tool to allow less experienced ultrasound 
examiners to achieve the same diagnostic performance as an expert. 
A study in China in 2011 showed that the operator’ level of confidence is positively 
associated with diagnostic performance. In addition, the conclusion was made that the 
accuracy of diagnosing ovarian tumours is greatly influenced by working experience 
and confidence score (Haiyan and Min, 2011). 
Numerous studies have shown that the morphological appearance of adnexal masses 
on ultrasound can be used to predict malignancy (Timmerman et al., 2007, Varras, 
2004, Berlanda et al., 2002, Morgante et al., 1999, Ferrazzi et al., 1997, Lerner et al., 
1994). Both Lee and colleagues Lee et al. (2005) and Alcázar et al. (2003) reported 
that when using a morphological scoring systems, less experienced operators who 
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lack the expertise to make subjective assessments of adnexal masses would achieve a 
higher diagnostic accuracy that is comparable with the results of more experienced 
examiners.  
A more recent prospective study (Alcazar et al., 2008) which included both pre- and 
post-menopausal asymptomatic women with adnexal masses found that an ultrasound 
scoring system provided good results with sensitivity and specificity of 95% in both 
of them, which was similar to previous reports (Guerriero et al., 2005, Berlanda et al., 
2002), confirming that ultrasound-based triage is an excellent method of classifying 
adnexal masses. However, the scoring system misclassified adnexal masses when 
tumour size was > 10 cm, thus limiting its accuracy for large tumours. Alcàzar (2008) 
concluded that even in highly skilled hands, when using grey scale and Doppler 
ultrasound triage, a false-positive rate of 5-10% has to be anticipated in discriminating 
benign from malignant adnexal masses. Furthermore, the false-positive rate in using 
an ultrasound-based scoring system in the largest multicentre study was 24%. This 
was supported by Sokalaska et. al., which demonstrated that, even in the hands of an 
experienced examiner, it was not possible to make a conclusive diagnosis in adnexal 
pathology using subjective evaluation of grey-scale and Doppler ultrasound (Sokalska 
et al., 2009). 
A study commenced in 2008 by Timmerman and colleagues (Timmerman et al., 
2008) has been described as the largest study to analyse the ultrasound features of 
benign and malignant adnexal masses. They introduced a simple rule for describing 
adnexal masses, consisting of five ultrasound features of malignancy (M-features) and 
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five ultrasound features suggestive of benign mass (B-features). These features are 
presented in Table 1. 
  
A mass is classified as malignant if at least one M-feature and none of the B-features 
are present, and vice versa. If no B- or M-features are present, or if both B- and M-
features are present, then the rules are considered inconclusive (unclassifiable mass) 
and a different diagnostic method should be used. They found that to accurately 
determine the nature of an adnexal mass, subjective impression of the ultrasound 
morphology can be used. They agreed with previous studies (Modesitt et al., 2003) in 
that unilocular adnexal cysts have a very low risk of malignancy and that any other 
morphological appearance was associated with an increased risk of malignancy. 
However, a significant limitation to this study was that this rule cannot be applied to 
nearly 25% of tumours, since not all masses will present features clearly predictive of 
benignity or malignancy. The rule worked well for advanced invasive malignancies, 
but not for stage I borderline tumours and stage I primary invasive malignancies 
(Timmerman et al., 2008). In other words, it was applicable to tumours that were 
easily classifiable using operator pattern recognition but less apparent in more 
difficult tumours. Therefore, their results were incomplete.  
Later, in 2013, Alcázar and colleagues commenced an external validation of the IOTA 
simple rule in a prospective study for which ultrasound scanning was performed by 
non-expert examiners. They concluded that the IOTA simple rule are undeniably 
simple, easy to learn and user friendly; additionally, their data yielded acceptable 
   
34 
 
results in terms of specificity (97.5%) in the hands of non-expert examiners. 
However, there was a 12% false-positive rate, which is relatively high, where 4 of 33 
(12%) malignant masses were misdiagnosed as benign. This could be concerning if 
the simple rules were applied to triage for conservative management (Alcázar et al., 
2013b). 
B-features M-features 
B1: Unilocular cyst M1: Irregular solid tumour 
B2: Presence of solid components with 
largest diameter <7 mm 
M2: Presence of ascites 
B3: Presence of acoustic shadows M3: At least four papillary structures 
B4: Smooth multilocular tumour, with largest 
diameter <100 mm 
M4: Irregular multilocular solid tumour with 
largest diameter ≥ 100 mm 
B5: No blood flow (colour score 1) M5: Very strong blood flow (colour score 4) 
Table 1: Ultrasound features used in the International Ovarian Tumour Analysis (IOTA) simple rules. 
 
 2.1.2.2.1.1. Sassone Scoring System (see Table 2) 
Sassone and colleagues (Sassone et al., 1991) devised a scoring system to characterize 
ovarian lesions using traditional grey-scale transvaginal ultrasonography relating 
ovarian morphology directly to risk of malignancy. It assigned a numeric value to 
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specific morphologic criteria, including inner wall structure, wall thickness, septal 
structure and echogenicity. The total score varies between 4 and 15, with a threshold 
value of 9 used to distinguish benign from malignant tumours. The researchers 
applied this scoring system in 143 women undergoing surgery for clinically detected 
pelvic masses, 20 of whom had ovarian malignancy. Using a score of ≥ 9 as indicative 
of cancer, the Sassone scoring was able to distinguish benign from malignant lesions 
with a sensitivity of 100%, specificity of 83%, positive predictive value (PPV) of 37% 
and negative predictive value (NPV) of 100%.  
       
Table 2: The original Sassone scoring system for adnexal masses (Sassone et al., 1991) 
 
Ferrazzi et al. (1997) agreed with this finding and added that it has the advantage of 
being more descriptive and helpful for routine examination. Sassone’s model was 
described by Geomini et al. (2009) as the most frequently validated scoring system. 
Furthermore, it has been reported and validated in numerous recent studies (Rossi et 
al., 2011, Geomini et al., 2009, Tempe et al., 2006, Alcázar et al., 2003, Mol et al., 
Value
Inner Wall 
Structure
Wall Thickness 
(mm)
Septa (mm) Echogenicity
1 Smooth Thin ≤3 mm No septa Sonolucent
2 Irregular ≤3 mm Thick >3 mm Thin ≤3 mm Low echogenicity
3
Papillaries >3 
mm
Not applicable, 
mostly solid
Thick >3 mm
Low echogenicity with 
echogenic core
4
Not applicable, 
mostly solid
Mixed echogenicity
5 High echogenicity
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2001, Buckshee et al., 1998). However, several other studies that used Sassone 
scoring were excluded from the current study because the articles were published in 
languages other than English. 
 2.1.2.2.1.2. DePriest Scoring System (Kentucky score, see 
table 3) 
Another similar scoring method was the morphology index described by DePriest et 
al. (1993). This index was based on tumour volume, wall structure and septal 
structure. A five-point scale (0-4) was developed within each category for specific 
criteria with the total points per evaluation varying from 0 to 12. Using a morphology 
index score of ≥ 5 as indicative of malignancy. In this study, this system had 
sensitivity of 89%, specificity of 73%, PPV of 46%, and NPV of 96% in 
postmenopausal women. The most reliable morphologic criterion in differentiating 
ovarian cancer from benign lesions was the wall structure (Varras, 2004, Geomini et 
al., 2009). 
  
Table 3: The DePriest scoring system (DePriest et al., 1993) 
 
Category 0 1 2 3 4
Volume <10 cm
3
10-50 cm
3
>50-200 cm
3
>200-500 cm
3
>500 cm
3
Cyst Wall 
Structure
Smooth <3 mm 
Thickness
Smooth  >3 
mm Thickness
Papillary Projection   
<3 mm
Papillary Projection 
≥3 mm
Predominantly 
Solid
Septa 
Structure
No Septal
Thin Septal <3 
mm
Thick Septal 3-10 
mm
Solid Area ≥10 mm
Predominantly 
Solid
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In 2003, Ueland and his colleagues (Ueland et al., 2003) demonstrated that De Priest’s 
Kentucky scoring system was an accurate and inexpensive method for distinguishing 
benign from malignant tumours. They explained that its only limitation was that the 
index was subject to interobserver variation.  
Similar to Sassone, many groups have validated and compared the Kentucky scoring 
system with other scoring systems (Lee et al., 2005, Varras, 2004, Ueland et al., 2003, 
Van Nagell Jr and Ueland, 1999, Ferrazzi et al., 1997).  
Although the use of a scoring system helps to improve test performance, the existence 
of multiple scoring systems may pose problems in clinical practice, mainly because 
there are too many of them and some of the parameters to be considered are often 
very complex. 
 2.1.2.2.1.3. Risk of Malignancy Index (see equation 2)  
To improve the preoperative assessment of adnexal masses, most of these parameters 
(menopausal status, ultrasound findings and serum CA125) have been combined into 
diagnostic models. Such models have been developed to guide clinicians to identify 
patients with pelvic masses who are likely to have ovarian cancer. Risk of Malignancy 
Index (RMI)  is a useful way of triaging women into low, moderate and high risk of 
malignancy (RCOG, 2003),which has been evaluated in numerous primary studies. 
Jacobs and colleagues developed the Risk of Malignancy Index (RMI) for referral of 
relevant women to gynaecologic oncologic centres (Jacobs et al., 1990) based on 
transabdominal ultrasound scan. Since then, various versions of the Risk of 
Malignancy Index have been published. However, the most commonly used version 
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in the UK is that published by the royal college of obstetricians and gynaecologists in 
October 2003 (RCOG, 2003) 
RMI= U x M x CA125    
  Equation 2: RMI model 
Where, U is an ultrasound score, and M is manoposal status, and the serum level of 
CA125 was applied directly to the formula. 
 
Each of the following grey-scale morphological features was given one point when 
present: bilateral lesions, multilocular lesions, solid areas, intra-abdominal metastases 
and ascites. If the sum of these points was 0, an ultrasound score U=0 was given, 
while a sum of 1 point an ultrasound score U=1, and a score of U=3 was given when 
the sum of ultrasound points ≥2 (Jacobs et al., 1990, Yazbek et al., 2006).  
 
RMI < 25 
RMI 
between  25 - 250 
RMI > 250 
 
Low Risk < 3% Moderate Risk 20% High Risk 75% 
 
Table 4: RMI categories as illustrated by (Prys Davies et al., 1993) 
 
M is menopausal status, where Premenopausal status yielded M = 1 and 
postmenopausal status yielded M = 3. 
 
The RMI was the first diagnostic model that combined demographics, sonographic 
and biochemical data in the assessment of women with adnexal masses. It provides a 
quantitative assessment of the risk of malignancy and can be used to differentiate 
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between benign and malignant lesions. At a cut-off level of 200, the sensitivity is 85% 
and the specificity is 97%.  
The main advantages of the RMI in comparison with others are that it is a simple 
scoring system and a reliable, cheap, convenient and cost-effective method of 
preoperative discrimination between benign and malignant adnexal masses (van den 
Akker et al., 2010, Harry et al., 2009, Chia et al., 2008, Bailey et al., 2006, Andersen 
et al., 2003, Tingulstad et al., 1999, Jacobs et al., 1990). 
It is worth noting that one of the issues of the RMI is that it is dependent on serum 
CA125, which is a non-specific marker for ovarian cancer: hence, it can lead to 
unnecessary surgical intervention (Ortashi, 2008). 
Yazbek and colleagues (Yazbek et al., 2006) used the same cut-off value in their 
prospective observational study. In addition, they combined the RMI with another test 
called the Ovarian Crescent Sign (OCS) to diagnose ovarian malignancy. They 
concluded that both RMI and OCS are useful tests to discriminate between invasive 
and non-invasive ovarian tumours.  
Tingulstad (1996) introduced RMI II by modifying the RMI scoring system described 
by Jacobs and re-evaluated its ability to differentiate benign from malignant ovarian 
lesions by utilizing Transvaginal instead of Transabdominal ultrasound, adjusting the 
ultrasound score to U=1 if no or one abnormality was seen rather than U= 0 for no 
abnormality. The reason for this was that Jacobs did not consider the value of serum 
CA125 level or the menopausal status in the case of no abnormality detected on 
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ultrasound with U = 0, will result in RMI =0, regardless of the other parameters 
(Tingulstad et al., 1996).  
Both RMI I and RMI II have been studied extensively in recent years and have been 
validated  retrospectively and prospectively in numerous clinical studies where a cut-
off value of 200 showed the best discrimination between benign and malignant 
adnexal masses, with high sensitivity 51-90% and specificity 51-97% levels (van den 
Akker et al., 2010, Lou et al., 2010, Geomini et al., 2009, Enakpene et al., 2009, 
Moolthiya et al., 2009, Harry et al., 2009, Ulusoy et al., 2007, Manjunath et al., 2001, 
Morgante et al., 1999).  
Another study compared the accuracy of RMI I and RMI II, finding that RMI II is 
more sensitive than RMI I with higher specificity of 89% to 92%. In addition, it 
recommended the use of the RMI II scoring system due to its simplicity and 
reproducibility (Le et al., 2009). 
Although two recent studies (Akdeniz et al., 2009, Moolthiya et al., 2009) agreed with 
the previous ones, they were excluded from this project because of the misuse of RMI 
I and RMI II. In the first study, the author applied an incorrect scoring for calculating 
the RMI, as he gave a score of U= 1 if no or one ultrasound feature was detected and a 
score of U= 3 if two or more of these features were detected, as well as giving a score 
of 2 for postmenopausal status instead of 3, which does not correspond to any of the 
RMI versions. The other study was excluded because the authors were trying to study 
the difference between RMI I and RMI II, except that they failed to identify the RMI 
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II correctly; they gave a score of U=0 for no features detected on ultrasound instead of 
U=1.  
In 1999, Tingulstad further modified the RMI II by combining the ultrasound score of 
zero or one to give U=1, whereas for two or more features, U=3 was used in the 
equation. This was described as RMI III, and had a sensitivity of 78% and specificity 
of 92%. The authors concluded that RMI III was the ideal scoring system for referral 
of women with suspected malignant pelvic masses (Tingulstad et al., 1999).  
A more recent study (Kader Ali Mohan et al., 2010),  undertaken in an Australian 
population, compared the performance of all three versions of RMI (I, II and III) and 
reported that the best results were obtained with RMI II, which had 79% sensitivity 
and 88% specificity, compared to 71% sensitivity and 89% specificity for RMI I and 
RMI III, respectively. The authors also concluded that no statistical differences were 
observed in sensitivity and specificity values between the three versions of RMI. 
Similar results were found in a previous study by (Clarke et al., 2009). 
Another study (Yamamoto et al., 2009) described a fourth RMI model (RMI 4) with 
the addition of tumour size score (S) as a fourth parameter. RMI 4 = U x M x S x 
CA125, where a total ultrasound score of 0 or 1 yielded U = 1, and a score of 2 
yielded U = 4. Premenopausal status yielded M = 1 and postmenopausal status 
yielded M = 4. A tumour size (single greatest diameter) of < 7 cm yielded S = 1, and 
≥ 7 cm yielded S= 2. The authors compared the performance of RMI 4 with the 
previous three versions and concluded that RMI 4 was more reliable in discriminating 
malignant tumours from benign than RMI I, II or III when a cut-off value of 450 was 
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used. Nevertheless, due to the retrospective nature of the study, RMI 4 requires 
further validation with a prospective study (Yamamoto et al., 2009).  
It has been recommended that a cut-off value of 200 is to be used for the RMI I in 
District General hospitals and health centres to increase referral to tertiary centres, 
and a cut-off value of 250 in specialized centres to maximize specificity and decrease 
false positives, thus reducing the number of interventions (Enakpene et al., 2009, Chia 
et al., 2008).  
It is documented that scoring systems are beneficial in estimating the risk of 
malignancy in adnexal mass; however, they perform less well when they are used by 
inexperienced examiners compared to experts, as concluded by Van Holsbeke et al. 
(2009).  
In 2011, an evidence review was published for NICE (National Institute for Health 
and Care Excellence) by the National Collaboration Centre for Cancer with the title of 
'Ovarian Cancer: the Recognition and Initial Management of Ovarian Cancer'. The 
recommendation was made in this review to use the RMI I as a malignancy index for 
women with suspected ovarian cancer based on the findings of the recent systematic 
review of diagnostic studies, which indicated that RMI I was superior in term of 
sensitivity and specificity to other comparators (Geomini et al., 2009) (NICE, 2011). 
To summarise, scoring systems still suffer limitation of subjectivity. This is supported 
by the finding of the recent IOTA study, which recommended that simple rule should 
be used as the principal test to characterize masses as benign or malignant in 
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premenopausal women because they perform superiorly to RMI in this particular 
group (Kaijser et al., 2013). 
2.1.2.2.1.4. PMI (Pelvic Mass Index) 
This scoring system combines transvaginal ultrasonography with Doppler; it is 
independent of CA125. PMI assesses grey scale features such as size, laterality, 
presence of solid elements, septae and free fluid, all scoring one point each. The 
presence or absence of positive blood flow on Doppler ultrasound within the septa 
and/or solid component scores 2 points or -2 accordingly. Peripheral blood flow 
within ovarian stroma is not considered significant. The maximum score is 7 and the 
minimum is -2. Scores between -2 and 0 are considered low risk, scores between 1 
and 2 intermediate and scores of greater than 3 are associated with high risk of 
malignancy. Sinha A. et al. (2015) aimed to validate the accuracy of PMI by 
comparing it to the RMI in a large patient cohort. They used 1,486 patients in a 
retrospective study over a seven-year period in a dedicated pelvic masses clinic in 
Wales. The authors explained that PMI is a fast way of estimating the risk of 
malignancy that leads to an accurate and reproducible diagnosis of the mass. They 
concluded that PMI is a useful tool in triaging patients with suspicious ovarian masses 
due to its high sensitivity (90.4%) and NPV (96.9%). When compared to RMI, it 
significantly outperforms RMI in diagnosing malignancy (AUC 0.823 vs. 0.770 
respectively: (Sinha A et al., 2015) 
2.1.2.2.1.5. ADNEX model 
Recently the IOTA group developed a new model called the ADNEX model (the 
Assessment of Different NEoplasias in the adneXa). This model contains three 
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clinical and six ultrasound predictors: age, serum CA125 level, type of centre 
(oncology centres vs. other hospitals), maximum diameter of lesion, proportion of 
solid tissue, more than ten cyst locules, number of papillary projections, acoustic 
shadows, and ascites. Their aim was to develop a risk prediction model to 
preoperatively distinguish between benign, borderline, stage 1 invasive, stage 2 to 4 
invasive, and secondary metastatic ovarian tumours. This huge study was performed 
in twenty-four ultrasound centres in ten different countries with a total of 5,909 
patients (Van Calster et al., 2014). 
Their final ADNEX model is available online at (www.iotagroup.org/adnexmodel/). 
This application has the advantage of calculating the risk even if the serum CA125 
level information is unavailable, despite the decrease in performance. It was found 
that the ADNEX model has the potential to optimize management of women with 
adnexal masses in addition to offering excellent discrimination between benign and 
malignant masses, as alleged by (Van Calster et al., 2014). Moreover, the study 
showed that the proportion of solid tissue and serum CA125 level were the strongest 
predictors, while the type of centre was the weakest predictor, indicating that other 
predictors were determining the malignancy rate. However, in this study, the 
histology results were obtained in all masses because the model was based on patients 
who were selected for surgery, and therefore, the test performance could decrease if 
applied to tumours which were managed expectantly.  
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2.1.2.2.2. Three-dimensional ultrasound 
Three-dimensional (3D) ultrasound was first used in 1989. In gynaecological imaging, 
the advantage of 3D over 2D ultrasound is that it improves the ability to visualize 
complex 3D structures (Prager et al., 2010). 
According to (Kurjak et al., 2000a), three-dimensional display allows the operator to 
visualize many overlapping vessels easily and quickly as well as to assess their 
relationship to other vessels or surrounding tissues. It permits viewing of the 
structures in three dimensions interactively, rather than having to assemble the 
sectional images in the operator’s mind.  
(Kurjak et al., 2003) alleged that 3D sonography, when combined with 3D power 
Doppler, can significantly improve diagnostic accuracy in the assessment of suspected 
ovarian lesions, and supported their conclusion by citing previous studies 
demonstrating that 3D volume acquisition allows for careful evaluation of the internal 
surfaces of the cyst walls for outgrowths not seen by 2D technology (Bonilla-Musoles 
et al., 1995, Merz, 1999). 
Another study that concurred with these findings found that evaluation with 3D 
ultrasound and 3D power Doppler can improve the diagnostic accuracy of ovarian 
tumours, where they had sensitivity of 90%, specificity of 89% and accuracy of 88% 
for prediction of ovarian malignancy when using 3D ultrasound (Laban et al., 2007). 
In contrast, in the most recent review of three-dimensional ultrasound in 
gynaecological clinical practice, Alcazar disclosed that this technique is affected by 
some factors such as machine settings and attenuation, where there is a needs for 
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standardization.  Therefore, it cannot yet be introduced into general practice. In 
addition, the author claims that there is a lack of robust data to support routine use of 
3D ultrasound (Alcázar et al., 2012).  
According to Wu and his colleagues, in their recent review to evaluate the present 
status and development of 3D ultrasonography in imaging the ovary, the three 
dimensions imaging improve spatial orientation and access multiplanar views, which 
provide additional information that can detect lesions not easily diagnosed by two-
dimensional ultrasound. Moreover, they added that 3D ultrasound is a reproducible 
technique that improves the diagnostic accuracy for assessing ovarian cancer. 
However, it still needs more experience in training and operating than 2D ultrasound 
(Wu et al., 2012).  
The role of 3D ultrasound in adnexal pathology is controversial and further research is 
needed in these areas to explore more potential uses of 3D ultrasound, as asserted by 
(Alcázar et al., 2012) and (Wu et al., 2012). 
   2.1.2.2.3. Contrast Ultrasound  
In 2009, a study was conducted to examine the efficiency of intravenous contrast 
ultrasound called SonoVue to discriminate between benign and malignant adnexal 
masses. The authors concluded that ultrasound contrast examination is not superior to 
B-mode ultrasound techniques. Although SonoVue is a safe drug, it is rather 
expensive and the technique involves an intravenous injection. Furthermore, the 
acquisition of the information from the ultrasound image is difficult and the analysis 
is time-consuming, as asserted by the researchers, which makes this technique 
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impractical to use in differentiating benign from malignant masses (Testa et al., 
2009). 
2.1.2.2.4. Doppler 
The Doppler effect enables ultrasound to be used to detect the motion of blood 
(Horskin, 2010). Doppler ultrasound has been used in medicine for almost forty years 
(Boote, 2003). It is used to measure blood velocity by means of Doppler frequency 
shift of the echoes received from red blood cells and allows the assessment of tumour 
vascularity (Rubin, 1994). The concept of Doppler is that malignant neoplasms have 
active blood vessel creation (angiogenesis) compared to normal or benign neoplasms. 
Benign lesions tend to form new tumour blood vessels peripherally from pre-existing 
blood vessels, whereas malignant tumours tend to form new tumour blood vessels 
centrally, as explained by (Jeong et al., 2000). 
There is conflicting evidence as to whether adding colour Doppler imaging to 
ultrasound screening can reduce the rate of false positive test results or not (Tate et 
al., 2010). This is due to two issues that arise from colour Doppler ultrasound: first, 
the assessments are subjective, and second, the assessments depend on the quality of 
the equipment and the settings used (Timmerman, 2000). 
Studies by Guerriero (2001, 1998) focused on the benefits of colour and power 
Doppler imaging to diagnose ovarian cancer. The earlier study explained that 
malignancy is suspected by power Doppler when arterial flow is visualized in an 
echogenic portion of a mass, unlike benign masses that have no similar arterial flow 
or when flow is seen only at the wall of the mass. It was concluded from that study 
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that power Doppler is helpful when B-mode is indecisive and that it could reduce the 
number of false positives and thus increase the diagnostic accuracy in atypical cases.  
In the later study, it was recommended that at least one of the two Doppler techniques 
(conventional or power) should be used in conjunction with B-mode imaging as a 
secondary test (Guerriero et al., 2001, Guerriero et al., 1998).  
A later study by (Tempe et al., 2006) examined the usefulness of colour Doppler in 
the preoperative assessment of ovarian tumours. They concluded that the overall 
effectiveness in diagnosing the type of lesion is enhanced when adding colour 
Doppler to ovarian morphology data.  
All the studies on colour Doppler imaging revealed a significant overlap in Doppler 
flow indices between benign and malignant ovarian tumours (Alcázar et al., 2003, 
Ueland et al., 2003, Van Nagell Jr and Ueland, 1999, Guerriero et al., 1998). 
Furthermore, Ueland (2003) concluded that the addition of Doppler flow studies did 
not improve the diagnostic accuracy of the morphologic index.  
In 2007, a book was published with a chapter titled: Ultrasound in ovarian carcinoma, 
in which the author discussed the performance of ultrasound in detecting 
malignancies based on morphological features and concluded that combining 
morphological and Doppler ultrasound assessment produces an ideal first imaging test 
for possible ovarian malignancies. However, the lower specificity of ultrasound 
requires further imaging evaluation, such as MRI, in patients where ultrasound is 
inconclusive (Webb, 2007).  
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2.1.2.2.4.1. Doppler indices 
In Doppler arterial resistance techniques (Doppler signal analysis), a threshold value 
is used to characterise the mass. Parameters such as Pulsatility index (PI), resistive 
index (RI), and peak systolic velocity (PSV) have been used.  A recent systematic 
review of the accuracy of ultrasonography with colour Doppler in ovarian tumours 
(Medeiros et al., 2009), showed that Doppler can detect malignancy or borderline 
lesions when RI is below 0.5 with a sensitivity of 87% and specificity of 90%. The 
authors concluded that Doppler is a useful preoperative test for predicting the 
diagnosis of pelvic masses and supported an earlier study (Kurjak and Predanic, 
1993), which reported that the presence of vessels in the central, septal, or papillary 
projections, in conjunction with a diffuse vascular arrangement, and RI of less than 
0.4, indicated that the mass was expected to be malignant. A possible limitation of 
this systematic review is the potential bias could be claimed due to all trials included 
were retrospective and there was a lack of blinding in their assessment.  
These results were in agreement with another study (Erdogan et al., 2005) using 
Doppler ultrasound assessment in the diagnosis of ovarian tumours which showed that 
detection of Doppler signals in a solid component offered a precise preoperative 
method to differentiate between benign and malignant ovarian masses.  
The major limitation of RI, PI and PSV is that the range of observed measurements in 
malignant masses overlaps with that observed in benign masses (Kurjak et al., 2003, 
Myers ER. et al., 2006). Therefore, Valentin et al. (1994) described Doppler as an 
impractical approach for diagnosing ovarian cancer from a clinical point of view. This 
argument is supported by another study (Laban et al., 2007), which concluded that RI 
measurements cannot be used alone for the detection of malignant ovarian tumours.  
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Furthermore, the authors explained that the reason for this is that there is considerable 
overlap between the RI measurements of benign and malignant ovarian masses. In 
addition, the overlap in RI range value between benign and malignant masses limits 
the efficiency of the application of threshold values: thus, cut-off values are not used. 
 
Jeong et al. (2000) explained in their study that a comparison of different studies 
shows that no standard has been set concerning which Doppler index to use or what 
cut-off value is most appropriate. However, they found from previous literature that 
resistive indexes (RI) less than 0.4 and pulsatility indexes (PI) less than 1.0 are 
generally considered to be suspicious for malignancy. Additionally, the authors 
disclosed the problems that are associated with Doppler ultrasound, which include 
operator dependence and lack of standard criteria in distinguishing benign from 
malignant waveforms. Moreover, certain Doppler indexes can be misleading in 
premenopausal women due to physiologic alteration in the ovary during the menstrual 
cycle that cause lowered blood vessel resistance, thereby mimicking malignancy. 
2.1.2.2.4.2. Three-dimensional Doppler 
A new technique of Doppler ultrasound provides three-dimensional (3D) imaging. 
Three-dimensional ultrasound was first used in 1989 (Prager et al., 2010). Three-
dimensional ultrasound utilizes the real-time capability of ultrasound to build a 
volume that can be constructed using high-performance work stations. (Hamid et al., 
2011, Nelson, 2006). 
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To date, not enough information has been presented to determine whether 3D imaging 
of the adnexa adds significant information that is not available from conventional 
two-dimensional (2D) scanning (Benacerraf, 2008). 
There are studies reporting that 3D power Doppler ultrasound may be useful for 
distinguishing benign from malignant ovarian tumours (Kurjak et al., 2003, Alcázar et 
al., 2005, Testa et al., 2005, Alcázar and Castillo, 2005). For example, Kurjak and 
colleagues claimed in their study that 3D power Doppler, when combined with the use 
of 3D sonography, will significantly improve the diagnostic accuracy of detecting 
stage 1 ovarian cancer, and supported their conclusion by citing evidence from a 
previous study conducted by (Cohen et al., 2001), which reported that 3D power 
Doppler better defines the morphological and vascular characteristics of ovarian 
lesions.  Another study supported these finding and disclosed that the accuracy of 
diagnosing suspected ovarian lesions is significantly enhanced when using 3D 
ultrasound in combination with 3D power Doppler, and that this approach provides 
better visualization of tumour vascularity and could significantly improve the 
diagnostic accuracy in preoperative sonographic assessment in suspected ovarian 
lesions (Laban et al., 2007). 
Alcazar studied tumour vascularity using 3D power Doppler in the early and 
advanced stages of ovarian cancer and found in his preliminary results that 
vascularization is higher in advanced stage and metastatic ovarian cancer than in the 
early stages (Alcázar, 2006). 
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In a previous group of studies in 1999, the researcher and his colleagues found that 
3D power Doppler imaging can detect structural abnormalities of malignant tumour 
vessels, such as arteriovenous shunts. Therefore, it improves and facilitates the 
morphological and functional evaluation of benign as well as malignant pelvic 
tumours (Kurjak and Kupešić, 1999, Kurjak et al., 2000a, Kurjak et al., 2000b). Later, 
the same group of researchers demonstrated the ability of 3D Doppler ultrasound to 
perform as a secondary test in screening for ovarian cancer and described it as a novel 
approach for early detection of ovarian cancer (Kurjak et al., 2005). 
Other studies suggested the need for further research (Alcázar, 2006, Rieck et al., 
2006) and that it should be used as an adjunct to morphologic assessment (Wilson et 
al., 2006). Although Fishman et. al. (2001) stated that the clinical value of 3D 
ultrasound is promising for early detection of ovarian carcinoma and need to be 
investigated deeply, Dai et al. (2008) concluded that it did not improve the diagnostic 
accuracy for the prediction of malignancy in adnexal masses. Moreover, they further 
highlighted that 2D transvaginal sonography may still remain an important modality 
for the prediction of adnexal malignancy. In a preliminary study on 3D analysis of the 
vascularization of solid masses in the adnexal area, the authors justified the purpose of 
the study by citing the inaccuracy of 2D B-mode and colour/power Doppler to 
differentiate between benign and malignant tumours. They concluded that 3D 
quantitative analysis did not significantly improve the accuracy appreciated by 2D 
Doppler imaging (Testa et al., 2005). 
 In addition, Jokubkiene et al. (2007) found that objective quantification of colour 
signals of the tumour using 3D ultrasound did not appear to add more to B-mode 
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imaging when compared to subjective quantification using 2D power Doppler 
ultrasound. In a recent review, Alcázar and Jurado (2011) determined that additional 
studies are necessary to establish the role of 3D ultrasound in clinical practice in 
gynaecological oncology.   
2.1.2.3. CT imaging 
 
CT has several advantages: it is widely available and can be done rapidly and easily. 
Moreover, CT of the abdomen or pelvis allows comprehensive evaluation of all 
possible sites of the primary tumour. This modality has a major advantage over US 
and MRI imaging, as it allows oral contrast agents to mark the bowel and help 
differentiate bowel from peritoneal implants. Therefore, CT is a very attractive 
method for evaluating the spread of the disease in women with adnexal malignancy. 
Nevertheless, available studies have not proven that CT is significantly superior to 
other modalities in staging ovarian malignancy.  
Jeong et al. (2000) pointed out that many studies have revealed that CT is neither 
sensitive enough nor specific enough to replace laparotomy and that the largest study 
to date comparing US, CT and MRI in the staging of ovarian cancer demonstrated 
little difference between the modalities (Kurtz et al., 1999). 
In contrast, a recent study demonstrated a higher sensitivity and specificity (79.2%, 
91.6%) when compared to transvaginal ultrasound (51.9%, 87.9%) respectively 
(Firoozabadi et al., 2011). However, this study has some pitfalls: for example, the 
examination and interpretation of the scans were carried out by different people, but 
their level of experience was not mentioned, and the sample size was relatively small 
(139 patients) compared to other similar studies.  
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Another study described CT and MRI as complementary imaging techniques and 
further explained that they can be used as an adjunct to ultrasound in specific cases 
but cannot be used as a first imaging modality of choice in tumour staging 
(Fischerova, 2011).  
 
2.1.2.4. Magnetic Resonance Imaging (MRI) 
 
The principle advantage of MR imaging is that it combines some of the best features 
of CT and US. Numerous types of tissue and fluid can be discriminated using MR 
imaging using their signal intensity characteristics. Jeong and his colleagues stated 
that malignant tumours do not have specific MR imaging signal intensity 
characteristics, so these tumours must be distinguished based on morphological 
criteria (Jeong et al., 2000). 
 
In most studies, MR imaging has proved superior and more accurate than endovaginal 
US in differentiation between benign and malignant adnexal masses; however, it is 
more expensive, time consuming and impractical to perform MR imaging in all 
patients with abnormalities (Yamashita et al., 1995, Komatsu et al., 1996, Yamashita 
et al., 1997). 
In 1999, Kurtz and colleagues performed a comparative study to determine the 
optimal imaging modality for diagnosing and staging ovarian cancer. Their results 
showed a noticeable accuracy in demonstrating the extent of the malignant spread for 
all the three imaging modalities (US, CT and MRI) and they all had high staging 
accuracies at ROC curve analysis of 0.91. However, they further explained that MRI 
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is superior to Doppler and CT in accurately diagnosing complex or solid ovarian 
masses at stage 3 malignant lesions (Kurtz et al., 1999).  
In a prospective study of women with suspected adnexal masses, both Doppler 
ultrasound and MRI were highly sensitive for identifying malignant lesions 
(ultrasound 100%, MRI 96.6%); however, the specificity of MRI was significantly 
greater (ultrasound 39.5%, MRI 83.7%): therefore, women who clinically have a low 
risk of malignancy but who have complex sonographic morphology may benefit from 
MRI (Sohaib et al., 2005). 
Similarly, a more recent study by Iyer and Lee described the role of MR, CT and 
PET/CT in detecting ovarian cancer. They found that MR imaging is useful as a 
secondary imaging technique for further investigating masses to define the extent of 
the disease when ultrasound is indecisive.  Lesions that are indeterminate on 
ultrasound can often be diagnosed with high specificity by MRI  (Iyer and Lee, 2010). 
 
A recent systematic review and meta-analysis of the preoperative identification of 
suspicious adnexal masses by Dodge and his colleague is presented in Table 5. The 
results showed that 3D ultrasound has higher sensitivity and specificity when 
compared to 2D ultrasound. Furthermore, morphological scoring systems revealed a 
respectable performance in their sensitivity and specificity. In contrast, colour 
Doppler was neither sensitive nor specific in the assessment of adnexal masses when 
compared to ultrasound. The combination of morphology and Doppler assessment had 
a higher sensitivity and specificity than either modality alone. In addition, of the three 
imaging modalities considered, MRI appeared to perform the best, even though the 
results were not statistically different from CT. Finally, the measurement of the 
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CA125 tumour marker seems to be less reliable than other available preoperative 
methods (Dodge et al., 2012). 
 
Method Pooled 
Sensitivity 
Pooled 
Specificity 
 
Sassone scoring system 
(cut-off point of 9) 
88.6% 77.5% 
Lerner scoring system 
 
90% 63% 
DePriest scoring system 
 
91% 69% 
Risk of malignancy 
index (RMI) 
RMI I  
(Cut off of 200) 
79.2% 91.7% 
RMI II 
(Cut off of 200) 
79% 81% 
RMI III 
(Cut off of 200) 
74% 91% 
Doppler 
sonography 
2D power Doppler 
 
49-100% 74-100% 
3D power Doppler 
 
68%-100% 40-98% 
Resistance index 
(RI) 
77.2% 89.8% 
Pulsatility index (PI) 80.6% 79.9% 
Combined 
morphology and 
Doppler 
2D ultrasound plus 
Doppler 
91% 91.7% 
3D ultrasound plus 
Doppler 
97.8- 100% 79.2- 84.2% 
Other imaging 
modalities 
MRI 
 
91.9% 88.4% 
CT 
 
87.2% 84% 
CA125 
Cut off of 35 U/ml 
78.7% 77.9% 
 
Table 5: Summary of the systemic review of preoperative methods to diagnose adnexal masses (Dodge et al., 
2012). 
Moreover, the most recent systematic review and meta-analysis, performed by Kaijser 
and his colleagues, which focused on the presurgical diagnosis of adnexal masses 
using mathematical models and scoring systems, update the results of previous 
systematic review (Dodge et al., 2012). The findings of this study are summarised in 
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Table 6. This update of the previous systematic review and meta-analysis 
demonstrates that the IOTA simple rule is currently the best diagnostic test available 
for diagnosing ovarian masses in premenopausal women (Kaijser et al., 2014). 
 
Model Cut-off Sensitivity Specificity 
Sassone >9 85% 80% 
Lerner >3 80% 61% 
Depriest >5 90% 68% 
Simple rule n/a 93% 81% 
RMI I 200 72% 92% 
RMI II 200 75% 875 
RMI III 200 70% 91% 
RMI IV 450 68% 94% 
 
Table 6: Pooled summary estimates of sensitivity and specificity in the new systematic review (Kaijser et al., 
2014)
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2.1.2.5. Laparoscopy and Laparotomy 
 
Laparoscopy is the insertion of a thin lighted tube (called a laparoscope) through the 
abdominal wall in order to inspect the inside of the abdomen and to remove tissue 
samples, while laparotomy is a surgical incision made in the wall of the abdomen 
(Myers ER. et al., 2006). The decision for surgery depends on the probability of 
malignancy (Kinkel et al., 2000). Furthermore, laparotomy is performed if there is a 
strong suspicion of malignancy (Benedet et al., 2000), while laparoscopy is frequently 
used in the diagnostic evaluation of adnexal masses. However, laparoscopic diagnosis 
raises concerns about the possibility of tumour spillage due to cyst rupture, which 
correlates with a worse prognosis. In addition, laparoscopy may lead to the diagnosis 
and resection of large numbers of functional cysts and other lesions that could have 
been followed up clinically without surgery. For these reasons, laparoscopy is 
reserved for patients with masses that are non-suspicious based on imaging findings 
(Jeong et al., 2000). 
 
In young women with non-malignant ovarian lesions such as endometriosis and 
benign cysts, treatment with laparoscopy can avoid laparotomy procedures (Jeong et 
al., 2000). Unlike young women, in postmenopausal women who are not suitable for 
conservative management, oophorectomy is recommended by RCOG even when the 
risk of malignancy is low (RCOG, 2003). According to Jeong et al. (2000), 
exploratory laparotomy is necessary in all cases of suspected ovarian cancer to 
confirm the diagnosis, determine the extent of the disease, and to resect the tumour.  
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Recently, a prospective observational study was commenced to assess long-term 
outcomes of expectant management for persistent adnexal masses in asymptomatic 
premenopausal women. They found that expectant management of cysts with benign 
ultrasound morphology is an option, especially as a significant proportion of masses 
resolved spontaneously with a very low risk of torsion (0.4%) and of cancer (0.9%: 
(Alcázar et al., 2013a). 
2.1.2.6. Texture analysis 
 
Image analysis methods are important to assist in detection and diagnosis. They have 
been developed to help physicians acquire diagnostic information and improve 
clinical decisions. Studies show that radiologists do not detect all abnormalities on 
images that are visible on retrospective review and do not always characterize the 
abnormality correctly. This can be caused by limitations in the human eye-brain 
visual system, reader fatigue, distraction, the presence of overlapping structures that 
camouflage disease in images, and the large number of normal cases seen in screening 
programs (Giger et al., 2008). 
 
Therefore, researchers have started to investigate computerized image analysis that 
aims to automate the detection of abnormalities, including analysis of breast images 
and chest radiographs (Toriwaki et al., 1973). However, it has been difficult to 
achieve the accuracy and the acceptance required for clinical use, as asserted by  
Giger et al. (2008). 
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Later, in the mid-1980s, a team of researchers at the University of Chicago dedicated 
their efforts to computer-aided diagnosis (CAD), which means using computer output 
as an aid to radiologists rather than completely automatic computer interpretation 
(Chan et al., 1987, Giger et al., 1987). Furthermore, Giger et al. (2008) defined CAD 
as a diagnosis made by a radiologist who uses the output from a computer analysis of 
the image data in their decision-making process, so that the final medical decision is 
made by the radiologist, not the computer. They explained further that the role of the 
computer analysis is not to replace the radiologist, but rather to aid him/her in image 
interpretation and decision making. 
 
Since then, the growth of CAD has been tremendous over the past twenty years. It has 
spread widely and quickly (Doi, 2007). Currently, CAD has been extended to include 
image analysis of various disease types, such as breast cancer, lung cancer, interstitial 
disease, colon cancer, osteoporosis, and vascular plaque aneurysms, using images 
acquired by different modalities, such as ultrasound, CT, PET, MRI and others. 
 
The goal of CAD is to reduce search, interpretation errors, and variation between and 
within observers. In an ultrasonic image, different tissues always have significantly 
different textures. 
 
Generally, texture of images refers to the appearance, structure and arrangement of 
the parts of an object within the image (Castellano et al., 2004). Texture cannot be 
precisely defined due to its wide variability (Mathias et al., 1999). In digital images, 
the concept of texture may be attributed to the distribution of grey-level values across 
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the pixels of a given region of interest in an image. In other words, texture analysis is 
a technique for evaluating the position and signal intensity characteristics of pixels. 
(Livens et al., 1997, page 581) revealed a more formal definition of texture as “the set 
of local neighbourhood properties of the grey levels of an image region.”  
According to Srinivasan and Shobha, texture analysis refers to a class of mathematical 
procedures and models that characterize the spatial variations within imagery as a 
means of extracting information. They explained in their study that there is no single 
method of texture representation that is adequate for a variety of textures, since 
texture has so many different dimensions (Sirinivasan and Shobha, 2008). 
Texture analysis can be divided into categories such as structural, model-based, 
statistical, and transform, depending on the means utilized to evaluate the 
interrelationship of the pixels (Castellano et al., 2004, Holli et al., 2010). Please refer 
to Figure 4 for an illustration. 
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                                                     Figure 4: Types and sub-types of texture analysis. 
 
In medical images, statistical methods are the most widely used. These methods 
analyse the spatial distribution of grey values by computing local features at each 
point in the image (Sirinivasan and Shobha, 2008). According to Tuceryan and Jain 
(1998), statistics are classified as a first-, second- or higher-order statistics according 
to the number of points which define the local feature. In first-order statistics, image 
properties depend merely on a singular pixel value, whereas second-order statistics 
are properties of pixel pairs.  
Texture analysis 
Transform 
Wavelet 
Structural Model-based Statistical 
Second- or 
higher-order  
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Gradient 
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First-order statistics do not consider pixel neighbourhood relationships. Common 
features include mean grey scale, standard deviation of the mean, skewness (deviation 
of the pixel distribution) and kurtosis (steepness of the pixel distribution), all of which 
can usually be detected visually. The limitation of this method is that it provides no 
information about the position of pixels relative to each other, due to texture analysis 
being based solely on the grey level of the histogram (Sirinivasan and Shobha, 2008). 
The second order statistical method uses grey-level run-length measures and the grey-
level co-occurrence matrix (GLCM). The latter shows how often each grey level 
occurs at a pixel located at a fixed geometric position relative to each other pixel, as a 
function of grey level. In this method, higher discrimination indices are obtained and 
cannot be visually detected. For that reason, second or higher order statistical methods 
are used in medical images texture analysis (Holli et al., 2010). The grey level co-
occurrence matrix (GLCM) is a measurement of an image’s statistical properties, 
visual characteristics, using information theory measure and correlation based 
information. (Xian, 2010) 
The co-occurrence matrix is the joint probability occurrence of grey level of two 
pixels within a defined spatial relationship in an image (Sharma and Singh, 2001). 
This feature will be explained in more depth in Chapter 4. 
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2.1.2.6.1. Application of texture analysis to medical images 
Numerous studies have demonstrated the value of texture analysis in the medical 
field. Image texture of medical images defines the internal structure of human tissue 
or organs (Szczypiński et al., 2009) as well as pathological changes (Xian, 2010).  
Texture analysis techniques in medical images were first reported in the 1960s, and 
acknowledged by Doi (2007). They have been useful in various types of diseases, 
such as diseases of the liver (Lee et al., 2003), thyroid (Smutek et al., 2003), breast 
(Alacam et al., 2003, Ramos et al., 2012), kidney, pancreas (Das et al., 2008), heart 
(Tsai and Kojima, 2005) and coronary arteries (Nailon et al., 1996) as well as brain 
tumours (Herlidou-Même et al., 2003). 
Texture analysis has also been applied to several imaging modalities such as 
ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), 
conventional x-ray and mammography. According to (Tsai and Kojima, 2005), the 
employment of texture analysis in medical imaging has proven to be valuable, 
especially for MRI, CT and ultrasound. Most of the previous works done in texture 
analysis encompass MRI images due to the great amount of details provided by this 
technique (Castellano et al., 2004). Texture analysis of all kinds of images is possible 
and has been achieved in literature. 
2.1.2.6.1.1. Texture analysis of ultrasound images 
Many researchers have focused their studies on quantifying the echo signal in B-mode 
scans. The principle of texture analysis in ultrasound images was explained by 
(Morris, 1988): if the structure of the tissue is affected by the disease process, this will 
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result in alteration of the ultrasound signal, meaning that the statistical measures will 
differ from those of normal tissue. For example, the transformation of cancerous 
tissue will change the tissue characteristics, such as density and elasticity. Therefore, 
textural features derived from cancerous tissue will differ from normal tissue based on 
the above-mentioned principle. 
Nailon and Spencer investigated the use of the statistical texture analysis technique to 
assess intravascular ultrasound in order to characterize intracoronary thrombus. 
Results from their study were difficult to interpret due to their relatively small data set 
(Nailon et al., 1996). 
Similarly, Vince and colleagues conducted a study that aimed to evaluate five texture 
analysis techniques and determine their ability to distinguish between plaque lesions 
of different compositions and found two of them to be adequate (Vince et al., 2000). 
In 2003, Smutek and colleagues used texture analysis in ultrasound to diagnose 
chronic inflammation of the thyroid gland. Their results showed that it is possible to 
gain objective, quantitative characteristics of the thyroid gland and use it for tissue 
classification (Smutek et al., 2003). 
Similarly, texture analysis was used to aid in the classification of breast tumours using 
ultrasound (Huang et al., 2008). Their results showed that analysis of sonographic 
characteristics can assist in differentiating between benign and malignant lesions. This 
study was in agreement with an early preliminary study done in 1988, which 
explained that texture analysis systems were applied successfully to tissue 
characterization in breast tumours. It concluded that applying texture analysis to a 
   
66 
 
binary classification of tumours into benign and positive classes was possible. 
Moreover, the application of texture analysis to the population studied reduced the 
incidence of false positive diagnosis by 40% when compared to cases of tumours that 
were readable by ultrasound. They also suggested that texture analysis is superior to 
professional radiologist working with the same images.  
In another study conducted by Chen et al. (2002), wavelet transform was used to 
diagnose solid breast masses and this performed well for breast tumour diagnosis. 
Texture analysis has also been studied extensively on liver-related diseases. A recent 
study by Xian (2010), using ultrasound, showed that the grey-level texture features 
technique was a feasible and excellent classification of liver tumours. Texture analysis 
can improve the diagnostic rule of the B-mode ultrasound images, as asserted by 
Vicas et al. (2011), who studied texture analysis as a non-invasive tool for the 
assessment of chronic hepatitis C. However, the role of human experts could not be 
reduced or eliminated in this study. 
In a slightly different field of ultrasound, a study was conducted to evaluate some of 
the analysis techniques in monitoring follicular response in ovulation induction. It 
demonstrated that analysis of ultrasound images can aid in developing a reliable non-
invasive technique to improve the clinical management of women undergoing ovarian 
stimulation (Pierson and Adams, 1995). 
Texture analysis of ultrasound images has also been applied to prostate cancer. In 
1993, Basset and colleagues used second-order statistics, namely co-occurrence 
matrices, to identify prostate tumours. Their results yielded fairly good tissue 
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signatures obtained with parameters derived from these matrices. In addition, 78% of 
the samples were classified with success, which was a high score considering that the 
images could not be discriminated visually (Basset et al., 1993). 
Braeckman and colleagues studied computer-aided ultrasonography for detecting 
prostate cancer using an ultrasound-based technology called HistoScanning. This is a 
technology that detects specific changes in tissue morphology by extracting and 
quantifying statistical features from backscattered ultrasound data. Furthermore, it has 
been developed to distinguish cancerous and noncancerous tissues in solid organs. 
They concluded that HistoScanning is an accurate non-invasive method to detect 
cancer foci and suggested that it might be useful as a triage test for prostate cancer 
(Braeckman et al., 2008b, Braeckman et al., 2008a). 
More recently, an attempt to create an online paradigm to characterise ovarian 
tumours was made by Acharya and colleagues. They used 3D transvaginal images in 
their analysis and applied several texture features including GLCM and Run Length 
Matrix (RLM). It was concluded that the use of CAD techniques using a combination 
of four texture features techniques has a good sensitivity of 94.3% and specificity of 
99.7% and has the advantage of being objective. However, this system has been tested 
on only twenty cases and needs to be clinically validated to assess the diagnostic 
accuracy of this method (Acharya et al., 2013). 
2.1.2.6.1.2. Texture analysis of CT images 
Texture analysis has also proven to be beneficial in improving the interpretation of 
CT images. For example, Gletsos et al. ( 2003) studied the grey level co-occurrence 
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matrix technique as a method to classify four types of liver tissue: normal liver, 
hepatic cysts, haemangioma and hepatocellular carcinomas. Another study 
investigated the feasibility of the same technique on CT images of interstitial lung 
diseases and reported a sensitivity and specificity of 73-93% and 90-98% respectively 
(Xu et al., 2006). 
Two most recent studies were initiated by the same group (Kumar and Moni): the 
first, in 2010, studied the characterization of liver tumours by CT and disclosed 
promising results, recommending the technique to be applied in the diagnosis of other 
types of liver disease. The second study, in 2012, proposed an automated computer-
aided diagnosis (CAD) system for recognizing different types of liver tumours by 
analyzing tumour texture images using texture recognition techniques. They achieved 
94% accuracy of the classifier when compared to other methods. In addition, they 
suggested that the proposed system can be extended to the diagnosis of other types of 
liver diseases as well (Kumar et al., 2012). 
2.1.2.6.1.3. Texture analysis on MRI images 
Similar to CT images, texture analysis has been also demonstrated to be useful in 
improving the interpretation of MRI images. It was first applied in the early 1980s 
(Herlidou-Même et al., 2003). Texture analysis has the advantage of discriminating 
complexity and offers information that is not visible to the human eye (Herlidou-
Même et al., 2003). 
Texture analysis on MRI images has been applied to multiple sclerosis related studies. 
In 1999, a study commenced using texture analysis to quantify the pathological 
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changes that occur within the spinal cord associated with multiple sclerosis. The 
spatial grey-level co-occurrence method was used in this study, justifying it from 
previous studies that applied this method in relevant application and because it 
performed well for small regions. Their results showed significant differences in 
texture between normal and multiple sclerosis images. Furthermore, texture is 
valuable in detecting changes in pathology early in the disease before spinal cord 
atrophy occurs (Mathias et al., 1999). Another recent study on multiple sclerosis 
achieved an accuracy of 88.4% (Theocharakis et al., 2009). 
According to Harrison et al. (2010), when classification of white matter and multiple 
sclerosis lesions were studied, excellent distinction was achieved when using texture 
measures with an accuracy between 96% and 100%. In the same year, another study 
demonstrated significant changes in texture measures of cerebral tissue between 
hemispheres and corpus callosum segments in traumatic brain injury patients. It was 
suggested that this technique may be used as a novel additional tool for identifying the 
invisible changes in cerebral tissue in mild traumatic brain injury, aiding clinicians to 
make an early diagnosis (Holli et al., 2010). 
2.1.2.6.1.4. Texture analysis on Mammography images 
A recent study conducted by (Ramaraj and Raghavan, 2011), which focused on 
wavelet techniques for cancer diagnosis, found that the wavelet transform is an 
excellent tool to investigate mammograms, MRI and ultrasound breast images. These 
results are in agreement with a previous study in 2007 where a high accuracy rate was 
found (89%) when investigating the feasibility of texture analysis in differentiating 
benign from malignant breast tissue (Karahaliou et al., 2007). 
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Beside ultrasound, CT, MRI and mammography, texture analysis techniques have 
also been applied to other imaging modalities, such as colposcopic imaging (Ji et al., 
2000) optical tomography (Baroni et al., 2007, Gossage et al., 2003) and capsule 
endoscopy (Li and Meng, 2009).  
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2.2. Summary 
Ovarian cancer is the second most common gynaecological malignancy; however, it 
remains the leading cause of death among these diseases. In spite of the diagnostic 
and therapeutic advances in the care of women with ovarian cancer, the overall five-
year survival rate remains unchanged. The reason for this is that most cases are 
diagnosed in the late stages of the disease, when the five-year survival rate falls below 
20%.  
Therefore, early detection of ovarian malignancy is of great clinical importance. 
Ultrasonography is currently considered the primary imaging modality for diagnosing 
adnexal masses. However, ultrasound is operator-dependent and thus the accuracy and 
reproducibility of the diagnosis are subject to the experience of the operator. 
In order to reduce operator dependency, texture analysis, which is able to 
quantitatively characterize tissue through texture content, will be used in this study to 
objectively differentiate between normal, benign and malignant ovarian tissue.  
Texture analysis is defined as the spatial distribution of the pixel grey value 
(intensity) of B-mode images. It is a descriptor of local brightness variation from pixel 
to pixel in a small neighbourhood through an image. Two features of texture analysis 
were tested in previous pilot research and suggested to be robust and demonstrated 
good repeatability in characterizing ovarian malignancy: these are grey level co-
occurrence matrix (GLCM) and wavelet analysis. Therefore, they will be used in this 
study, along with applying another modality called Acoustic Structural Quantification 
(ASQ). 
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A previous pilot study suggested that texture analysis is beneficial in objectively 
differentiating ovarian lesions (Hamid, 2011).  This study will involve a large number 
of patients and is expected to help confirm and validate the sensitivity and specificity 
of this method. 
The texture analysis technique will be compared to widely-used scoring systems such 
as the Risk of Malignancy Index (RMI), the Pelvic Mass Index (PMI) and the 
ADNEX model, and the ASQ texture analysis technique, will also be applied. 
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3. Acoustic Structure Quantification 
(ASQ) 
 
This chapter will introduce and test a new method called ASQ. It is divided into four 
main sections: section A will include a definition of the new term, followed by some 
background information and a phantom study where the repeatability and 
reproducibility will be tested, while section B will study the influence factors, such as 
ROI size, ROI depth, Focus, Gain setting and frequency, on ASQ. Then, in section C, 
the influence of pre-defined image parameters on ASQ output will be discussed. 
Lastly, section D will demonstrate the application of ASQ to images of benign and 
malignant masses. 
3.1. (A) Introduction, how ASQ works and 
background  
 
Ultrasonography represents an excellent examination modality that is non-invasive, 
inexpensive and can be performed repeatedly with no risk to the patient. However, the 
diagnostic performance of ultrasonography in general depends on the empirical and 
qualitative reading skills of the examiner (Kuroda et al., 2012). The human eye cannot 
distinguish between more than fifteen to twenty shades of grey in ultrasound images 
(Lagalla and Midiri, 1998): it is therefore worthwhile developing a new technique that 
can overcome these limitations. 
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Acoustic structure quantification (ASQ) is new software that analyses the statistical 
information of the acquired (receiving) echo signals (Toshiba Medical Systems, 
Europe). This is accomplished by looking at the speckle pattern in a certain region of 
interest (ROI) (De Kant, 2011). It is a non-invasive tool that can assist the ultrasound 
operator in the assessment, characterisation and follow-up of fibrotic disease during a 
standard ultrasound scan. Liver ASQ assesses tissue homogeneity quantitatively and 
depicts tissue properties in a convenient colour-coded display. Therefore, the aim of 
this chapter is to investigate the suitability of ASQ in diagnosing ovarian cancer. 
3.1.1 How ASQ works 
 
Although ASQ is ready-to-use software, it was thought that a brief explanation of how 
it works is necessary.  It is a software that analyses the statistical information 
contained in the received echo signals: it takes the raw data in a ROI and then 
analyses the speckle pattern, which produces a parametric image and quantification of 
tissue type for tissue characterization. Some basic concepts of ultrasound have to be 
introduced to understand the ASQ concept. These include the origin of ultrasound 
speckle, the Probability Density Function (PDF), the χ2 function, and the modified χ2 
function called C
2
.
 
Having explained these concepts, the process of how ASQ works 
can be understood. First, the ultrasound speckle is a random, deterministic 
interference pattern in an image formed when ultrasound interacts with many sub-
resolution scatterers. This speckle pattern is an interference pattern formed as a result 
of ultrasound scatter. 
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In general, for a simple reflection, the dimensions of the reflecting surface must be 
greater than several wavelengths of the ultrasound wave. When small targets, smaller 
than the wavelength of ultrasound, are scanned, it will cause scatter called Rayleigh 
Scattering. Please refer to Figure 5: 
 
 
 
 
 
 
 
 
 
 
Figure 5: Rayleigh scattering (adopted from Toshiba catalogue)  
 
Therefore, a tissue composed of structures < λ of the ultrasound will produce a 
speckle pattern. The texture of the observed speckle pattern as a result of scattering 
does not correspond to the underlying structure, which means no spatial information. 
The local brightness (amplitude) of the speckle pattern, however, does reflect the local 
echogenicity of the underlying scatterers. 
 
Because speckle is random, the echo signal from scatterers alone has a zero mean, 
two-dimensional Gaussian probability density function (PDF). This is the Rayleigh 
PDF, a function that describes the relative likelihood that this random variable will 
take on a given value (De Kant, 2011). Please see Figure 6. 
• 
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Figure 6: Rayleigh PDF 
 
This means in practice that if tissue is made up of scatterers alone (no reflective 
surfaces), the resulting image is a representation of the PDF for that tissue. 
Second, the χ2 function is simply a statistical test which compares one distribution 
against another. Please refer to equation 3. 
 
 
Where  
 
                                                                 Equation 3: The χ2 function 
If the sample is exactly the same as the normal population, χ2  = 1. 
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Therefore, when ASQ is first applied, it uses a modified χ2 called C2. Where C2 is 
divided by degree of freedom (n-1) to get the averaging and normalize the test. Please 
see equation 4. 
 
         
 
Equation 4: C
2 
equation 
Secondly, a population variance is required that corresponds to normal liver; however, 
it is difficult to achieve in a diseased liver, and it is also difficult to use a standard 
value from the normal livers of other patients, because the variance changes due to 
machine settings, overlying tissue etc. 
So to overcome this problem, we calculate an approximate value from the average of 
samples taken in the user defined ROI by applying certain thresholds, then: 
 
Equation 5 
 Thresholds are also applied to calculate a modified     , so  
 
                                   
Equation 6 
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Finally we get ASQ: 
 
                                   
 
Equation 7: ASQ equation 
 
To produce Cm
2
 a large ROI is drawn, avoiding reflective surfaces. Many (~300) 
small secondary ROIs (about twice the size of the resolution of the system) are 
automatically created within the large ROI. This raw data is stored as a 2x2 matrix for 
and the mean and variance in each small ROI is then calculated. A histogram of Cm
2 
to then produced.   
 
If the tissue is completely homogenous, then Cm
2
 =1 and the histogram will show a 
normal distribution because the sample (numerator) and the normal tissue 
(denominator) will be the same. Please see Figure 7. 
 
Figure 7: normal distribution in histogram of a homogenous phantom. 
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However, if the sample variance (numerator) is different due to heterogeneity in the 
sample, Cm
2
 >1 the bandwidth of the histogram will increase and the curve will be 
shifted to the right: please refer to Figure 8. 
 
               
Figure 8: Example of homogenous tissue histogram and non-homogenous tissue. 
 
If there is a point reflector in the image, it will show as discrete, high amplitude 
signals, which will affect the Cm
2
 curve (produce a tail to the curve). This tail is 
removed from the analysis and displayed as a separate entity called the blue curve. 
Please refer to figures 9 and 10. 
 
Figure 9: The tail in the curve produced by a discrete high amplitude signals. 
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Figure 10: The blue curve in the histogram. 
 
Additional analysis information produced in the ASQ software is the Q-Q graph. This 
graph shows the variation between the “normalised” PDF (calculated denominator) 
and a theoretical PDF. The more closely these lines are matched, the better the 
denominator value used in the         (Please refer to Figure 11). 
 
Figure 11: The Q-Q graph in ASQ window. 
 
2
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ASQ offers two modes of presentation: the first is a statistical graph, which draws 
distribution curve parameters in response to the fibre structure that reflects the 
ultrasound beam (shown in figure10). The second display is like familiar images with 
colour Doppler of the different values superimposed on a B-mode image (Hung, 
2010). See figure 9. 
 
A PDF (probability density function) graph is similar to a histogram: it is of a random 
variable and is a function which describes the density of probability at each point in 
the sample space (De Kant, 2011) 
     
3.1.2. ASQ background 
 
This valuable diagnostic tool allows the clinician to perform comprehensive 
ultrasound diagnostic in specific regions of the body, such as the abdomen (Toshiba 
Medical Systems, Europe).  
Toshiba Medical Systems Europe introduced the new ASQ technology in Zoetermeer 
in the Netherlands in October 2009. It is a newly developed advanced clinical 
application that can analyse echo signal data at more than 100 times higher resolution 
than normal greyscale or colour flow images using a special hardware extension 
(Toshiba Ultrasound raw data interface). 
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Naohisa Kamiyama, the designer of ASQ, explained that most ultrasound units are 
unable to accept pure acoustical radio frequency (RF) data: instead, only selected 
segments of this signal are extracted for display on the typical B-mode image seen on 
the screen. Moreover, ASQ begins with a signal processor that receives the raw RF 
signal and extracts data that possibly indicate extremely small structures or fibre 
strands (Brosky, 2009). 
 
“ASQ analyses the spatial echo patterns in a region of interest 
selected by the user on a greyscale image acquired during the 
normal ultrasound examination. ASQ operates in the background 
with the raw data from this region and extracts a parameter and 
its complete probability distribution curve, related to the 
homogeneity or smoothness of the structures reflecting the 
ultrasound beam sent by the Aplio AG into the body”. 
(Explains Dr. Noahisa Kamiyama from Toshiba ultrasound R&D 
who has designed the ASQ algorithm). The parameter may 
indicate pathologic changes of tissue, e.g. fibrotic transformation 
of liver paranchyma. (Medical Physics, 2009 (online)) 
 
ASQ is expected to be less subjective and operator dependent than conventional 
ultrasound imaging. ASQ offer qualitative visual results (parametric imaging) as well 
as quantitative results (De Kant, 2011). 
Since 2009, several studies have tested the efficiency of ASQ on liver diseases. 
Toyoda and Kumada 2009 conducted a study in late 2009 that reports the relationship 
between data analysis by ASQ and liver histology results for 148 cases. They 
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confirmed that ASQ results closely match histological classification of patients 
(Toyoda et al., 2009). 
In early 2013, a study was performed in China to assess the diagnostic value of ASQ 
technology in both homogeneous fatty liver and chronic hepatitis B infected liver. A 
total of 205 patients were included in this study. The researchers in this study 
concluded that ASQ quantitative parameters can reflect the severity of homogenous 
fatty liver to a certain extent (Wang et al., 2013). Later in the same year, a similar 
study was done in Italy but on hepatic fibrosis. ASQ diagnostic accuracy was 
compared against liver biopsy and it was concluded that ASQ is a promising new 
technology which offers encouraging results in the diagnosis of both liver cirrhosis 
and fibrosis. Nevertheless, to date, it has not reached sufficient diagnostic 
performance to replace current methods (Ricci et al., 2013). 
A similar study to test the efficacy of ASQ was carried out on Japanese patients with 
hepatic stenosis, with a relatively small sample of 42 patients. The results suggest that 
ASQ is a useful technology for evaluating tissue characteristics of hepatic stenosis 
and its follow-up (Onodera, 2013). 
However, no research has been done on the reliability and reproducibility of this new 
technique. Therefore, this chapter will test ASQ for repeatability and reproducibility 
and determine factors that affect ASQ output. 
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3.2. Repeatability and reproducibility (Phantom 
studies) 
 
The objective of this section is to determine the variability and reliability of image 
ASQ caused by random variation during image acquisition, which will affect the 
reliability of the ASQ technique. This will include three subsections, which are to 
determine: 
I. The repeatability (consistency) of the image produced due to variation caused 
by the ASQ software. 
II. The repeatability (consistency) of the image produced due to the random 
variation caused by the operator. 
III. The reproducibility (agreement) of the images acquired by two operators 
under identical conditions: by how much are the two likely to differ? 
Intra- and inter-operator repeatability and reproducibility are important variables that 
permit investigation and examination. The reliability of the imaging technique may 
affect the accuracy of the diagnosis: therefore, it is essential to understand the 
reproducibility and repeatability of the ultrasound image (Li et al., 2004). In addition, 
it is necessary to confirm that a single operator can obtain the same results when 
repeated measurements are made using the same method under identical conditions, 
as asserted by (Bailey et al., 2007). Since ultrasound is an operator-dependent 
modality, the degree of variation caused by the operator (intra-operator) must also be 
recognised to ensure that the application of the ASQ technique in ultrasound is 
reliable. 
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The B-mode ultrasound image is exposed to many confounders, which include 
instrumentation, scanning and reading protocols and operator variables. Therefore, the 
validity and reliability of imaging assessments are very important aspects for use in 
routine clinical practice and research. 
In this study, repeatability refers to the reliability of the instrument (ASQ software) 
and the operator in producing a consistent image (in terms of its texture) when 
repeated within a short period of time under identical conditions, while reproducibility 
refers to the agreement between two operators performing a similar scan. 
3.2.1. Materials, methodology and statistical analysis 
The aim of this section is to describe the key topics related to this study. It is divided 
into two main sections. The first section describes the materials used in this study 
with an overview of the equipment and the statistical tests used. This includes 
Ultrasound principles and Transvaginal transducer. The second section discusses the 
methods used and the procedures followed to accomplish this study, and then briefly 
explains both the Coefficient of Variation (CoV) and the Bland-Altman plot, which 
are the statistical methods used in this section. 
3.1.3.1. Materials 
3.1.3.1.1. Ultrasound scanner:  
Ultrasound is an effective and safe investigation tool that can answer a number of 
clinical questions without the use of ionising radiation (Guy, 2008). It has the 
advantage of being non-invasive, safe, readily available and inexpensive when 
compared to other imaging modalities (Lee et al., 2005). Moreover, Barnett (2000) 
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disclosed that in general, simple B-mode imaging does not produce harmful 
temperature increases in tissue. 
Ultrasound scanner machines were first used in the medical field in the late 1960s, 
and it is becoming increasingly important as a diagnostic imaging device. Toshiba 
Aplio (Toshiba Medical System, Europe) was used to scan the participants and 
acquire the images for this study (see Figure 12). The specifications of this scanner 
are given in Appendix I.   
                  ………………  
 Figure 12: Ultrasound machine by Toshiba. 
 
3.1.3.1.2. Ultrasound Transducer:  
 
An ultrasound scanner works by sending high frequency sound pulses into the 
patient’s body. The sound waves travel through the patient’s body, passing through 
different types of tissue. The speed of sound varies with different tissue types: for 
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instance, the average speed of sound through human tissues is 1540 m/s; the speed of 
sound through fat is 1459 m/s and it passes through bone at 4080 m/s. Whenever 
sound encounters two adjacent tissue types with different acoustic properties, a 
proportion of the sound energy is reflected. These boundaries between different tissue 
types are called acoustic interfaces. The physical property of tissue that describes how 
much resistance an ultrasound beam encounters as it passes through a tissue is called 
Acoustic impedance. It depends on: the density of the tissue (d, in kg/m3) and the 
speed of the sound wave (c, in m/s), and they are related by: 
Z = d × c                 Equation 8: Acoustic impedance 
 
So, if the density of a tissue increases, impedance increases and if the speed of sound 
increases, then impedance also increases. The ability of an ultrasound wave to transfer 
from one tissue type to another depends on the difference in impedance of the two 
tissues. If the difference is large, then the sound is reflected (Rumack, 2005) 
 The scanner calculates the distance from the probe to the acoustic interfaces based on 
the time taken for echoes to return to the probe. The distances and intensities are then 
displayed on a screen to form a two-dimensional (2D) image (see Figure 13). 
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Figure 13: how an Ultrasound scanner works 
 
An ultrasound image is composed of array of pixels of different density. Each pixel 
represents a discrete intensity that results from the reflection of the ultrasound beam. 
An image is composed of thousands of pixels. It is represented by one of 256 (0 to 
255) shades of grey ranging from black (represented as ‘0’) to white (represented as 
‘255’ – (Sanders, 1998). 
The transducer probe is any device that converts one form of energy to another. In 
the case of ultrasound, the transducer converts electrical energy to mechanical energy 
and vice versa.  In other words, it is the part of the machine that produces the sound 
waves and receives the echoes (Rumack, 2005, Sanders, 1998). It consists of one or 
more crystals in a plastic housing. These crystals are called piezoelectric (PZ) 
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crystals. Transducers used in medical ultrasound employ the piezoelectric effect to 
generate sound waves and detect echo signals. The piezoelectric effect was discovered 
in the 1880s. Langevin found that when a force is applied perpendicular to the faces 
of quartz crystal, an electrical charge results (Rumack, 2005). This charge can be 
detected and amplified, producing a useful electrical signal. Conversely, if an 
electrical signal is applied to the crystal, the crystal vibrates, sending a sound wave 
into the medium: hence the dual action of the piezoelectric transducer as a detector 
and transmitter of acoustic signals (Zagzebski, 1996, Rumack, 2011). This signal is 
then processed to form the ultrasound image and displayed on a screen. The same 
piezoelectric crystals are used for sending and receiving the ultrasound pulses: 
therefore, they have to operate in a switched or pulsed mode. This means that they 
emit a quick sound pulse, rest and then listen for the echo. This switching between 
transmitting and receiving modes happens many thousands of times a second 
(Sanders, 1998). The most commonly used crystals are lead zirconate titanate. The 
matching layers (plastic nose) lie in front of the transducer element and provide an 
acoustic impedance difference between the transducer element and the skin. A 
damping material such as rubber is attached to the back of the transducer element to 
decrease secondary reverberations of the crystal with the returning signals. 
Decreasing the ring time results in an increase in depth resolution – see Figure 14. 
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Figure 14: Ultrasound Probe components 
 
Ultrasound probes are designed so that they can be positioned as close to the subject 
tissue as possible so that resolution can be kept as high as possible. For this reason, 
specially designed probes are available that can be inserted through different cavities 
of the body, such as the oesophagus for examination of the stomach, the vagina for 
examination of the uterus and the ovaries and the rectum for examination of the 
prostate gland. 
The Transvaginal transducer is widely used for scanning the female reproductive 
system in general and for ovarian cancer diagnosis in specific. It has several 
advantages over the Transabdominal transducer, as summarised in Table 7. The Royal 
College of Obstetricians and Gynaecologists suggested in its guidelines that ovarian 
cysts should normally be assessed using Transvaginal ultrasound: the reason for this is 
that it provides superior quality (more detail) than the Transabdominal method 
(RCOG, 2003). 
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In the present study, a 6.0 MHz Toshiba Transvaginal transducer model PVT-661VT 
was used to scan the participants (see Figure 15) 
 
 
Figure 15: Transvaginal Ultrasound probe 
 
Advantages of Transvaginal Sonography 
 
 
Use of higher-frequency transducer with better resolution. 
Examination of patients who are unable to fill their bladder. 
Examination of obese patients. 
Evaluation of retroverted uterus. 
Better distinction between adnexal masses and bowel loops. 
Better characterisation of the internal characteristics of a pelvic mass. 
Better detail of a pelvic lesion. 
Better detail of the endometrium. 
 
Table 7: Advantages of transvaginal transducer (Rumack, 2011) 
According to (Lagalla and Midiri, 1998), the quality of an ultrasound image is 
associated with its ability to represent the real anatomy of the structures being 
examined as closely as possible. This capability depends on the axial spatial 
resolution, the lateral spatial resolution and the contrast resolution. 
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The axial spatial resolution refers to the capability of the ultrasound system to 
represent separately objects which are arranged along the axis of the beam. This 
parameter is highly dependent on the transducer frequency: the higher the transducer 
frequency, the better the axial resolution. However, this causes a decrease in the depth 
of beam penetration.  
The lateral spatial resolution refers to the system’s ability to discriminate between two 
objects situated at the same depth perpendicular to the ultrasound beam. This 
parameter is dependent on the dimension of the US beam and it can be improved by 
using a narrow beam (Lagalla and Midiri, 1998). 
The contrast resolution refers to the US system’s ability to distinguish differences 
between neighbouring tissue regions. This parameter is dependent on the spatial 
resolution and the image noise. 
Similar to other types of endo-cavity transducer, the advantage of the Transvaginal 
transducer is that it can be placed in close proximity to the organ under investigation 
(please refer to Table 7). Hence, there is less attenuation from overriding tissue, and a 
higher frequency can be used to increase the axial resolution. Furthermore, image 
distortion and artefacts due to tissue heterogeneity or a strongly reflecting interface 
between the transducer and the organ are also reduced (Whittingham and Martin, 
2010). 
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3.1.3.2. Methods  
An original guide document by the National Physical Laboratory (2005) was used for 
the experimental setup for the repeatability test. It was titled: “Measurement Good 
Practice Guide No. 52” (Laboratory, 2005). 
“The repeatability of the measurement can be quantified in either 
of 2 ways: 
I. Set the equipment to perform a number of consecutive tests 
(e.g. 10) using identical conditions and without removing 
the specimen between measurements. In this case, the only 
variables are those relating to the performance of the 
measurement system and associated statistical (random) 
effects in data capturing and analysis by the software. For 
simplicity, this will be referred to as ‘instrument-only 
repeatability’. 
II. As above, but with the specimen removed completely in 
between measurements. In this case, effects due to 
variability in the test set-up are introduced. This will 
include resetting the device and the precision of 
repositioning the sample. This will be referred as the 
‘instrument-operator repeatability’“ 
 
3.1.3.2.1. Intra-operator Repeatability  
 
The objective of this section is to assess the reliability (consistency) of the images 
produced in ASQ due to the random variation caused by the operator. 
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The operator acquired a series of ten images using the Toshiba Aplio scanner using 
three different transducers; the 6.0 MHz Transvaginal transducer (model PVT-
661VT), the linear transducer (model PLT-7045BT) with 7.5 MHz and the curve 
transducer (model PVT-375BT) with 3.5 MHz. The transducer was removed from the 
test object in between scans, where 10 images are acquired for each transducer. Please 
refer to Figures 17, 18 and 19 for images of the different types of transducers. 
An RMI phantom model 403 GS LE was used as a test object (see Figure 20). The 
machine setting was kept constant across image acquisition processes; it was set to the 
manufacturer’s pre-defined setting: Endo-Vaginal-Gynae. The ASQ button was 
enabled before taking the images. They were then saved as raw data images on the 
machine. The images then were transferred to the PC in DICOM files for further 
analysis. A large ROI (see Figure 16) was drawn in the centre of the image using PC-
ASQR version 1.11R001 software. 
 
Figure 16: ASQ window with large ROI 
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A coefficient of variation (CoV) was calculated for each transducer. The ultrasound 
repeatability CoV reflects the variability of the images due to random variation in the 
scans caused by the operator. The lower the COV, the smaller the variation between 
repeats, and therefore the higher the repeatability (Bailey et al., 2007). 
To assess the reliability of the ASQ software, ten consecutive ROI were drawn in the 
same image in the ASQ window after images were transferred as a DICOM file to a 
PC. The Mean (µ)  and Standard Deviation (SD) were calculated as well as the CoV 
for each transducer image. 
 
Figure 17: Linear Probe                                      Figure 18: Convex probe 
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Figure 19: Transvaginal Probe (TV) 
 
 
Figure 20: Images of RMI phantom model 403 GS LE 
 
 
3.1.3.2.2. Inter-operator Reproducibility  
 
To assess the reproducibility, all scanning procedures were performed by two 
operators. The first operator performed the scan, and after he finished, the second 
operator performed his scan. Between scans, the transducer was repositioned. This 
procedure was repeated for the three different transducers. All machine variables were 
kept constant, such as transducer frequency, focal position and gain setting, as well as 
the depth and size of the ROI when using the ASQ software to draw the ROI. 
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3.1.3.2.3. Coefficient of Variation (CoV) 
 
 The standard deviation (SD) of a set of measurements is often used to describe the 
variability by expressing the SD as a percentage of the mean. The resulting measure is 
called the Coefficient of Variation (Armitage et al., 2009, lang and Secic, 2006a). See 
equation 8. 
CoV = (SD/mean) x 100% 
Equation 9:  Coefficient of Variation 
The Coefficient of Variation (Cov) is used to measure the consistency of the data (the 
uniformity in the data from the mean) (Bruton et al., 2000). It has the advantage of 
being independent of the units of observation (Altman, 1995). Furthermore, the CoV 
is widely used to measure random error (Dudely, 2010). In this study, CoV was used 
to determine the variation (consistency) in the ASQ software repeatability, intra-
operator repeatability and influence of the ROI size variance on the mean. 
 
3.1.3.2.4. Bland-Altman plot 
 
The Bland-Altman plot is used for assessing the agreement between two methods of 
clinical measurement. It is a scatter plot with the difference of the two measurements 
for each sample on the vertical axis and the average of the two measurements on the 
horizontal axis. Three horizontal reference lines are superimposed on the scatter plot: 
one of them at the average difference between means (x-axis values), along with two 
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lines to mark the upper and lower control limits of plus and minus 1.96   
respectively, where  is the SD of the measurements mean differences. The graphical 
approach that plots differences against means is the most informative approach 
(Bassani et al., 2007). The presentation of the 95% limits of agreement is for visual 
judgement of how well two methods of measurement agree: the smaller the range 
between these two limits, the better the agreement is (Myles and Cui, 2007). 
 
In this study, the Bland-Altman plot was used to show the amount of disagreement 
between two different operators and to represent reproducibility visually. 
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3.1.3.3. Results 
 
3.1.3.3.1. Intra-operator repeatability  
 
Ten consecutive images were acquired from the test object.  The CoVs for the three 
different transducers ranged from 1.4% to 2.2%, with the linear probe showing the 
smallest variation (1.4%) and the curved probe showing the largest variation (2.2%). 
Table 8 summarises the mean, standard deviation (SD) and the CoV for the three 
different transducers used. 
 
Probe Type Mean SD CoV (%) 
Linear 102.4 1.4 1.37% 
Curve 96.1 2.1 2.2% 
TV 101.7 1.6 1.6% 
Table 8: Intra-operator repeatability (different images). 
 
3.1.3.3.2. Repeatability of ASQ software  
 
Ten consecutive ROI were drawn on the same image in the ASQ window. The CoVs 
for the three different transducers range from 0% to 0.32% with the linear probe 
showing the largest variation (0.32%), while both the TV and the curved probe 
showed no variation (0%). Table 9 summarises the mean, standard deviation (SD) and 
the CoV for the three different transducers used. 
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Probe Type Mean SD CoV (%) 
Linear 100.1 .32 0.32% 
Curve 93 0 0 % 
TV 102 0 0% 
 
Table 9: ASQ software repeatability (same image)  
 
3.1.3.3.3. Inter-operator reproducibility  
 
The inter-observer mean differences  SD between paired images for the three different 
transducer types tested are presented in Table 10. P-values were calculated using the 
Mann-Whitney U test as the data were non-normally distributed. For all three probes, 
there were no significance differences between operator 1 and operator 2, with p-
values of .436 for the linear probe and .579 for both the curved and the TV probes.  
 
Bland-Altman plots were drawn for the three probes and tested for graphic evaluation 
of the agreement between ASQ feature derived from the images obtained by the two 
operators. Figures 21, 22 and 23 are examples of Bland-Altman plots showing the 
distribution of the mean values in the three probes. All probes show different patterns: 
i.e. there is random variation in the difference between the two operators. The 
difference in the paired derived ASQ means between the two operators do not exhibit 
any systematic pattern, as the mean value increases for all three probe types. In other 
words, the difference between the two operators does not increase (or decrease) 
systematically as the mean value increases. 
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The mean CoV for inter-operator repeatability are 1.03, 1.2 and 2.1% for the linear, 
curved and TV probe respectively. All three probes show very low variation, with 
values below 2.5%. The mean CoVs for all three probes are presented in Table 11. 
 
 
 Linear Probe Curve Probe TV Probe 
Mean Diff   -.60 -.80 -1.0 
Std. Dev. 2.27 4.44 4.87 
 
Table 10: Inter-operator mean difference and standard deviation 
 
 
Mean Coefficient of Variation (CoV %) 
Linear Probe Curve probe TV probe 
1.03 2.1 1.2 
 
Table 11: Coefficient of variation for inter-operator reproducibility. 
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Figure 21: Example of Bland-Altman plot showing the random distribution of the difference between the two 
operators (curve probe) 
 
 
 
Figure 22: Example of Bland-Altman plot showing the random distribution of the difference between the two 
operators (linear probe). 
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Figure 23: Example of Bland-Altman plot showing the random distribution of the difference between the two 
operators (TV probe). 
3.1.3.4. Discussion  
 
Repeated measurements are most likely to vary (Swinscow, 1997). The degree of the 
variation will determine the reliability of the measurements acquired. Bruton et al. 
(2000) specified that reliability refers to the consistency or repeatability of such 
measurements, and is usually performed to assess the performance of the instrument 
and the operator. De Vet et al. (2006), pointed out that reliability is an essential 
requirement for measuring outcomes in medical disciplines, such as the assessment of 
radiographs.  
 
In this chapter, a set of experiments were carried out to evaluate the reliability of B-
mode images with the ASQ feature enabled, particularly in the random variation 
inherited from the ASQ software and from the operator. Since the reliability of the 
measurement (image acquisition) determines the sensitivity and the specificity when 
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used for classifications or predictions, establishing the degree of these variations is 
essential. The scatter (variation) in the extracted ASQ feature was evaluated as a 
measure to determine reliability of the image texture. According to Fry (2002), the 
scatter in the data is a useful measure for quantifying the effect each parameter has on 
the accuracy of the measurement. The variation caused by image acquisition 
procedure can be further divided into ASQ software variation and operator variation. 
 
Generally, ASQ features in all three transducers evaluated demonstrated excellent 
repeatability for ASQ software, with all transducers showing less than 0.4% variance 
from the mean. The results indicate that ASQ software is able to produce reliable 
ASQ output measures. 
 
In this section, we also assessed the intra- and inter-operator reliability in image 
acquisition. It was observed that for all types of transducers, their intra-operator CoVs 
are 1.37% - 2.2%, which are higher than the ASQ software CoVs. This can be 
explained by the fact that the variations in the scanning process are a combination of 
both the ultrasound system and the operator. However, CoV of 2.2% or less is 
considered very low and indicates that this is a reliable technique. 
 
Regarding inter-operator reproducibility, the Bland-Altman plots clearly illustrate that 
the differences between the two operators did not appear to increase as the mean value 
of the ASQ increases using the linear probe and are due to random variation. The 
same pattern was observed for the two other probes: the curved and TV probes. In 
other words, there is no obvious relationship noted between the differences of the two 
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operators and their means for all probes evaluated. This indicates that the increases in 
the derived ASQ mean values do not affect the difference between the two operators. 
According to Bland and Altman (2010), if the differences are proportional to the 
mean, a logarithmic transformation of the data has to be performed before analysis is 
carried out. 
 
The CoV calculated to measure the consistency of the image produced by two 
different operators shows a very small variation (excellent agreement). 
 
From the results above, it can be concluded that the ultrasound system with ASQ 
features is able to produce consistent images. Since the results show that scanning 
using a phantom is able to produce consistent images, it is worth continuing to an 
assessment of other factors that might influence the reliability of ASQ output 
measurements. This is addressed in the next section.  
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3.3. (B) Influence of ROI size, ROI depth, 
Focus, Gain setting and transducer 
frequency on ASQ 
 
The objective of this section is to assess factors that potentially affect the ASQ curve, 
namely the ROI size, ROI depth, focus, gain setting, and transducer frequency. 
Subsection 1 reviews the influence of those five factors on the ASQ curve. Subsection 
2 contains the methodology and statistical analysis, while subsection 3 presents the 
results, which are discussed in subsection 4. Finally, subsection 5 summarises this 
chapter. 
3.3.1.  Background 
It was reported that besides the variation in the imaged tissue itself, the output 
measurement may also vary due to other factors. Since there were no available articles 
or publications on ASQ image properties, studies of texture analysis were considered 
as a reference for background information for ASQ. This is due to the similar nature 
of ASQ and texture analysis in the fact that they are both statistically analysed by 
computer software.  
 
According to Castellano et al. (2004), the effect of external factors on some texture 
parameters must be taken into consideration before using texture analysis techniques. 
If this is not addressed, then the value obtained may not reflect the actual texture of 
the tissue, which may in turn influence the performance of the texture analysis 
technique when applied for classification, as pointed out by Chan and McCarty 
(1990). 
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In previous work on a tissue-equivalent phantom, it was reported that some texture 
features exhibit a dependency on the size of the area from which the features were 
extracted (He et al., 2004).  
 
In the same way, the influence of the ROI size has been reported in clinical image 
studies. For example, a study was done to discriminate prostate tissue from the 
ultrasound images. It was found that results from using smaller ROI were not as good 
as results using larger ROI. This demonstrates that the size of ROI will affect the 
performance of the extracted feature (Basset et al., 1993). Furthermore, He et al. 
(2004)  argued that determining the appropriate ROI size is crucial due to the 
variation that might be in the pathological area and that the tumour size is generally 
larger than the size of the normal area. 
 
Beside the ROI size, another factor that needs to be considered when acquiring the 
ASQ images is the depth of the ROI. In 1988, Morris conducted a study which 
revealed that some features of the texture analysis are dependent on the ROI depth 
(Morris, 1988). To overcome this limitation, some studies used a fixed ROI depth. 
However, this approach restricts the flexibility of the technique because real-life 
lesions may appear at various depths. 
 
It has been reported by several studies that even when imaging the same tissue, the 
value of the extracted features may vary under different scanner settings (Collewet et 
al., 2004, Chan and McCarty, 1990). Gain and focus position are examples of such 
factors. Therefore, in this section, the five main factors that may influence the 
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performance of the ASQ will be tested in a set of experiments to acknowledge the 
factors that have an effect on ASQ and to use them with caution in tissue studies.   
3.3.2. Methodology and statistical analysis 
3.3.2.1. Influence of ROI size 
 
The objective of this section is to evaluate the influence of the ROI size on the ASQ 
feature, particularly on the mean of the output curve. 
 
Ten images were acquired using a Toshiba Aplio 500 scanner with three different 
transducers: a 6.0 MHZ Transvaginal transducer (model PVT-661VT), a curve 
transducer (model PVT-375BT) at 3.5 MHz and a linear transducer (model PLT-
7045BT) at 7.5 MHz (as seen in Figures 17, 18 and 19 respectively). An RMI model 
403 GS LE phantom was used as a test object (please refer to Figure 20). 
 
The machine settings were kept constant by using the manufacturer’s pre-defined 
setting: Endo-Vaginal-Gynae. The ASQ button was enabled in the machine before 
taking the images. The set of ten images were saved as raw data on the ultrasound 
machine hardware and then transferred to the PC in a DICOM file for further analysis. 
Figure 24 illustrates the experimental setup. 
 
ASQ software, PC-ASQR Version 1.11R001, was used to draw the different ROI 
sizes on the images and acquire the output curve. The same process was repeated for 
the three different transducers. The mean of the output curve was documented from 
two different ROI sizes: large ROI and small ROI. The significance of the difference 
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was calculated in each transducer using the Mann-Whitney U test p-value to test for 
significance because of the  non-parametric data found when tested for normality. 
 
 
3.3.2.2. Influence of ROI Depth 
 
The objective of this section is to evaluate the influence of the ROI depth on the ASQ; 
whether as the depth of the ROI increases, the value of the mean of the output curve 
tends to increase/decrease as well. The procedure carried out for the image acquisition 
was similar to the ROI size assessment (see previous paragraph). The focus was kept 
constant in all images, while the ROI were drawn at two different depths (2cm and 4 
cm) in each image. The p-value were calculated to determine the relationship between 
the ROI depth and the ASQ mean of the output curve, i.e. whether there is a 
significant difference when changing the ROI depth regarding the focus. 
3.3.2.3. Influence of Gain setting 
 
The objective of this section is to evaluate the influence of the scanner gain setting on 
the ASQ output curve, i.e. whether there is a significant difference of the mean when 
changing the gain setting. 
Ten images were acquired using a Toshiba Aplio 500 scanner with three different 
transducers; a 6.0 MHZ Transvaginal transducer (model PVT-661VT), a 3.5 MHz 
curved transducer (model PVT-375BT) with and a 7.5 MHz linear transducer (model 
PLT-7045BT). An RMI model 403 GS LE phantom was used as a test object. The 
machine settings were kept constant by using the manufacturer’s pre-defined setting: 
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ASQ setting (except for the gain). The ASQ button was enabled in the machine before 
taking the images. The images were acquired at two different gain settings: 85 % 
(low) and 100 % (high). The set of ten images were saved as raw data on the 
ultrasound machine hardware and then transferred to the PC in a DICOM file for 
further analysis. Please refer to Figure 24 for the experimental setup and the process 
flow illustration. A relatively large ROI was drawn in the centre of the image for the 
output curve using the ASQ software version 1.11R001. 
 
 
 
 
    
 
Figure 24: Experiment process flow illustration. 
 
 
 
 
ASQ ASQ software 
500 
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3.3.2.4. Influence of focus position 
The objective of this section is to evaluate the influence of the focal position in the 
ultrasound image on the ASQ output curve, i.e. whether there is a significant 
difference of the mean when changing the focal position. 
The same procedure was followed with the same ultrasound machine and type of 
transducers used as in the gain setting experiment (see previous section). The only 
part of the procedure that was different is that the gain was kept constant along with 
the other factors and ten images were acquired with two different focal positions, one 
at 2 cm and the other at 4 cm. 
 
3.3.2.5. Influence of transducer frequency 
 
The objective of this section is to have an understanding of the influence of transducer 
frequency on the ASQ output curve. 
A similar procedure was followed using the same ultrasound machine and type of 
transducers as in the gain setting experiment (see gain section). All variables were 
kept constant, i.e. the gain setting, focal position, depth of ROI and size of ROI. The 
only difference here is the frequency of the transducer. For the linear transducer, three 
different frequencies were tested: 8.4, 7.2 and 6.2 MHz; for the curved transducer, 
four different frequencies were tested: 6, 5, 4 and 3 MHz. For the TV transducer, 
three frequencies were tested: 8, 7.2 and 6 MHz. For each frequency, ten images were 
acquired and saved as raw data. These images were then transferred to the PC in a 
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DICOM file for further analysis. A relatively large ROI was drawn in the centre of the 
image for output curve using the ASQ software version 1.11R001. 
3.3.3. Results  
3.3.3.1. Sample characteristics 
 
A Shapiro-Wilk normality test (p >.05) and a visual inspection of the histograms, 
normal Q-Q plots and box plots showed that some of the variables were not normally 
distributed when calculating the z-value, by dividing the skewness and kurtosis values 
over the standard error for each of them. Therefore, a non-parametric test (Mann-
Whiteny U) was used to calculate the p-values for all of the variables to keep the 
results consistent.  
3.3.3.2. Influence of ROI size  
The median was calculated for each transducer from the output curve in each image. 
These results are presented in Tables 12, 13 and 14. These results show that there is a 
significant difference between the large ROI and the small ROI in the linear 
transducer with p-value <.001, while in the curved and TV transducers, the difference 
is not significant, with p-values of 0.105 and  0.912 respectively (see Figures 25 and 
26). 
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         Figure 25: ASQ window with large ROI                  Figure 26: ASQ window with small ROI      
 
 Median  p-value Significance? 
Large ROI 110 
<.001 Yes  
Small ROI 112 
Table 12: Summary of the influence of the ROI size on the mean of output curve using Linear Probe 
 
 Median p-value Significance? 
Large ROI 98.50 
0.105 No 
Small ROI 97.50 
Table 13: Summary of the influence of the ROI size on the mean of output curve using Curve Probe. 
 
 Median p-value Significance? 
Large ROI 103 
0.912 No 
Small ROI 103 
Table 14: Summary of the influence of the ROI size on the mean of output curve using TV Probe. 
3.3.3.3. Influence of the ROI depth 
The median was calculated for each transducer due to the non-normal distribution of 
some of the variable data from the output curve in each image. These results are 
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presented in Tables 15, 16 and 17. Furthermore, it shows that there is no significant 
difference for either the curved or the TV probe, with p-values of .769 and .631 
respectively, when placing the ROI at depths of 2cm or 4cm. On the other hand, the 
linear probe showed a significant difference in the median when drawing the ROI at 2 
cm and 4 cm with p-value <.001 using the Mann-Whitney U test (see Figures 27 and 
28). 
 
 
    
Figure 27: ASQ window with ROI at 2cm depth      Figure 28: ASQ window with ROI at 4cm depth 
 
 Median p-value Significance? 
2cm depth 112 
<.001 Yes  
4cm depth 103 
Table 15: Summary of the influence of the ROI depth on the mean of output curve using linear probe. 
 
 Median p-value Significance? 
2cm depth 98.5 
0.769 No  
4cm depth 99 
Table 16: Summary of the influence of the ROI depth on the mean of output curve using curved probe. 
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 Mean p-value Significance? 
2cm depth 104 
0.631 No  
4cm depth 103.5 
Table 17: Summary of the influence of the ROI depth on the mean of output curve using TV probe. 
 
3.3.3.4. Influence of the focus setting 
 The results of the influence of the focus on the output curve are summarised in 
Tables 18, 19 and 20. The linear and TV probes showed a significant difference in the 
output curve mean when changing the focus from 2 cm to 4 cm, with p-values of .003 
and <.001 respectively. In contrast, there was no significant difference in the output 
curve mean when changing the focus from 2cm to 4cm in the curved transducer, with 
a p-value of .579.  
 
Figures 29 and 30 illustrate how the images were taken with different focal positions 
prior to saving and transferring them to PC in a DICOM file. 
 
  
     Figure 29: ASQ window with focus at 2 cm.                   Figure 30: ASQ window with focus at 4 cm. 
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 Median p-value Significance? 
Focus at 2cm  112 
0.003 Yes  
Focus at 4cm  109 
Table 18: Summary of the influence of the Focus setting on the mean of output curve using linear probe 
 
 Median p-value Significance? 
Focus at 2cm 98.5 
0.579 No  
Focus at 4cm 100 
Table 19: Summary of the influence of the focus setting on the mean of output curve using curved probe 
 
 Median p-value Significance? 
Focus at 2cm 103 
<.001 Yes   
Focus at 4cm 106 
Table 20: Summary of the influence of the focus setting on the mean of output curve using TV probe. 
3.3.3.5. Influence of gain setting 
Tables 21, 22 and 23 show the results when changing the gain settings on the three 
different transducers respectively. The median was calculated. In all three transducers, 
the gain setting did not give any significant difference in the mean of the output curve, 
with p-values of .393 for the linear probe and .853 for both the curved and TV probes 
(see Figures 31 and 32). 
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Figure 31: ASQ window with High Gain of 100 %            Figure 32: ASQ window with low Gain of 85 % 
 
 Median p-value Significance? 
High gain 112 
0.393 No  
Low gain 110 
Table 21: Summary of the influence of the gain setting on the mean of output curve using linear Probe. 
 
 Median p-value Significance? 
High gain 101 
0.853 No  
Low gain 101 
Table 22: Summary of the influence of the gain setting on the mean of output curve using curve Probe. 
 
 Median p-value Significance? 
High gain 102 
0.853 No  
Low gain 102.5 
Table 23: Summary of the influence of the gain setting on the mean of output curve using TV Probe. 
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3.3.3.6. Influence of transducer frequency 
 
The influence of frequency on the output curve is summarised in Tables 24, 25 and 
26. The mean and median of the ASQ output curve were calculated for all 
frequencies. For the linear probe, the 8.4 MHz frequency was significantly different 
when compared to the 7.2 MHz frequency as well as when compared to the 6.2 MHz 
frequency, with both p-values of < .001. However, there was no significant difference 
seen when comparing the p-values of 7.2 with 6.2 MHz, with a p-value of .739. 
For the curved probe, four different frequencies were tested against each other. In all 
frequencies, no significance difference was seen when compared to each other, with 
p-values ranging from .165 to .796 using the Mann-Whitney U test. 
 
When testing the TV probe, no significant differences were seen between the 
frequencies 8 and 7 MHz and between frequencies 7 and 6 MHz, with p-values .280 
and .089 respectively. The only significant difference shown was between 8 and 6 
MHz, with a p-value of .003. 
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Frequency 
(MHz) 
Mean Median P-value Significance? 
8.4 71.6 72 (8.4 with 7.2) 
<.001 
Yes  
7.2 103.6 104 (7.2 with 6.2) 
.739 
No 
6.2 103.3 103.5 (8.4 with 6.2) 
<.001 
Yes  
 
Table 24: Influence of frequency in linear transducer. 
 
Frequency 
(MHz) 
Mean Median P-value Significance? 
6 96.4 97 (6 with 5) .436 
 
No 
5 95.6 95.5 (5 with 4) .739 
 
4 95 95 (4 with 3) .796 
 
3 93.8 95 (6 with 3) .353 
 
(6 with 4) .165 
 
Table 25: influence of frequency in curved transducer. 
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Frequency 
(MHz) 
Mean Median P-value Significance? 
8 104.5 105 (8 with 7.2) 
.280 
No 
  
7.2 103.1 104.5 (7.2 with 6) 
.089 
No  
 
6 101.1 101 (8 with 6) .003 Yes  
Table 26: influence of frequency in TV transducer. 
 
3.3.4. Discussion  
 
The success of applying the ASQ technique is subject, among other factors, to the 
reliability of the extracted features. Five factors associated with the reliability were 
considered in this section: (i) ROI size, (ii) ROI depth, (iii) focus, (iv) gain setting and 
(v) transducer frequency. 
 
The results for the influence of ROI size on the mean of the output curve show that 
the size of the ROI does not affect the occurrence curve mean. This can be clearly 
seen in both the TV transducer and the curved transducer. Yet, in the linear 
transducer, the variation is inversely proportional to the size of the ROI. In other 
words, the larger the ROI size, the more reliable the mean of the output curve, with 
less variation, and the smaller the ROI, the more variation can be seen in the mean. 
This indicates that the linear transducer is ROI-size dependent. This could be 
explained by the fact that a smaller number of samples are used in the smaller ROI, 
which gives more variation. In other words, a small ROI would have an insufficient 
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numbers of pixels to reliably compute the ASQ mean output. As different lesions may 
have different sizes, a minimum size that ensures that the variation in ASQ parameters 
in each ROI is captured needs to be established. 
 
It is important to note that a relatively large ROI size should be used for any particular 
study using the linear probe to avoid misleading results due to the difference in the 
ROI size. This transducer, however, was not used in the study of images of ovarian 
masses. 
These results do not apply to the TV or the curved transducer. It has been shown that 
the ROI size does not affect the mean of the output curve. Moreover, the mean of the 
output curve will have minimal variation when using different ROI sizes that will not 
affect its reliability.  
 
ROI depth is another determinant of the mean of the output curve. The ultrasound 
beam causes a depth dependence of the B-mode image texture, as described by 
Oosterveld et al. (1991). This can be explained by the fact that the intensity 
progressively decreases as the beam passes though tissues as a result of scattering, 
refraction and absorption phenomena (Lagalla and Midiri, 1998).  
 
The attenuation on the ultrasound signal as it advances through the tissue is one of the 
underlying factors that affect the B-mode image texture. According to Morris (1988), 
the correction of this variation in the raw image is not straightforward and might not 
even be possible.  To overcome this problem, some studies have confined the ROI 
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position to a fixed depth to avoid depth dependency. For instance, (Bader et al., 2000) 
stated in their study that all tumours were located at depths between 2 cm and 3 cm.  
 
Since the position of the lesion may vary, it is crucial to understand the influence of 
the ROI depth on the mean of the output curve. We have evaluated the effect of ROI 
depth on the mean of the output curve on three different transducer types. In both the 
TV and the curved transducers, the depth did not significantly affect the mean of the 
output curve, while in the linear transducer, a significant difference was seen when 
using different depths for the ROI. 
 
The third factor that may affect the ASQ output curve is the position of the focus. 
Generally, the ultrasound beam spreads out, or undergoes divergence, as it moves 
away from the transducer  (International Society of Radiology: (Tole, 2005)): 
therefore, it is possible to focus the ultrasound beam to cause narrowing of the beam 
and thus improve (lateral) resolution. The beam can be narrowed at a predetermined 
distance from the transducer. The point at which the beam is at its narrowest is the 
focal point or focal zone and is the point of greatest intensity and best lateral 
resolution (George, 2006).  
The fact that the focus position does affect the mean of the output curve in the TV 
probe led us to decide to keep the focus position at the level of the drawn ROI to 
acquire the greatest intensity and the best lateral resolution to ensure reliable results. 
 
The fourth factor that may influence the mean of the output curve in the ASQ 
software is the gain setting. The results of testing the effect of high gain (100 %) and 
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low gain (85 %) showed that all three probes are independent of the gain setting. This 
means that using either high or low gain when acquiring the raw data on the 
ultrasound machine will not affect the mean of the output curve in the ASQ software. 
This could be explained by the fact that the ASQ software uses the raw data, which is 
initially not affected by the gain setting.  
 
Transducer frequency results showed that the mean of the output curve is not affected 
by the frequency chosen to capture the ultrasound images except when choosing 8.4 
or 8 MHz in the linear and the TV probe respectively. These higher frequencies seem 
to affect the mean of the output curve in the ASQ. 
 
Based on the findings from this chapter, three factors do not influence the mean of the 
output curve in the ASQ software using the TV probe: these are ROI size, ROI depth 
and the gain setting. Nevertheless, the focal position does have a significant effect on 
the output curve. Moreover, transducer frequency does affect the mean of the output 
curve only if a high frequency is chosen (8 MHz); otherwise lower frequencies do not 
influence the mean of the output curve. These findings permit us to use the ASQ 
software on ovarian masses with confidence that these factors will not affect the 
reliability of the reading, while taking caution when positioning the focus on the 
image before storing the raw data as well as using low transducer frequencies. 
3.3.5. Testing ASQ settings  
 
Since ASQ is a new and evolving technique, further exploration was needed to 
understand the correct procedure to be used. Usually only Toshiba Aplio 500 
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machines come with an ASQ pre-setting and an ASQ button. However, it was worth 
testing different Toshiba models to acquire raw images that could be used in the ASQ 
window and analysed using the ASQ software. 
 
For this purpose, the aim of this test is to compare the Toshiba Aplio 400 to the 500 
model as well as to test three different pre-settings on the same machine. Using a 
linear probe, ten images were acquired in the Aplio 500 and stored as raw data, and 
then copied as a DICOM file to be analysed using the ASQ software. In the Aplio 
400, the machine was set up by a Toshiba engineer to enable raw data store button in 
the control panel. Then ten images were acquired using a similar technique and stored 
as a raw file. These images were then transferred as a DICOM file to a personal PC to 
be analysed using ASQ software. 
 
Then three different pre-settings were tested: these are pre-set off (the raw data) with 
ASQ on, pre-set on with ASQ on and pre-set on with ASQ off. In each setting, ten 
images were acquired and stored as raw data, all other variables were kept constant 
throughout the test. Images then were copied to a flash memory drive as a DICOM 
file to be analysed using the ASQ software. 
3.3.5.1. Results   
 
Two different tests were done to investigate the most reliable setting of the machine to 
acquire the images before transferring them to be analysed using ASQ. First, the 
different machine models (Aplio 500 and Aplio 400) were compared when saving 
images as a raw store without enabling the ASQ button. The p-value was .912, 
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indicating no significant difference between the two models when storing the images 
as a raw store without enabling the ASQ button before saving the images. Table 27 
summarises the results. 
Second, three different pre-settings of the machine were compared: these are pre-set 
button off with ASQ on, pre-set button on with ASQ on and pre-set button on with 
ASQ off. Surprisingly, there were no significant differences between pre-set button on 
and off when the ASQ button was on, with a p-value of .796, while there was a 
significant difference when the ASQ button was on compared to when the ASQ 
button was off even when the pre-set button was on, with a p-value <.001. (Please 
refer to Table 28 for results). 
 
Machine Model  Median  P-value  Significant? 
Aplio 500 72 
.912 No  
Aplio 400 72 
 
Table 27: The difference between Toshiba model Ultrasound machines  
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Machine setting Mean Median P-value Significance? 
Pre-set OFF 
ASQ on 
105.1 
 
.796 No 
Pre-set on 
ASQ on 
104.9 
 
  
Pre-set on 
ASQ off 
71.3 71 <.001 Yes 
 
Table 28: Summary of the results of ASQ machine settings. 
 
3.3.5.2. Discussion and Conclusion  
 
ASQ software was initially designed to work with Toshiba Aplio 500 machines. 
However, further testing had to be done on the Toshiba machines to investigate the 
right setting to acquire images before analysing it using ASQ software. It was possible 
to acquire images on Aplio 400 after setting a raw store button on the machine. 
Unfortunately, this gave misleading results when analysed using ASQ software. 
Because we used a phantom that consisted of uniform tissue, we expected the mean 
and median of the output curve to be around 100 to represent the uniformity of the 
tissue, but the mean and median of the output curve were shifted to the 70s.  
 
When testing the machine setting, it was found that the pre-set button on the control 
panel screen was not significantly affecting the raw stored images when analysed 
using ASQ software. On the other hand, the ASQ button had a major influence on the 
image property before storing. This could be explained by the fact that the pre-set 
105 
105 
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button only enabled the machine to switch on precision; Precision is defined as an 
adaptive processing algorithm which looks at the returning echo signals and uses 
image processing techniques to extract the real information from the background 
noise. This has the effect of reducing the clutter in the image and producing an image 
with finer detail (Brosky, 2009). 
 However, the precision button was found to have no effect on the raw store images. 
Another reason is that the manufacturer of the ASQ has set this button to enable some 
filters that are not available on older Aplio models. 
 
From these tests, it can be concluded that ASQ software will not work properly and 
reliably on images taken from machines other than Aplio 500. Moreover, the ASQ 
button has to be enabled on the machine before storing images in raw form.  
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3.4.  (C) Influence of pre-defined image 
parameters on ASQ output 
 
In the ASQ software window, there is a bar of multiple pre-defined parameters that 
can be altered before selecting the ROI. These parameters have a dramatic effect on 
the output graph shape, average, mode and SD values. 
 
These parameters are the x and y values for the sample chosen, the sample steps, 
sweep intervals and the total number of samples. The software comes with default 
settings for these parameters, which are shown in Table 29. However, these default 
settings were originally created to be used on liver tissue. Therefore, in this section, 
the default setting will be tested on a phantom used in Ultrasound in an attempt to 
create a set of parameters that are most useful to be used on images of ovarian masses. 
 
Samples  
x 21 y 19 
Sample steps 
x 0 y 2 
Sweep intervals  
x 2 y 4 
Actual size 
Number of samples 315 
 
Table 29: The default settings in the ASQ software window 
 
The large ROI is the region that is drawn within the area of interest, while the small 
ROI is the sample areas, within the large ROI, that are used to determine the cm
2
 
value, as explained by Toshiba engineer. The size of the small ROIs is determined by 
the value of X and Y in the toolbar setting. 
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In other words, when drawing a ROI on an image, it consists of number of small ROI 
next to each other, and samples x and y represent a pre-set number of scan lines that 
will be used on both the x axis and the y axis in the small ROI. Within the large ROI, 
at least 100 small ROIs are needed in order for the statistics to be meaningful. The 
sample steps represent the number of un-sampled pixels between each sampled pixel 
in the small ROI. This can be determined in the x and y planes independently. When 
the SS is 0 in each plane, every pixel in the ROI is used for the analysis. The smaller 
the sample steps, the greater the number of sampled pixels within the small ROI. The 
sweep interval determines how close the small ROIs are, as they are being 
interrogated: in other words, it represents the gap between two small ROI. For our 
small pathological structures, we need them to be as close as possible, so that we can 
detect very small areas of speckle variation. 
 
Finally, the number of samples gives the actual number of small ROI that will be 
calculated when drawing the ROI on an image. It is controlled by the values of x and 
y. Furthermore, it needs to be adjusted to more than 100, as advised by the Toshiba 
engineer. 
3.4.1. Methodology  
The goal of these experiments is to define a set of parameters that can allow us to 
draw the smallest ROI (e.g. 1 x 1 cm) without affecting the reliability of the output 
graph and at the same time ensuring reliable values. 
 
   
130 
 
Ten images were acquired using a Toshiba Aplio scanner. A linear transducer (model 
PLT-7045BT) with 7.5 MHz was used for this section to establish new parameter 
settings to be used later on images of ovarian masses. The reason for this is that the 
linear transducer has the simplest image and gives a square shaped ROI that is easier 
to draw and measure.  
 
An RMI model 403 GS LE phantom was used as a test object. The machine settings 
were kept constant by using the manufacturer’s pre-defined setting: Endo-Vaginal-
Gynae. The ASQ button was enabled in the machine before taking the images. The set 
of ten images were saved as a raw store on the ultrasound hardware and then 
transferred to the PC in a DICOM file for further analysis. Figure 33 illustrates the 
experimental setup. 
 
The same set of ten images were used throughout this section while changing the pre-
defined parameters from the left bar shown on the software window (please refer to 
Figure 33).  In the ten images, the ROI were drawn twice: once with the default 
parameter setting and the other with changing the steps x, y and sweeps x, y to 0, 0 
and 1, 1 respectively. The mean and SD were calculated for both sets of data and 
compared using t-tests to calculate the p-value for the significance of the difference.  
 
As advised by Toshiba engineers, to ensure reliable results, the actual sample size 
should not fall below 100. Therefore, several different parameters were used to reach 
the optimum set with at least a sample size of 100. To achieve that, a set of 
experiments were done (please see the flow chart in Figure 34). 
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Figure 33: Block diagram of ASQ parameter assessment. 
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Figure 34: Flow chart of experiments 
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3.4.2. Results  
When altering the x and y values of the sample, the values of (x 11 and y 13) were 
found to give an actual size of 115 samples (see Figure 35) and simultaneously allow 
us to draw the smallest ROI required (1 x 1 cm): please refer to Table 30 for a 
summary of the different values with their corresponding actual number of samples. 
 
Sample values Mean  Number of samples 
x 17   y 19 101 255 
x 15   y 17 101 207 
x 13   y 15 99 151 
x 11   y 13 98 115 
x 9    y 11 96 79 
x 7    y 9 91 51 
 
Table 30: Summary of different x and y samples with their corresponding numbers of samples. 
 
 
Figure 35: ASQ window with the chosen set of parameters. 
The output 
curve 
represented 
by the red 
curve 
The ROI 
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parameter 
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set of 
parameters 
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After defining the best set of parameters, it was tested against tissue images 
(inhomogeneous tissue) to test for significance. When comparing the default setting 
with the decrease in sample steps and sweep interval to minimum, there was a 
significant difference between them, with a p-value of .004 (see Table 31). Similarly, 
when applying the decreased sample steps and sweep intervals setting to human tissue 
there was a significance difference, with a p-value of 0.043 (see Table 32).  
 
Subsequently, the phantom images (homogenous) were compared to tissue images 
(inhomogeneous: see Figure 36) and found to have a significant difference between 
the means, with p-values of .001 in both the default and the decreased setting, which 
are summarised in Table 33. 
 
 Median  P-VALUE Significant? 
Default setting 103 
0.004 Yes Decrease steps 0,0 
Sweeps 1,1 
101 
 
Table 31: ASQ Phantom images (homogeneous) 
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Figure 36: ASQ window for tissue image with default setting. 
 
 Default setting Decrease steps 
0,0 sweeps 1 ,1 
P-value 
 Median                 Median   
Red 119.5 113  0.043 
Blue  163.5 167  0.912 
 
Table 32: ASQ tissue images (inhomogeneous) 
 
 Homogeneous  Inhomogeneous P-value 
 Median                             Median   
Default 103 119.5   <.001 
 Steps0,0 
sweeps 1,1 
101 113   <.001 
 
Table 33: The significance of the difference between the phantom images and the tissue images. 
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When using the pre-defined default settings, which are sample size of 299 with x 21 
and y 19, the equipment will not allow the operator to draw a small ROI: hence, we 
had to find out which sample values of x and y would allow the drawing of small ROI 
(1 x 1 cm) without decreasing the sample size below 100, as advised by Toshiba 
engineers. All possible x and y values were tested to reach the required values. The 
resulting sample values were x 11 and y 13, which gives a sample size of 115. 
Afterwards, the chosen values were compared to the default sample size in tissue to 
test for significance. The p-value was .001, indicating a significant difference between 
the default sample size and the chosen one (please refer to Table 34). 
 
 
 
 
Setting 
 
(x21,y19) 
Sample size 299 
Steps 0,0 sweeps 
1,1 
(x11,y13) 
Sample size 115 
Steps 0,0 sweeps 
1,1 
 
P-value 
 Median                   Median 
 
 
Red 113 105.5 <.001 
blue 167 172 0.529 
 
Table 34:  The effect of the sample size parameter on the mean of the curve in tissue images. 
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Figure 37: ASQ window for tissue image with chosen pre-set parameters. 
 
To ensure that the new chosen parameters are reliable, we compared drawing large 
ROI to the desired small ROI (1 x 1 cm). There was no significant difference in the 
mean when using a small ROI or a large ROI with a p-value of .143 (see Table 35). 
Further testing was done on tissue images by applying the newly chosen parameters 
and comparing the large ROI with the anticipated small ROI (see Figure 37). No 
significant difference was seen, with a p-value of .165 (shown in Table 36). 
 
Setting: (x11,y13) 
Sample size 115 
Steps 0,0 sweeps 1,1 
 
Large ROI 
 
Small ROI 
 (1 x1 cm) 
 
P-value 
 
Median 
 
97 
 
99 
 
.143 
 
Table 35: Comparison between drawing large ROI and smallest ROI with the new chosen setting on phantom 
images. 
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Setting (x11,y13) 
Sample size 115 
Steps 0,0 sweeps 1,1 
 
Large ROI 
 
Small ROI 
 (1 x1 cm) 
 
P-value 
         Median                        Median 
 
 
Red 105.5 96.5 .165 
blue 172 170 0.739 
 
 
Table 36: Comparison between drawing large ROI and smallest ROI with the new chosen setting on tissue images. 
 
3.4.3. Discussion  
ASQ is a new, advanced technique that was introduced by Toshiba Medical Systems 
in 2009 to give a considerably higher resolution of ultrasound images. It has been 
proven, by several studies in the past few years, to be useful in diagnosing certain 
liver diseases (Onodera, 2013, Ricci et al., 2013, Wang et al., 2013). However, to 
apply this new method to other parts or organs of the body, such as the ovaries, it is 
essential to test it, as different organs have different normal textures and hence give 
different speckle patterns. 
 
Testing the parameters of ASQ images was not an easy task. The reason for this is 
that very little information is available about this evolving application. Therefore, 
improvisation was needed to acquire the best results possible from the ultrasound 
images.  
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As seen from the results section, a set of parameters were chosen to be used on 
ovarian masses that allowed the drawing of small ROI (1 x 1 cm) without 
compromising the sample size. The reason for this is that the ovaries are much smaller 
in size than the liver: therefore, a smaller ROI was needed. No differences were 
observed when drawing small and large ROI, which ensured that the chosen 
parameters were reliable. When comparing the mean of phantom images to tissue 
images, a significant difference was observed as expected. This proves that the newly 
chosen set of parameters can be useful on inhomogeneous tissue and is not only 
applicable to phantoms. 
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3.5. (D) Applying ASQ to Images of Benign and 
Malignant Masses  
 
The previous three sections explored ASQ and tested it for robustness as well as 
reliability and repeatability. They also tested the factors that could affect the output 
curve of the ASQ, and determined the best predefined parameters to be used. 
Consequently, we want to apply this new method of analysis to pelvic masses in an 
attempt to distinguish benign from malignant tissue. The aim of this section is to 
conduct a small study in which we apply ASQ analysis to images of pelvic masses to 
document the ability of ASQ in discriminating benign from malignant ovarian masses. 
 
3.5.1.  Methodology and Statistical analysis 
To get the ethical approval, a full protocol for the proposed study of image texture 
analysis of Transvaginal ultrasound in diagnosing ovarian cancer was submitted to the 
Dyfed Powys Research Ethics Committee. The study received full ethical approval on 
18
th
 July 2013 (Ref. 13/WA/0206), as shown in appendix III. This project was also 
submitted to Cardiff and Vale NHS trust research and development committee, and 
was approved for commencement on 26
th
 April 2013, as shown in appendix II.  
 
Toshiba Aplio 500 was used in this study after it had been tested for reliability and 
repeatability (see section A in this chapter). However, only the Transvaginal probe (6 
MHz) was used to acquire the images of pelvic masses.  
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ASQ software, PC-ASQR Version 1.11R001, was used to draw the different ROI 
sizes on the images and acquire the output curve. The statistical analysis (Q-Q plot, 
Shapiro Wilk test and Mann-Whitney U test) was performed using SPSS 17.0 for 
windows (SPSS Inc, Chicago, Illinois, USA). 
3.5.1.1. Participants  
Study population: women age 18 and above with known pelvic masses. 
Inclusion criteria: All patients with confirmed pelvic masses and scheduled for 
surgery. Exclusion criteria:  Patients with other Gynaecological malignancy, i.e. not 
pelvic masses, pregnant patients, patients with a previous history of bilateral 
oophorectomy, difficult scans and unclear scan images and age less than 18 years old. 
Any patient with normal morphology or incomplete/ missing ultrasound results data 
were excluded from this study. 
Patient withdrawal during the study: participants were free to withdraw from the study 
at any time.  
3.5.1.2. Procedure:  Recruitment and Consent 
 
Participants were selected from a pelvic mass clinic and Gynaecology oncology 
clinics. All patients with known adnexal mass and scheduled for surgery were 
identified by members of the research team. The researcher approached the potential 
participant and informed them of the research study.  
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The study was explained and written information provided.  Patients were given up to 
24 hours to decide if they wanted to participate in the study, and then, after answering 
any question they had regarding the study, an appointment was booked for the scan. 
On the day of the scan, written consent was obtained before starting the scan. All 
participants were booked for an ultrasound scan of the pelvis prior to their surgery. 
 
The scanning procedure was the same for all participants in this study. A transvaginal 
transducer was used to perform the scan, and then, once the pelvic mass was 
identified on the screen, the ASQ button was enabled and the pre-set was on the ASQ 
setting. Images were stored as raw store clips on the machine hard drive. After the 
patients had left, images were transferred as DICOM files to a personal computer for 
off-line analysis. Then ASQ software was used to download the images. A ROI was 
drawn on the mass, which gives a graph that represents the normal and abnormal 
tissue in the ROI. The readings of the red and blue curves as well as the ratio between 
them were documented for each mass.  
3.5.2. Results 
A total of 45 masses were collected from 44 participants for the purpose of this study. 
Twenty-seven participants were premenopausal and seventeen were postmenopausal. 
Their ages ranged from 26 to 53 years in the premenopausal group (mean 41, median 
43) and from 52 to 90 years (mean 64, median 58) in the postmenopausal group. 
 
Histological specimens in all masses (n=45) included thirty-four benign masses, such 
as serous cystadenoma, mucinous cystadenoma, cystadenofibroma, dermoid, fibroid 
and endometrioma, and eleven malignant masses. 
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The output mean curves were categorised into two groups according to the type of 
lesion: benign or malignant. A Q-Q plot was used to determine the normality of the 
data by visual inspection. For normally distributed data, the plot should show a linear 
relationship; furthermore, the Shapiro-Wilk test was also used to test for normality. 
Figure 38 shows an example of normally distributed data (red curve - technique 2) 
while Figure 39 shows an example of non-normally distributed (blue curve - 
technique 1).  
 
Figure 38: Example of Q-Q plot for normally distributed data (Red curve- technique 2) 
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Figure 39: Example of Q-Q plot for a non-Normally distributed data (the ratio between the red and blue curve- 
technique 1) 
 
 Shapiro-Wilk Sig. Normally distributed? 
Red curve (all mass 
included) 
.119 Yes 
Blue curve (all mass 
included) 
.874 Yes 
Ratio (all mass included) <.05 No 
Red curve (only solid 
area) 
.963 Yes 
Blue curve (only solid 
area) 
.993 Yes 
Ratio (only solid area) <.05 No 
 
Table 37: Shapiro-Wilk test results for normality of the data. 
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Two analysis techniques were used. The first included the whole mass in the ROI for 
analysis, while the second technique only included the solid area of the mass in the 
ROI. 
The results of the Shapiro-Wilk test for normality are summarised in Table 37. They 
show that the red and blue curves both have normally distributed data in both 
techniques used (when >.05 is considered normal data), while the ratio between red 
and blue curves shows non-normally distributed data values <.05 in both techniques. 
 
The mean and standard deviation of both the red and the blue curve and the ratio 
between them were calculated and are summarised in Tables 38 and 39 for the two 
different techniques respectively. 
 
Type of curve Mass type Mean  SD 
Red curve with all mass in 
ROI 
Benign 123 30.8 
Malignant 123.5 14.4 
Blue curve with all mass in 
ROI 
Benign 175 39 
Malignant 184 24.4 
The ratio between Red and 
Blue 
Benign .77 .99 
Malignant 1.02 1.08 
 
Table 38: Summary of mean and standard deviation of the curves (ROI including the whole mass) 
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Type of curve Mass type Mean  SD 
Red curve with only solid 
area in ROI 
Benign 117.5 12.9 
Malignant 120.6 7.5 
Blue curve with only solid 
area in ROI 
Benign 168 22 
Malignant 177 25 
Ratio between Red and 
Blue 
Benign .65 .9 
Malignant .55 .4 
 
Table 39: Summary of mean and standard deviation of the curves (ROI including the solid area only) 
 
In the first technique, the means were similar in the benign and malignant masses, but 
they were different in the blue curve, with the malignant masses having the higher 
mean (184). In the ratio between the red and the blue curve, the malignant masses had 
higher mean (1.02) than the benign masses (.77). 
 
In the second technique there were no similarities in mean values in all three groups 
(red, blue and ratio). Malignant masses had higher mean in the red and blue curve but 
lower mean in the ratio (.55) when compared to the benign masses. 
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Type of curve Mass type P-value Significant 
different? 
Red curve with all mass 
in ROI 
Benign-Malignant .956 NO 
  
Blue curve with all mass 
in ROI 
Benign-Malignant .471 NO 
  
The ratio between Red 
and Blue 
Benign-Malignant .489 NO 
  
 
Table 40: Summary results of the significance test (ROI includes the whole mass) 
 
 
 
Type of curve Mass type P-value Significant 
different? 
Red curve with only solid 
in ROI 
Benign-Malignant .518 NO 
  
Blue curve with only solid 
in ROI 
Benign-Malignant .323 NO 
  
The ratio between Red and 
Blue 
Benign-Malignant .748 NO 
  
 
Table 41: Summary results of the significance test (ROI includes only the solid area). 
 
The non-parametric Mann-Whitney U test was used to calculate the significance 
between the benign and malignant masses on data from both techniques. The results 
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when including the whole mass in the ROI show that the two groups were not 
significantly different in red, blue and the ratio between red and blue, with p-values > 
0.05.  
 
When using the second technique, which only included the solid area of the mass in 
the ROI, there were still no significance difference between the benign and the 
malignant masses in any of the curves, with p-values of .51, .32 and .74 for the red 
curve, the blue curve and the ratio between them respectively. The results for both 
techniques used are summarised in Tables 40 and 41. 
 
An attempt to analyse a simple cyst was performed; however, there were no curves 
produced when applying the ROI on a simple cyst or any anechoic area. Therefore, 
the images of a simple cyst were not included in the analysis. 
 
No further statistical tests were performed due to the non-significant differences 
between the two groups, with all p-values >.05. 
 
3.5.3. Discussion and Conclusion 
 
Acoustic structural quantification (ASQ) was originally designed by Toshiba Medical 
Systems to help in the diagnosis of liver diseases. It has been demonstrated to have 
the ability to separate homogenous from inhomogeneous tissue. In this section, an 
attempt was made to apply the ASQ analysis to pelvic masses in order to assess the 
   
149 
 
diagnosis of the nature of the mass by defining the difference between homogeneity 
of benign and malignant tissue. 
 
Tissue characterisation can be used in conjunction with a visual interpretation of an 
ultrasound image to improve diagnosis. The aim of this section was to determine the 
ability of ASQ analysis in characterising ovarian tissue. In particular, we investigated 
the appropriateness of this method in discriminating benign from malignant tissue. 
  
At the beginning of the study, the calculation of sample size was based on the 
assumption that ASQ  may distinguish between benign and malignant masses with 5% 
significance level and 80% power: thus, a total of 200 women (100 participants with 
benign masses and 100 with malignant) were required for the study to demonstrate a 
significant difference. However, recruitment of participants for this study was 
somewhat difficult and slow. This was because we were dealing with women who had 
a suspicious mass and were waiting for surgery to have it removed: they were all very 
anxious, some were very ill and most of them did not want to have an additional 
internal scan, which can be uncomfortable in some cases when repeated in short 
period of time. Over a period of 18 months, only 44 women agreed to participate in 
this study, and after reviewing the preliminary results, a decision was made to stop the 
recruitment due to non-significant results. 
 
 It was agreed that there was no point in increasing the sample size if the results were 
not showing any discrimination ability between benign and malignant masses. 
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It is unknown whether a statistically significant difference between any of the 
parameters would have been found if it was practically possible to recruit a greater 
number of patients. 
 
There were variations observed in all of the output curves values extracted from the 
same tissue type. For example, the SD of the extracted values from the red curve for 
benign tissue was 30.8 for technique 1 and 12.9 for technique 2. Similarly, the SD for 
the blue curve was 39 and 22 for technique 1 and technique 2 respectively. 
 
In this study, two techniques for drawing the ROI were adopted. It can be seen from 
the results that selecting only the solid area from the mass did not improve the 
discrimination between benign and malignant masses. This is confirmed by the 
significance test results, whereby for technique 2, all output curve values were not 
statistically significant despite the fact that the mean values were different in both the 
benign and malignant groups (117.5 and 120.8 for the red curve and 168 and 177 for 
the blue curve). The results indicate that excluding the anechoic area from the analysis 
does not improve the diagnosis: this could be explained by the fact that the anechoic 
area originally does not give output curve values when analysed alone because only 
the images with raw data were used in the ASQ software. 
 
This failure to discriminate the benign from the malignant masses using ASQ could 
be because most of the masses in both groups were fibrotic in nature, such as 
cystadenofibroma, fibroids, and adenocarcinoma. 
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This study has shown that quantitative ASQ analysis of B-mode images demonstrates 
an insignificant difference between benign and malignant tissue. This means that ASQ 
does not work on pelvic masses because both benign and malignant masses exhibit 
homogeneity and heterogeneity in the same way. 
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3.6. Summary 
 
In this chapter, a new technique called ASQ was explored in four main sections. 
Section A provided background information about this new software and how it 
works, followed by a repeatability and reproducibility study, while section B tested 
the influence of four main factors on the ASQ output. Section C determined the pre-
defined parameters of the ASQ software that can be used on ovarian tissue without 
compromising the image quality. Finally, section D explained the study that was done 
by analysing pelvic masses images using ASQ analysis. 
3.6.1. Section A 
A brief explanation of how ASQ works was introduced at the beginning of this 
chapter. The consistency of the image texture is an important factor in ASQ. The 
repeatability and reproducibility issues were therefore assessed to determine the 
consistency in the image texture, to which random variations inherent in the 
ultrasound scanner and the scanning process could contribute. This was done by 
calculating the CoV. A tissue-equivalent phantom was used for this purpose. This 
section also evaluated the agreement in the repeatability produced by two different 
operators. The results for the ASQ software repeatability show very low variation in 
the images produced under identical conditions, and good agreement was found in the 
images obtained by two different operators for all three probes used. 
 
Based on finding from this section, it can be concluded that ASQ software is able to 
produce consistent images. This section has also established that intra-operator 
repeatability and good agreement between two operators are achievable. Therefore, it 
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is worth continuing to a similar assessment in a clinical setting, which involves more 
complex scanning processes: this is done in the next section. 
 
3.6.2 Section B 
The experimental evaluation of three transducers presented in this section aims to 
determine the robustness of ASQ software. A tissue-equivalent phantom was used as 
a test object. Several key factors that may affect the performance of ASQ were 
considered, namely ROI size, ROI depth, focal position, gain setting and transducer 
frequency. These factors were evaluated using p-values to determine significance. The 
ROI size was evaluated using two different sizes: large and small. The ROI depth 
dependency was evaluated by drawing ROI at two different depths: 2 cm and 4 cm. 
The focus was positioned at 2 cm and then at 4 cm to test for significance on the mean 
of the output curve. The gain was set at 100 % and 85 % to evaluate its effect on the 
mean of the output curve. All available frequencies in each transducer were tested. 
Three frequencies were found for the linear probe (8.4, 7.2 and 6.2 MHz) while four 
frequency setting were available for the curved probe (6, 5, 4 and 3 MHz). In the TV 
probe, three frequencies were available for testing (8, 7.2 and 6 MHz). 
 
Of the four factors that might influence the ASQ output, focal position was found to 
significantly affect the output in the images from the TV probe. On the other hand, the 
linear probe was significantly dependant on three of the factors, namely ROI size, 
ROI depth and focus position. Interestingly, the curve transducer was independent 
from all factors. In other words, the mean of the output curve was not affected by any 
of the four factors in the images acquired by the curved probe. Transducer frequency 
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did not affect the mean of the output curve in all three transducers except when using 
high frequencies such as 8 MHz. 
 
The findings from this section permit further study in a clinical setting with the TV 
probe with confidence that the output measurements are reliable, with caution when 
using focal position. 
3.6.3 Section C  
The pre-defined parameters of the ASQ window were tested in this section to 
determine the appropriate parameters values to be used on ovarian masses. (Please 
refer to Figure 27 for the flow chart of the experiment). Since the default setting was 
provided originally with the software to be used on liver tissue, it was necessary to 
find out the best parameters to be used with ovaries. The values of x 11, y 13, sample 
steps of 0, 0 and sweep intervals of 1, 1 with an actual sample size of 115, were found 
to be suitable for the application of ASQ on ovarian masses. Further testing of a 
smaller ROI size (1 x 1 cm) was done on both phantom and tissue images to test for 
significance. There were no significant differences between larger ROI and the 
desired smaller ROI in both phantom and tissue images, which permit the use of those 
chosen parameters in the clinical setting and their application to smaller masses. 
 
The phantom images were then compared to tissue images and demonstrated to have 
significant differences between the means, which shows that these sets of parameters 
are applicable to human tissue and not only valid on phantom images. 
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3.6.4. Section D 
In this section, a prospective study was conducted by applying ASQ to images of 
pelvic masses. An explanation of the recruitment procedure was given, followed by 
the results of the study. Forty-five masses were saved as raw images to be analysed 
using ASQ software. Data were tested for normality using both the Shapiro-Wilk test 
and Q-Q plot. Then when non-normally distributed data were identified, a non-
parametric statistical test was used (Mann-Whitney U test) to calculate the p-value for 
the significance of the difference. Lastly, a discussion and conclusion to the study was 
provided, concluding that ASQ cannot differentiate between the homogeneity of 
benign and malignant tissues. 
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4. Texture Analysis Features 
This chapter will investigate the possible use of texture analysis features in the 
diagnosis of pelvic masses by applying these features to ultrasound images of the 
masses. The chapter is divided into three main sections. Section A will explain the 
materials and methods used in this research; then section B will show the results 
produced after collecting and analyzing the data, and section C will discuss these 
results and compare them to other studies done in the same field. 
The aim of this chapter is to investigate the use of texture analysis features, namely 
the Grey Level Co-occurrence Matrix (GLCM) and the Wavelet feature, as previous 
research Hamid (2011) has concluded that they are the best features to be used to 
diagnose ovarian masses. 
In this previous preliminary study, the author investigated the robustness of five 
different texture analysis features using phantom. It was found that GLCM and 
wavelet were not affected by factors such as, ROI size, ROI depth and gain setting. 
After that the chosen texture analysis features were applied to thirty ultrasound 
images (ten normal ovaries, nine cysts and eleven malignant masses). A significant 
difference was found between all categories with 91% sensitivity between normal 
tissue and malignant and between cysts and malignant using GLCM and 89, 90% 
using wavelet feature, respectively (Hamid, 2011). However, Hamid did not consider 
comparing the malignant masses with benign masses.  
   
157 
 
Therefor, this current study will use a larger number of prospective participants and 
compare benign and malignant masses using GLCM and wavelet as well as 
comparing the benign subgroups such as: endometrioma, fibroids and dermoids to 
malignant masses. After that the results will be compared  to other widely used 
scoring systems  such as, RMI, PMI and ADNEX, which has not been done before in 
any other study. As well  as dividing the data into pre- and postmenopausal groups 
and analyse them separately. 
(A) Materials and Methods 
The materials used in this study were introduced and explained in the previous 
chapter, which provided an overview of the equipment and the principles of 
Ultrasound and transvaginal transducers (Please refer to Chapter 3, section A). 
In this chapter, texture analysis concepts and texture analysis software (MaZda 4.6, 
Institute of Electronics, Technical University of Lodz, Poland) are described. After 
that the methods used and the procedures followed to accomplish this study, including 
the study design, sample size and recruitment of participants, are explained. 
4.1. Materials 
4.1.1. MaZda Software 
In order to extract the textural features from the ultrasound images, MaZda software 
version 4.6 (Institute of Electronics, University of Lodz, Poland) was used in this 
study. A brief explanation for this software is given in this section. More details about 
this software are available online at: http://www.eletel.p.lodz.pl/mazda/ 
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MaZda is an abbreviation derived from the term ‘Macierz Zdarzen’, which means ‘co-
occurrence matrix’ in Polish. It was developed in 1996 specifically for the analysis of 
image texture (Szczypiński et al., 2009). It was the first program created to conduct a 
quantitative analysis of texture within a freely selected region of interest (ROI) and to 
provide an interpretation of computed results. At first, the use of MaZda was aimed at 
analysis of MRI images. Nevertheless, it revealed its effectiveness in analysis of other 
types of images such as x-ray, CT and ultrasound images (please refer to Figure 40). 
This program is the most widely used for texture analysis. There are only few other 
examples of image texture analysis of software available. The other non-commercial 
packages, such as KeyRes and LS2W, provide only a limited set of the functions that 
are present in MaZda (Szczypiński et al., 2009). 
MaZda is used for texture analysis in 2D and 3D images. It provides a complete path 
for quantitative analysis of image textures, including computation of texture features, 
procedures for feature selection and extraction, data classification methods, and 
various data visualization and image segmentation tools. 
The MaZda package is a reliable and robust tool for the analysis of image textures, as 
confirmed by (Szczypiński et al., 2009). 
4.1.2. Region of interest (ROI) selection 
Region of interest are sets of pixels in 2D images selected to be analysed. In order to 
avoid unnecessary processing, defining a specific region of interest (ROI) will 
concentrate the computation effort on the part of the image that is under investigation. 
This is supported by a study done in 2003 about an automatic technique for 
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morphological analysis, which found that better performance was seen when ROIs 
were obtained manually. This was explained by the fact that using a fully automatic 
algorithm would involve an additional error factor (the process of automatically 
finding the margins of the mass): (Zimmer et al., 2003). 
MaZda software ROIs can be of arbitrary shape. It allows up to sixteen ROIs within a 
single image. These regions can be overlapped if needed. In this study, only one ROI 
is drawn around the mass and used in the analysis, with some cases of drawing several 
ROIs around the cystic areas to be excluded from the analysis of the complex mass, as 
performed by (Hamid et al., 2011). 
 
Figure 40:  flowchart of analysis pathways in Mazda package (adopted from (Szczypiński et al., 2009) 
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4.1.3. Texture features 
MaZda software computes six types of textural features: Histogram-based (first-order 
statistics), GLCM, RLM, Gradient, AR and Wavelet. Based on previous preliminary 
research (Hamid et al., 2011) only two of the six features, which are GLCM and 
Wavelet, were used in this study. Hamid and colleagues explained that the histogram-
based features were not included in their study because they are computed from the 
intensity of pixels without considering any spatial relations between pixels within the 
image and supported their choice using findings from Bader et al. ( 2000) that showed 
insignificant results when using a histogram-based texture feature to distinguish 
benign tumours from carcinomas. 
4.1.3.1. Grey level Co-occurrence matrix (GLCM) 
Harliack (1979) was the primary author who proposed the co-occurrence matrix 
parameters. GLCM is a second-order statistical technique that allows for the 
extraction of statistical information from the image regarding the distribution of pairs 
of pixels. It is computed by defining a direction, a distance and a pair of pixels 
separated by this distance, computed across the defined direction, which are analysed. 
(M. Hajek et al., 2006, Alqahtani et al., 2010, Singh et al., 1997, Beekman and Visser, 
2004). Numerous co-occurrence matrices can be computed for a single image, one for 
each pair of pixels with a defined distance and direction. 
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Figure 41: Showing computation of co-occurrence matrix with pixel of interest (Lu et al., 2006) 
 
Normally a set of 220 co-occurrence matrices are computed, for five different pixels 
distances from 1 to 5 pixels, and four different directions (Ɵ=0°, 45°, 90° and 135°) 
(see Figure 41). Please refer to section 2.1.2.6 in Chapter 2 for background 
information.  
 
 
4.1.3.2. Wavelet  
This is a transform method of texture analysis. The principle of transform methods is 
that the texture properties are represented in space where the coordinate system is 
closely related to the feature of texture, such as frequency and size (Materka A and M, 
1998). The wavelet images are scaled up to five times in both horizontal and vertical 
directions: this results in image transformation into twenty frequency channels. 
Energies computed within the channels provide data on texture frequency components 
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and are used as texture characterizing features (Szczypiński et al., 2009, Castellano et 
al., 2004). 
4.1.3.3. Tissue characterisation 
It is evident from the available literature that visual inspection alone for the diagnosis 
of tissue pathologies can be prone to bias and can lack sensitivity and reliability. One 
main reason for this is that diagnosis largely depends on the sonographer, who 
observes tissue characteristics from the image and compares them with images of 
different pathologies to come out with a diagnosis. The other alternative to this 
method is the application of invasive methodologies, such as needle-guided biopsy. 
Although this is a very robust technique with less chance of error, it has the 
disadvantage of being invasive in nature and is therefore too impractical to be the 
method of choice for all patients.  
To address this problem, researchers have developed quantitative criteria with the 
help of computer systems to aid diagnosis. The use of texture analysis described in 
this chapter attempts to address this shortcoming of subjective analysis and provide a 
better diagnostic tool to distinguish benign from malignant ovarian masses. As 
described in the section above, the commonly used texture analysis methods are based 
on grey level distribution of individual pixels and their relationship with adjacent 
pixels. 
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4.1.4. Data acquisition and image analysis 
The role of texture analysis of medical images has become increasingly important in 
the field of diagnostic imaging. Many researchers have focused on assisting texture 
analysis through the development of computer-aided diagnosis systems. These 
systems have the ability to enhance the precision and accuracy of image 
characterisation. 
A computer-aided quantitative evaluation system for adnexal masses may be divided 
into five parts: 
1. Acquiring an image: a device such as MRI, CT or ultrasound can be used to 
generate the digital image. In this study, an ultrasound machine was used. 
2. Defining the region of interest (ROI) within the image. A different size and 
shape of the ROI can be defined within an image as well as multiple ROI per 
image. 
3. Extraction of the texture features from the defined ROI in the image. 
4. Determination of the most suitable texture parameters to analyse the image for 
the purpose required. 
5. Data analysis and classification of the texture features within the image. 
4.2. Method 
In this section, subject recruitment is described, an overview of patient management is 
considered and the statistical methods used in data entry and analysis are described. 
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4.2.1. Study Design 
 
This study was a quantitative prospective cross-sectional study on women with known 
pelvic masses who were booked for surgery. 
4.2.1.1. Choice of Methods 
4.2.1.1.1. Sample size 
In setting up the study, it was important to recruit a sufficient number of participants 
to demonstrate the differences between the two groups. 
Statistical advice was obtained to determine the required number for each arm, in 
order to test the null hypothesis (the primary end point): i.e. the ability of GLCM and 
wavelet features to analyse images of ovarian masses and categorise them as benign 
or malignant. However, there have been no previous studies on texture analysis to 
distinguish between benign and malignant ovarian masses. Moreover, studies which 
used other morphological scores have suffered from limitations, including the 
subjectivity of the score, because it depends on the sonographer’s experience. In view 
of these factors, the calculation of sample size was based on the assumption that 
texture analysis may distinguish between benign and malignant masses with 5% 
significance level and 80% power: thus, a total of 200 women (100 participants in 
each arm) were required for the study to demonstrate a significant difference.  
The use of power calculation provides a scientific basis for the number of subjects 
required to make up the sample size that is needed to reject the null hypothesis with a 
given level of significance (usually 80%). 
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4.2.2. Participants  
 
Study population: women aged eighteen and above with known pelvic masses. 
Inclusion criteria: All patients with confirmed pelvic masses and scheduled for 
surgery.  
Exclusion criteria: Patients with other Gynaecological malignancy, i.e. not pelvic 
masses, pregnant patients, patients with a previous history of bilateral oophorectomy, 
difficult scans and unclear scan images and patients aged less than eighteen years old. 
Postmenopausal status, defined as amenorrhea of twelve months following natural or 
surgical menopause, or one year or greater of hormone-replacement therapy begun for 
menopausal symptoms (Menon et al., 2008, 2009). In the current study, only women 
with confirmed adnexal masses were included. Any patient with normal morphology 
or incomplete/missing ultrasound data was excluded from this study. 
Patient withdrawal during the study: participants were at liberty to withdraw from the 
study at any time.  
4.2.3. Procedure: Recruitment and Consent 
Participants were selected from a pelvic mass clinic and Gynaecology oncology 
clinics. All patients with known adnexal mass were identified by members of the 
research team. The researcher approached  the potential participants and informed 
them of the research study.  
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The study was explained and written information was provided. Participant 
information sheets and consent forms were provided so that the patients could find out 
more about the study before deciding whether or not to participate. (Please see 
Appendices IV and V). Patients were given up to 24 hours to decide if they wanted to 
participate in the study, and then, after answering any questions they had regarding 
the study, an appointment was booked for the scan. 
On the day of the scan, written consent was obtained before starting the scan. All 
participants were booked for an ultrasound scan of the pelvis prior to their surgery. 
Randomization/ treatment assignment: the researcher was blinded from any 
ultrasound scan reports done for the participants in clinics to avoid bias in the 
diagnosis of ovarian lesions.  
Side effect:  Ultrasound is a safe modality with no documented side effects. 
Transvaginal scanning is a routine procedure that does not raise any problems except 
slight discomfort by some patients. To handle any other side effects that might arise, a 
qualified healthcare professional was present at all times during scanning. 
 
4.2.4. Demographic Data 
The following demographic data were obtained for all study women: age, menopausal 
status, history of previous hysterectomy.  
Postmenopausal status was defined as the absence of menses for a minimum of twelve 
months or an age of more than fifty years in women who had a prior hysterectomy. 
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Family history was considered positive if the patient had a first-degree relative (i.e. 
mother, sister, or daughter) or a second-degree relative (i.e. grandmother, 
granddaughter, aunt or niece) with documented ovarian or breast cancer. 
4.2.5. Ultrasound 
The scanning procedure was the same in all participants in this study. All ultrasound 
procedures were undertaken by the researcher or the co-researchers only for the 
purpose of this study.  
Ovarian morphology dimensions and volume were reviewed. The volume was 
determined using the formula for an ovoid (d1 × d2 × d3 × 0.532).  
 
Ovarian morphology was classified on ultrasound as:  
Normal: - ovary of uniform hypoechogenicity and with a smooth outline with 
or without a single inclusion cyst or spots of calcifications 
- Inclusion cyst must be single, less than 10 mm in diameter and not 
distorting the outline of the ovary; 
- Simple cyst: a single, thin-walled, anechoic cyst with no septa or 
papillary projections; 
- Complex: any case in which the ovary has any non-uniform ovarian 
echogenicity, excluding single simple or inclusion cysts. (Menon et al., 
2009); 
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In women with bilateral ovarian masses, data from both sides were used for the 
analysis, i.e. complex morphology and simple cyst or dermoid on one side and a 
complex mass on the other one. 
The following morphological ultrasound information was recorded in each case: 
volume of the ovary, site and volume of the cyst, cystic wall structure, and cystic wall 
thickness, presence of septation and septal thickness, presence of solid areas within 
the cyst, papillation height if present and echogenicity.  
Presence or absence of Doppler signal and the site of the signal were documented for 
each cyst.  
In addition to applying texture analysis features (GLCM and wavelet), RMI, PMI and 
ADNEX scoring systems were calculated for the masses in this study for comparison 
of the diagnostic performance. Please refer to Chapter 2 for a brief explanation and 
tables of scores of the RMI, PMI and the ADNEX model. 
Histopathological diagnosis was obtained in women who underwent surgery and used 
as the gold standard. In cases where participants were managed conservatively and no 
histology results were available, ultrasound diagnosis by an expert examiner was used 
in typical adnexal masses (endometrioma, typical dermoid and simple cyst) as well as 
the use of a second diagnostic model such as MRI or CT where appropriate. In 
addition, for those with no histology, follow-up at a minimum of twelve months after 
the ultrasound scan was used as recommended in the ROCkeTS study protocol. This 
project is a new ongoing study that aims to develop and validate new risk prediction 
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models that estimate the probability of having ovarian cancer in women with 
symptoms (unpublished) (Saundar et al., 2015). 
4.2.6. Data Analysis 
All data were statistically analysed using the Statistical Package for Social Sciences 
(SPSS) program version 17.0 for windows (SPSS Inc, Chicago, Illinois, USA), 
Database Access 2010 and Microsoft Excel 2010 software in order to calculate the 
statistical differences and measure the variances. This software is widely used 
instrument in statistiscs and social sciences. Therefore, the researcher considers the 
two software applications as appropriate to be used for this piece of research.  
Assumed Sensitivity 97% (95% CI 91.5% to 99.0%) based on 100 malignant. 
Assumed Specificity 85% (95% CI 76.7% to 90.7%) based on 100 benign. 
Obtaining these figures would serve as proof of the principle that the new method is 
capable of performing at least as well as existing methods, and it has the advantage of 
being objective, with minimal operator dependence anticipated. These assumptions 
were calculated by a professional medical statistician prior to commencing the study. 
As long as the data is normally distributed, the use of parametric tests is the 
appropriate method to test independent data (Lang and Secic, 2006b).  
The nonparametric statistical technique known as chi-square was used to examine the 
categorical demographic variables. The Mann-Whitney U test was used in this study, 
as it is often viewed as the nonparametric correspondent of the Student t-test and can 
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be used where the data is suspected to be not normally distributed. Moreover, the 
Mann-Whitney test is less likely than the t-test to falsely indicate significance if 
outliers are present (Motulsky and Brown, 2006). Continuous demographic variables 
were compared using independent t-tests if data were normally distributed and non-
parametric tests when the data were not normally distributed. 
Ninety-five percent confidence intervals were calculated where appropriate. The alpha 
level was set at 0.05 and any p-value less than the alpha level is considered 
statistically significant. This is a conventionally used level to ascertain differences and 
confirm significance between groups, which therefore, by definition, is statistically 
significant (Lang and Secic, 2006b).  
In statistics, logistic regression is used to estimate the possibility that a specific event 
will occur by using a number of predictor variables which might be either numerical 
or categorical and fitting the data to a logit function (logistic curve) (Kleinbaum, 
2010). Logistic regression has a down-side of overestimating the Odds ratio if the 
sample size is less than 500. By increasing the sample size, this overestimation 
contracts until it reaches the true population value. However, in a single study, 
overestimation due to the small sample size might not affect the interpretation of the 
results due to the fact that this will be much lower than the standard error of the 
estimate (Kleinbaum, 2010). In this study, logistic regression was used at the end of 
the analysis to explore a different way of analysing the data by using the variables in a 
logistic regression model. 
   
171 
 
4.2.6.1. Performance measures 
Sensitivity, specificity, positive predictive value (PPV), and accuracy were calculated 
to evaluate the performance of the texture features. The true negative (TN) is the 
number of benign samples identified as benign. The true positive (TP) is the number 
of malignant images identified as malignant. The number of malignant masses 
detected as benign is quantified by the false-negative (FN) measure. False-positive 
(FP) is the number of benign samples identified as malignant. 
The sensitivity is the proportion of actual positive (malignant) cases which are 
correctly identified, while the specificity is the proportion of actual negative (benign) 
cases which are correctly identified. The PPV is the ratio of true positives to 
combined true and false positives, and the accuracy is the ratio of the number of 
correctly classified samples to the total number of samples. (Please refer to Table 42 
for the calculation of the performance tests). 
 
 
    
 
 
 
Table 42:  Calculation of statistical performance tests. (TP is true positive, FP is false positive, TN is true negative 
and FN is false negative) 
 
 
PPV 𝑻𝑷
𝑻𝑷 + 𝑭𝑷
 
 
Sensitivity 𝑻𝑷
𝑻𝑷 + 𝑭𝑵
 
 
NPV 𝑇𝑁
𝑇𝑁 + 𝐹𝑁
 
 
Specificity 𝑇𝑁
𝑇𝑁 + 𝐹𝑃
 
 
Accuracy 𝑇𝑃 + 𝑇𝑁
𝑇𝑃 + 𝑇𝑁 + 𝐹𝑁 + 𝐹𝑃
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4.2.7. Location of Study and Access Arrangements 
 
This study took place in the Medical Physics and Clinical Engineering Department 
and Doppler Department at the University Hospital of Wales (UHW), Cardiff, UK. As 
well as Pelvic mass clinic in UHW . No other departments or laboratories were 
included. 
 
4.2.8. Ethical Considerations 
 
This study uses human participants: therefore, there are several important ethical 
issues relating to the design and implementation of the study. The ethical principle 
governing research is that patients should not be harmed as a result of participating in 
the research (Silverman, 1985). Moreover, the dignity, rights, safety and well-being of 
participants in research must be of primary consideration (Power and Kuyken, 1998). 
The ethical committee provides independent expert opinion on whether the proposed 
research is ethical and respects the dignity, rights, safety and well-being of 
participants. For this reason, a full protocol for the proposed study of image texture 
analysis of Transvaginal ultrasound in diagnosing ovarian cancer was submitted to the 
Dyfed Powys Research Ethics Committee. The study received full ethical approval on 
18
th
 July 2013 (Ref. 13/WA/0206), as shown in appendix III. This project was also 
submitted to Cardiff and Vale NHS trust research and development committee, and 
was approved for commencement on 26
th
 April 2013, as shown in appendix II.  
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4.3. Results: texture analysis 
 
A total of 226 patients fitted  the criteria and were recruited for this study in the 
period between November 2013 and May 2015. Of these patients, 63 (27.8%) were 
then excluded from the analysis for several reasons, such as participants refusing to 
have the internal scan (n=20), incomplete data required for the analysis (n=7), no 
histology found (n=34) three months after the scan due to participants being managed 
conservatively and not proceeding to surgery, and finally participants agreeing to have 
the scan and then cancelling (n=2). 
Therefore, only 163 patients (169 masses) were analysed for the purpose of this study, 
of whom 95 were premenopausal and 68 postmenopausal. Their ages ranged from 18 
to 53 years in the premenopausal group (mean 41, median 42) and from 52 to 91 years 
(mean 67, median 66) in the postmenopausal group. In total, 169 ovarian masses were 
used for texture analysis.  
Histopathology results of the masses showed 116 benign, 29 malignant and 24 simple 
cysts.  
A total of 81 of the benign masses were premenopausal and 35 postmenopausal. Of 
the malignant masses, 8 were premenopausal and 21 postmenopausal and of the 
simple cyst, 9 were premenopausal and 15 postmenopausal.  
For the purpose of the analysis, the benign group were further divided into subgroups 
using ultrasound diagnosis, including 32 mature teratomas (dermoid), 27 
endometriomas, 24 fibroids and 33 other suspicious benign masses. The histology  
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results of these suspicious masses were documented and are summarised in Table 43. 
The most commonly identified of these suspicious benign masses were the fibroma 
(18%) and both the serous and mucinous cystadenoma (15%) as well as the cyst 
adenofibroma (15%). 
The malignant tumours were classified using histopathology and the results are 
summarised in Table 44. They include both serous and mucinous adenocarcinoma, 
adult granulosa cells, poorly differentiated adenocarcinoma and borderline serous and 
mucinous cystadenoma and a couple of unknown malignant classification. The most 
commonly found type was the borderline serous cystadenoma (24%) followed by the 
high grade serous adenocarcinoma (17%) and the grade 3 carcinoma (14%). 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 43: Summary of histology results of 33 suspicious benign masses. 
Type of mass Frequency Percentage (%) 
Fibroma 6 18.2 
Serous 
cystadenoma 
5 15.2 
Cyst 
adenofibroma 
5 15.2 
Adenofibroma 2 6 
Mucinous 
cystadenoma 
5 15.2 
Leiomyoma 2 6 
Epithelial cysts 2 6 
Adenomyosis 1 3 
Endometriosis 1 3 
Degenerated 
fibroid 
1 3 
Pedunculated 
fibroid 
1 3 
Benign 
unknown type 
2 6 
Total 33 100% 
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Table 44: Summary of histology results of 29 malignant masses 
 
For each group (cyst, benign and malignant masses), the mean, median, standard 
deviation and standard error of the mean (s.e.) of the extracted features were 
calculated and summarised in Table 45. The mean values of the GLCM and wavelet 
features are presented visually in Figure 42 and Figure 43, respectively. 
Type of mass Frequency Percentage (%) 
High grade serous 
adenocarcinoma 
5 17.2% 
Invasive 
squamous cell 
carcinoma 
1 3.5% 
Adult granulosa 
cell 
2 6.9% 
Poorly 
differentiated 
adenocarcinoma 
2 6.9% 
Appendicle 
mucinous 
neoplasm 
1 3.5% 
Endometrial 
adenocarcinoma 
1 3.5% 
Grade 3 
carcinoma 
4 13.8% 
Borderline serous 
cystadenoma 
7 24% 
Borderline 
mucinous 
cystadenoma 
3 10.3% 
Borderline serous 
epithelia 
neoplasm 
1 3.5% 
Unknown 
classification 
2 6.9% 
Total 29 100% 
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Of the three groups, the malignant tissue exhibited the highest GLCM mean value 
(512), while cysts exhibited the lowest GLCM value (90). The mean value for the 
benign tissue is 320. The same pattern was observed in the wavelet feature, with the 
malignant tissue having the highest mean value (30809) and the cyst having the 
lowest mean value (3823). 
 
 
 
 
 
 
 
 
 
 
 
 
Table 45: Summary of the mean, median, standard deviation, and standard error of the mean of the extracted 
features. 
 
 
Texture 
feature 
Tissue type Mean Median SD S.E. 
GLCM Cyst 90 60 82 18 
Benign 320 250 229 21 
Malignant 512 376 341 63 
Wavelet Cyst 3823 7714 4360 930 
Benign 21642 17191 15286 1407 
Malignant 30809 26337 21036 3906 
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Figure 43: Graph showing mean values of wavelet feature for benign, malignant and simple cyst tissue. 
 
Figure 42: Graph showing mean value of GLCM feature for benign, malignant and simple cyst tissue. 
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4.3.1. Normality testing  
Before testing the significance of the difference between means, it is important to 
know whether the data is normally distributed in order to decide which test to use: 
either parametric statistical tests such as t-tests for normally distributed data or the 
non-parametric tests such as the Mann-Whitney U test for non-normally distributed 
data. 
The Shapiro-Wilk test was used to test for normality and it was found that most of the 
data in this study were not normally distributed, except for the wavelet feature in the 
cysts, which appeared to be normally distributed (.427). Results are summarised in 
Table 46. 
Furthermore, a Q-Q plot was used to visually inspect the normality of the data. It was 
noticed that in the GLCM feature, not all tissue types were following the line, which 
means that they were not normally distributed. Please refer to Figures 44 to 49 for Q-
Q plots of different types of tissue in both the GLCM feature and the wavelet feature. 
Texture 
feature 
Tissue type 
Shapiro-
Wilk test 
(sig.) 
Normally 
distributed? 
GLCM 
Cyst <.05 No 
Benign <.05 No 
Malignant .031 No 
Wavelet 
Cyst .427 Yes 
Benign <.05 No 
Malignant .007 No 
                                        
                                Table 46: Shapiro-Wilk test for normality 
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Figure 43: Q-Q plot for GLCM in the simple cyst tissue. 
 
Figure 44: Q-Q plot for GLCM in the benign tissue. 
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Figure 45: Q-Q plot for GLCM in the malignant tissue. 
 
Figure 46: Q-Q plot for wavelet in the simple cyst tissue. 
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Figure 47: Q-Q plot for wavelet in the benign tissue. 
 
 
 
 
 
 
Figure 48: Q-Q plot for wavelet in the malignant tissue. 
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4.3.2. Test for significance  
The values of the extracted features were compared in pairs: benign and malignant; 
cysts and malignant; and benign and cysts. The results for the GLCM feature show 
that all differences between group pairs were statistically significant: the p-value was 
<.05 in all groups. 
The results for the wavelet feature were similar to the GLCM for all three groups, 
with a significant difference of p <.05 in all groups. The results for both GLCM and 
wavelet features are summarised in Table 47.  
Texture feature Group pair P-value  
Significantly 
different? 
GLCM 
Benign-Cyst <.05 Yes  
Benign-Malignant .004 Yes  
Cyst-Malignant <.05 Yes  
Wavelet 
Benign-Cyst <.05 Yes 
Benign-Malignant .027 Yes  
Cyst-Malignant <.05 Yes  
 
Table 47: Summary results of the significance test in all group pairs for both GLCM and wavelet. 
 
For further analysis, the benign group was sub-divided into four groups, namely 
teratomas, endometriomas, fibroids and other suspicious or difficult to diagnose 
benign masses. When comparing these subgroups to the suspicious benign masses, it 
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was found that GLCM could significantly differentiate the benign suspicious group 
from the teratomas (p=.021) and from the endometriomas (p=.011). On the other 
hand, GLCM could not differentiate the benign masses from the fibroids (p=.449). 
Texture feature Group pair P-value  
Significantly 
different? 
GLCM 
Benign-teratoma .021 Yes  
Benign-
endometrioma 
.011 Yes  
Benign-fibroid .449 No   
Wavelet 
Benign-teratoma .014 Yes 
Benign-
endometrioma 
.170 No  
Benign-fibroid .693 No  
 
Table 48: Tests of significant difference for the benign subgroups. 
 
The wavelet feature only significantly differentiated between the benign suspicious 
group and the teratomas (p=.014); however, there was no significant difference 
between the benign suspicious group and the endometriomas or between the benign 
suspicious group and the fibroids (p=.170, p=.693) respectively. Results are 
summarised in Table 48. 
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Texture 
feature 
Group pair P-value  
Significantly 
different? 
GLCM 
Malignant-teratoma .697 No  
Malignant-endometrioma <.05 Yes  
Malignant -fibroid .009 Yes  
Wavelet 
Malignant -teratoma .988 No  
Malignant -endometrioma .004 Yes  
Malignant -fibroid .061 No  
 
Table 49: Tests of significant difference test for malignant vs. benign subgroups. 
 
When comparing these subgroups of benign masses with the malignant masses, it was 
found that the GLCM feature could significantly differentiate between the malignant 
masses and both endometriomas (p<.05) and fibroids (p=.009), but it could not 
differentiate them from the teratoma masses (p= 697).   
When using the wavelet feature to compare groups, a significant difference was 
noticed between the malignant masses and the endometriomas (p =.004), while in the 
other two groups, comparing the malignant masses with the teratomas (p=.988) and 
with the fibroids (p=.061), no significant differences were seen. These p-values are 
summarised in Table 49. 
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4.3.3. ROC and AUC 
Receiver operating curve (ROC) analysis was performed to determine the ability of 
the GLCM feature to discriminate between cysts and benign masses, and between 
benign and malignant masses (i.e. for those group pairs that demonstrate a statistically 
significant difference (p<0.05). The corresponding ROC curves are shown in Figure 
48 & 49  (between benign and malignant masses), Figure 50 & 51 (between cyst and 
benign masses), and Figure 52 & 53 (between cysts and malignant masses). An AUC 
close to 1 indicates a strong discriminatory power/ability of the indicator variable, 
while the AUC close to 0.5 indicates that the variable has little discriminatory power. 
 
Figure 49: ROC curve for GLCM feature to discriminate between benign and malignant masses 
 
 
 
 
AUC=.668 
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Figure 50: ROC curve for Wavelet feature to discriminate between benign and malignant masses 
 
 
 
Figure 51: ROC curve for GLCM feature to discriminate between cysts and benign masses 
 
 
 
AUC=.630 
AUC=.895 
   
187 
 
 
Figure 52: ROC curve for wavelet feature to discriminate between cysts and benign masses 
 
 
 
 
Figure 53: ROC curve for GLCM feature to discriminate between cysts and malignant masses 
 
 
 
 
AUC=.944 
AUC=.814 
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Figure 54: ROC curve for Wavelet feature to discriminate between cyst and malignant masses 
 
 
Table 50 presents the area under the curve (AUC), which reflects the ability of the 
GLCM and the wavelet features in discriminating between the groups. It shows that 
the GLCM is a poor indicator (AUC=.668) for distinguishing between benign and 
malignant masses; on the other hand, it is an excellent indicator in both discriminating 
between malignant masses and cysts (AUC=.994) and between benign masses and 
cysts (AUC=.895). Results are similar when applying the wavelet feature, which is a 
poor indicator (AUC=.630) to differentiate between benign and malignant masses but 
a good indicator (AUC=.894) to differentiate between malignant masses and cysts as 
well as between benign masses and cysts (AUC=.814).  
To evaluate the ability of the texture feature to correctly classify masses, a threshold 
value was selected to get the highest possible sensitivity and specificity. For instance, 
in discriminating between benign and malignant masses, the use of 245 as a threshold 
AUC=.894 
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value led to an estimated sensitivity of 72% and specificity of 60%. Table 51 presents 
examples of the threshold value in both GLCM and wavelet features. 
Texture 
feature 
Group pair AUC  S.E. 
 
 
Discriminatory 
ability 
GLCM 
Benign-Malignant .668 .060 Poor 
Malignant-Cyst .994 .029 Excellent 
Benign-Cyst .895 .037 Excellent 
Wavelet 
Benign-Malignant .630 .061 Poor 
Malignant –Cyst .894 .044 Good 
Benign-Cyst .814 .037 Good 
  
Table 50: Area under the curve (AUC) with standard error (S.E.) associated with both GLCM and Wavelet 
features 
 
Texture feature Group pair Threshold value Sensitivity (%) Specificity (%) 
GLCM Benign-malignant 245 72% 60% 
Malignant-Cyst 86 97% 62% 
Benign-cyst 100.5 93% 70% 
Wavelet 
 
 
Benign-malignant 17191 60% 60% 
Malignant-Cyst 
 
10484 90% 59% 
Benign-cyst 
 
10826 72% 62% 
  
Table 51: Sensitivity and Specificity associated with GLCM and Wavelet features. 
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Furthermore, when comparing the malignant masses with the benign subgroups, ROC 
curves were generated only for the group pairs that showed a significant difference. 
Therefore, an ROC curve was created for the malignant–endometrioma pair and for 
the malignant–fibroid pair for the GLCM feature and for the malignant–
endometrioma pair using the wavelet feature. Results showed that the GLCM feature 
had a good (AUC=0.8) discriminatory ability in distinguishing between malignant 
masses and endmetriomas, while it presents a fair ability (AUC= .711) when 
distinguishing malignant masses from fibroids. Moreover, the wavelet feature 
revealed a fair ability to distinguish between malignant masses and endmetriomas 
(AUC= .723). Results are summarised in Table 52. ROC curves for these subgroups 
are presented in Figures 54, 55 and 56. 
 
Texture feature Group pair AUC Discriminatory ability 
GLCM Malignant-endometrioma .8 Good 
Malignant- fibroid .711 Fair 
Wavelet Malignant-endometrioma .723 Fair 
 
Table 52: The area under the curve (AUC) associated with both GLCM and Wavelet features in the subgroups 
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Figure 55: ROC curve of the GLCM feature to discriminate between malignant masses and endometriomas 
 
 
 
Figure 56: ROC curve of the GLCM feature to discriminate between malignant and fibroid masses 
 
AUC=.8 
AUC=.711 
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Figure 57: ROC curve of the wavelet feature to discriminate between malignant masses and endmetriomas 
 
To evaluate the ability of the texture feature to correctly classify masses in these 
subgroups, a threshold value was again selected here to get the highest possible 
sensitivity and specificity. However, sensitivity was prioritised over specificity. In the 
GLCM feature, a threshold value of 292.3 was found to give a sensitivity of 70% and 
a specificity of 82% when attempting to distinguish between malignant masses and 
endometriomas. For comparison between malignant masses and fibroids using the 
same texture feature, a threshold value of 265.3 was found to give a sensitivity of 
72% and a specificity of 63%. 
In the wavelet feature, a threshold value of 16242.5 was seen to give a sensitivity of 
70% and a specificity of 60% when comparing malignant masses and endometriomas. 
Results are summarised in Table 53. 
 
 
AUC=.723 
   
193 
 
Texture 
feature 
Group pair Threshold 
value 
Sensitivity 
(%) 
Specificity 
(%) 
GLCM Malignant- 
endometrioma 
292.3 70% 82% 
Malignant- 
fibroid 
265.3 72% 63% 
Wavelet 
 
 
Malignant- 
endometrioma 
16242.5 70% 60% 
  
Table 53: Sensitivity and specificity associated with GLCM and Wavelet features in the subgroups 
 
4.3.4. Diagnostic scoring systems 
 
Further assessment was done using the widely used scoring systems, which are PMI 
on grey scale, RMI and the ADNEX model.  
4.3.4.1. RMI 
When applying RMI scores to the data, only 99 masses were applicable, of which 14 
were excluded due to missing CA125 values. The remaining 85 masses were divided 
into three categories when applying the RMI scoring system: the high risk group with 
RMI >250, the moderate group with RMI between 25-250 and the low risk group with 
RMI <25. According to RMI, 15 (17.6%) masses were in the high risk group, 32 
(37.6%) in the moderate risk group and 38 (44.7%) in the low risk group, of which 11 
had a score of 0 due to a U score of 0. In the high risk group (RMI>250), 8 masses 
were diagnosed as benign by histology, which means that these masses gave false 
positive results. On the other hand, 15 masses were diagnosed as malignant in the low 
risk group (<250), which means that they were false negative results. Please refer to 
Table 54. 
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Type of the test Malignant by histology Benign by histology 
RMI  >250 True positive (TP) 
7 
False positive (FP) 
8 
<250 False negative  (FN) 
15 
True negative (TN) 
55 
Total 22 63 
 
Table 54: 2x2 contingency table for RMI scores 
 
 
 
4.3.4.2. PMI 
In this study, we also applied the PMI score to compare it with our texture analysis 
results. In total, 102 of 169 masses were eligible for the PMI score. The results were 
divided into three groups: low risk (-2 – 0) intermediate (1-2) and high risk (above 3). 
Forty (39.2%) masses were found to be low risk, while thirteen (12.7%) were in the 
intermediate group and forty-nine (44.1%) were in the high risk group. In the high 
risk group, thirty-six masses had been diagnosed as benign by histology, which means 
that they were false positive results, while in the low risk group, three masses were 
diagnosed as malignant in the histology, which means that they were in the false 
negative group. Please refer to Table 55. 
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Type of the test Malignant by histology Benign by histology 
High risk and 
intermediate risk 
(TP) 
26 
(FP) 
36 
Low risk 
(FN) 
3 
(TN) 
37 
Total 29 73 
 
Table 55: 2x2 contingency table for PMI score 
 
4.3.4.3. ADNEX 
The new model made available by the IOTA group – the ADNEX model – was 
applicable to 81 of the 169 masses in this study. Fifty-two (64%) masses were 
considered most probably benign and twenty-nine (36%) were considered to be at 
high risk of malignancy. In this high risk of malignancy group, eleven masses were 
benign according to histology, which makes them false positive results, while in the 
low risk group, another eleven masses were found to be malignant by histology, 
which categorises them as false negatives. Please refer to Table 56. 
Type of the test Malignant by histology Benign by histology 
High risk >50% (TP) 
18 
(FP) 
11 
Low risk  <50% (FN) 
11 
(TN) 
41 
Total 29 52 
            Table 56: 2x2 contingency table for the ADNEX score. 
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4.3.4.4. Sensitivity and Specificity 
The following table (Table 57) presents a summary of the diagnostic performance of 
the texture features of interest and the most commonly used scoring systems. PMI 
showed the best overall sensitivity (90%) and NPV (93%) amongst the indices; 
however, it had the lowest specificity of them all (51%). In contrast, RMI showed the 
highest specificity (87%), while compromising on sensitivity, which was the lowest in 
all indices (32%) and NPV (80%). GLCM and wavelets present similar specificity 
(60%) with somewhat higher sensitivity in the GLCM (72% compared to 60%) in the 
wavelet and NPV (90%). Moreover, the ADNEX score showed a similar sensitivity 
(62%) and NPV (80%) to the wavelet, with a much higher specificity (80%). 
Correlation Sensitivity Specificity PPV NPV Accuracy 
GLCM 72% (95% CI: 53-91%) 60% 25% 90% 60% 
Wavelet 60% (95% CI: 37-83%) 60% 22% 90% 60% 
RMI 32% (95% CI: 0-65%) 87% 50% 80% 73% 
PMI 90% (95% CI: 80-100%) 51% 42% 93% 62% 
ADNEX 62% (95% CI: 29-95%) 80% 62% 80% 73% 
  
Table 57: Summary of the sensitivity, specificity, PPV, NPV and accuracy of the texture analysis features GLCM 
and wavelet compared to RMI, PMI and ADNEX. 
 
4.3.5. Tissue characterisation 
In this study, a comparison was done between masses to test the ability of the selected 
texture feature to distinguish between different types of mass. In this section, we 
explore further by testing the ability of these features to distinguish between different 
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types of tissue. For this purpose, a sample of twenty normal ovarian tissues was 
analysed using both GLCM and wavelet. Then it was compared to the analysis of 
solid areas taken from malignant masses. 
The results show a significant difference between the two different tissues with p<.05 
when using the GLCM, with a mean value of 190.6 for the normal ovary compared to 
503 in the malignant tissue and p=.004 when using the wavelet feature, with a mean 
of 17089 in the normal ovary and 38761.5 in the malignant tissue. Please refer to 
Table 58 for a summary of the results. 
Texture 
Feature 
Tissue type Mean Median P-value Significantly 
different? 
GLCM Normal ovary 190.6 167.3 <.05 Yes 
Malignant 503 464.5 
Wavelet Normal ovary 17089 14254 .004 Yes 
Malignant 38761.5 31810 
 
Table 58: The significance test between normal ovarian tissue and malignant solid tissue. 
 
4.3.6. Premenopausal group 
 
 
Subdividing the study population into the categories of pre- and postmenopausal 
status allowed more in-depth analysis of the performance of the three indices. 
Ninety-eight women were found in the premenopausal group, with eighty-one benign, 
eight malignant and nine simple cysts. Similar to the total population analysis, group 
   
198 
 
of pairs were compared to each other to test for significance. When using the GLCM, 
all group pairs were still found to have a significant difference in the premenopausal 
group. However, when applying the wavelet feature, the malignant and benign masses 
could not be differentiated significantly (p=.366). The other two groups of pairs 
(benign-cyst and malignant-cyst) still had significant differences. Results are 
illustrated in Table 59. 
 
Texture Feature Group pair P-value Significantly 
different? 
GLCM Benign-cyst <.05 Yes 
Malignant-benign .022 Yes  
Malignant-cyst <.05 Yes 
Wavelet Benign-cyst <.05 Yes 
Malignant-benign 0.366 No 
Malignant-cyst <.05 Yes 
 
Table 59: Summary of results of the significance test in premenopausal women 
 
Following the analysis of the total population, ROC curves were generated and AUC 
were calculated. As mentioned above, only the group pairs with significant 
differences were used in these ROC curves. When distinguishing between benign and 
malignant masses, GLCM showed a fair ability, with AUC=.747 in the 
premenopausal group compared to the total population analysis, which had poor 
ability (AUC=.668). Please refer to Table 60. 
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In the other group pairs – the benign compared to the simple cysts – both GLCM and 
wavelet showed good discriminatory ability, with AUC=.879 and .850 respectively. 
In the group pair of malignant compared to simple cysts, both features showed 
excellent discriminatory ability in the premenopausal population (AUC= .944, .986) 
for GLCM and wavelet respectively. ROC curves for all pairs are illustrated in 
Figures 59 to 63. These results are similar to the total population analysis. Please refer 
to Tables 50 and 60 for the comparison. 
Texture feature Group pair AUC S.E. Discriminatory 
ability 
GLCM Benign-malignant .747 .079 Fair  
Benign-Cyst .879 .070 Good  
Malignant-cyst .944 .059 Excellent 
Wavelet Benign-malignant .597 .105 Poor 
Benign-cyst .850 .045 Good 
Malignant-cyst .986 .022 Excellent 
 
Table 60: The area under the curve (AUC) and standard error (S.E.) associated with both GLCM and Wavelet 
features in premenopausal women 
 
Similar to the total population, a threshold value was selected to get the highest 
possible sensitivity and specificity. In the GLCM feature, a threshold value of 279.5 
gave a sensitivity of 75% and a specificity of 60% when comparing the benign with 
the malignant masses (See Table 61 for all threshold values). 
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Texture feature Group pair Threshold value Sensitivity (%) Specificity (%) 
GLCM Benign-malignant 279.5 75% 60% 
Malignant-cyst 177.5 100% 90% 
Benign-cyst  108 89% 78% 
Wavelet Benign-malignant 18284 50% 46% 
Benign-cyst 
 
10982 75% 78% 
Malignant-cyst 
 
11146 100% 78% 
 
Table 61: Sensitivity and Specificity associated with GLCM and Wavelet features in premenopausal women 
 
 
 
 
Figure 58: ROC curve for the GLCM feature for the difference between malignant and benign masses in the 
premenopausal group. 
 
 
AUC=.747 
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Figure 59: ROC curve for the GLCM feature for the difference between benign masses and cysts in the 
premenopausal group. 
 
 
 
 
Figure 60: ROC curve for the wavelet feature for the difference between benign masses and cysts in the 
premenopausal group. 
 
 
AUC=.850 
AUC=.879 
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Figure 61: ROC curve for the GLCM feature for the difference between malignant masses and cysts in the 
premenopausal group. 
 
 
 
 
Figure 62: ROC curve for the wavelet feature for the difference between malignant masses and cysts in the 
premenopausal group. 
 
AUC=.944 
AUC=.986 
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4.3.6.1. PMI  
When applying PMI scores in the premenopausal group, fifty-six masses were found. 
A contingency table was created and showed that eight masses were found to be 
malignant by histology. Six of them had a high or intermediate score in the PMI, 
which were the true positive results. Forty-eight masses were diagnosed as benign by 
histology and thirty-seven of them were classed as low risk on PMI, which were the 
true negative results. A summary of the results is showed in Table 62. 
Type of the test Malignant by histology Benign by histology 
High risk and intermediate 
risk 
(TP) 
6 
(FP) 
11 
Low risk (FN) 
2 
(TN) 
37 
Total 8 48 
 
Table 62: 2x2 contingency table for PMI score in premenopausal women. 
 
4.3.6.2. RMI 
Here we applied RMI to the premenopausal group. Forty-nine masses were used for 
the analysis. Seven masses were diagnosed as malignant by histology; however, only 
one mass was found to have a high score in RMI, which was the true positive result. 
On the other hand, out of forty-two benign masses according to histology, forty had a 
low risk on the RMI score, which were the true negative results. Table 63 gives a 
summary of the results. 
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Type of the test Malignant by histology Benign by histology 
RMI  >250  (TP) 
1 
(FP) 
2 
<250  (FN) 
6 
 (TN) 
40 
Total 7 42 
 
Table 63: 2x2 contingency table for RMI score in premenopausal group 
 
4.3.6.3. ADNEX 
When applying the ADNEX scoring system to the premenopausal group, thirty-nine 
masses were analysed. A total of eight masses were found to be malignant by 
histology; four of them were found to have a high risk score by ADNEX, which were 
the true positive results. In the benign group, thirty-one masses were seen by 
histology. Twenty-five of them had a low risk score in the ADNEX and were the true 
negative results. Please see Table 64 for a summary of these results. 
 
Type of the test Malignant by histology Benign by histology 
High risk >50% (TP) 
4 
(FP) 
6 
Low risk  <50% (FN) 
4 
(TN) 
25 
Total 8 31 
 
Table 64: 2x2 contingency table for the ADNEX score in the premenopausal group 
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4.3.6.4. Sensitivity and specificity  
The following table (Table 65) presents a summary of the diagnostic performance of 
the texture feature GLCM and the most commonly used scoring systems when 
analysing the premenopausal group. GLCM and PMI had the highest sensitivity 
(75%) compared to ADNEX and the wavelet feature (50%), while RMI had the 
lowest sensitivity (14%). However, RMI had the highest specificity (95%), followed 
by ADNEX (80%) and then GLCM (60%), and wavelet had the lowest specificity 
(46%). As can be seen, the sensitivity of wavelet, RMI, PMI and ADNEX (60%, 32%, 
90% and 62% respectively in the total population) dropped when analysing the 
premenopausal group specifically, while the performance improved in the GLCM 
(sensitivity was 72% in total population). In the specificity performance, RMI 
improved from 87% to 95%, and PMI improved from 51% to 77%, while wavelet 
performance decreased from 60% to 48%. No change was seen in either GLCM or 
ADNEX. 
Correlation Sensitivity Specificity PPV NPV Accuracy 
GLCM 75% (95% CI: 42-100%) 60% 15% 96% 60% 
Wavelet  50% (95% CI: 1-99%) 46% 1% 90% 46% 
RMI 14% (95% CI: too wide) 95% 33% 87% 84% 
PMI 75% (95% CI: 42-100%) 77% 35% 95% 77% 
ADNEX 50% (95% CI: 1-99%) 80% 40% 86% 74% 
 
Table 65: Summary of the sensitivity, specificity, PPV, NPV and accuracy of the texture analysis feature GLCM 
compared to RMI, PMI and ADNEX in the premenopausal group 
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4.3.7. Postmenopausal group 
 
Seventy-one women were found in the postmenopausal group, with thirty-five benign, 
twenty-one malignant and fifteen simple cysts. Similar to the total population 
analysis, group of pairs were compared to each other to test for significance. 
Significant differences were seen between the benign and the cyst group pair and 
between the malignant and the cyst group pair, but no significant difference was 
found between malignant and benign groups (p=.110). All group pairs in the wavelet 
feature showed a significant difference, unlike the results from the premenopausal 
group, where the difference between malignant and benign groups was not significant. 
Please see Table 66 for a summary of the results. 
For those group pairs that demonstrate a statistically significance difference (p<0.05), 
ROC curves were created to determine the ability of the GLCM feature to 
discriminate between cysts and benign masses, and between cysts and malignant 
masses. For the wavelet feature, all three group pairs were analysed using a ROC 
curve. Please refer to Figures 64 to 68. 
Area under the curve (AUC) results were somewhat similar to those for the 
premenopausal group. Excellent discriminatory ability was seen when comparing the 
cysts with the benign and the malignant masses when using the GLCM feature as well 
as between the cysts and the benign masses when using the wavelet feature. Good 
discriminatory ability between cysts and malignant masses was seen when using the 
wavelet feature. When comparing the benign with the malignant masses, the wavelet 
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feature showed poor discriminatory ability (AUC=.683) in the postmenopausal group. 
A summary of the results is shown in Table 67. 
Correlation Sensitivity Specificity PPV NPV Accuracy 
GLCM 75% (95% CI: 42-100%) 60% 15% 96% 60% 
Wavelet  50% (95% CI: 1-99%) 46% 1% 90% 46% 
RMI 14% (95% CI: too wide) 95% 33% 87% 84% 
PMI 75% (95% CI: 42-100%) 77% 35% 95% 77% 
ADNEX 50% (95% CI: 1-99%) 80% 40% 86% 74% 
 
Table 66: Summary results of the significance test in postmenopausal women 
 
Texture feature Group pair AUC S.E. Discriminatory 
ability 
GLCM Benign-malignant .629 .085 Poor  
Benign-Cyst .920 .043 Excellent 
Malignant-cyst .943 .035 Excellent 
Wavelet Benign-malignant .683 .079 Poor 
Benign-cyst .768 .066 Fair 
Malignant-cyst .863 .061 Good 
 
Table 67: The area under the curve (AUC) and standard error (S.E.) associated with both GLCM and Wavelet 
features in postmenopausal women 
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Table 68: Sensitivity and specificity associated with GLCM and Wavelet features in postmenopausal women 
 
 
 
 
 
 
Figure 63: ROC curve for the wavelet feature for the difference between malignant and benign masses in the 
postmenopausal group 
Texture 
feature 
Group pair Threshold 
value 
Sensitivity 
(%) 
Specificity 
(%) 
GLCM Benign-malignant 267 71% 55% 
Benign-cyst 107.4 97% 70% 
Malignant-cyst 101.7 95% 73% 
Wavelet 
 
 
Benign-malignant 18283.9 62% 60% 
Benign-cyst 11104.9 71% 60% 
Malignant-cyst 
 
10964.2 86% 60% 
AUC=.683 
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Figure 64: ROC curve for the GLCM feature for the difference between benign masses and cysts in the 
postmenopausal group 
 
 
 
Figure 65: ROC curve for the wavelet feature for the difference between benign masses and cysts in the 
postmenopausal group 
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Figure 66: ROC curve for the GLCM feature for the difference between malignant masses and cysts in the 
postmenopausal group 
 
 
 
Figure 67: ROC curve of the wavelet feature for the difference between malignant masses and cysts in the 
postmenopausal group 
 
AUC=.943 
AUC=.863 
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4.3.7.1. PMI 
In the postmenopausal group, thirty-nine masses were analysed using the PMI score. 
Nineteen of them were malignant and scored as high risk on the PMI: these were the 
true positive results. Six were benign and scored as low risk on the PMI: these were 
the true negative results. Table 69 is the contingency table created for the PMI in the 
postmenopausal group.    
Type of the test Malignant by histology Benign by histology 
High risk and 
intermediate risk 
(TP) 
19 
(FP) 
12 
Low risk (FN) 
2 
(TN) 
6 
Total 21 18 
 
Table 69: 2x2 contingency table for PMI score in postmenopausal women. 
 
4.3.7.2. RMI 
In the postmenopausal group, twenty-nine masses were analysed using the RMI score. 
By histology, fifteen of them were found to be malignant. However, only six of these 
fifteen were classified as high risk using the RMI score (true positive results). The 
other fourteen masses were benign, and nine of them were true negative results: their 
RMI scores were <250, placing them in the low risk group. Table 70 summarises the 
results for the RMI scores in the postmenopausal group. 
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Type of the test Malignant by histology Benign by histology 
High risk and 
intermediate risk 
(TP) 
19 
(FP) 
12 
Low risk (FN) 
2 
(TN) 
6 
Total 21 18 
 
Table 70: 2x2 contingency table for RMI score in postmenopausal group 
 
4.3.7.3. ADNEX 
 
In the postmenopausal group, thirty-nine masses were analysed using the ADNEX 
scoring system. Twenty-one of them were found to be malignant by histology, and 
fourteen were high risk when using ADNEX (true positive results). The other 
seventeen were found to be benign by histology. Thirteen of them had low risk 
according to ADNEX, representing true negative results. Please refer to Table 71 for 
the contingency table of the ADNEX score in the postmenopausal group. 
Type of the test Malignant by histology Benign by histology 
High risk >50% (TP) 
14 
(FP) 
4 
Low risk  <50% (FN) 
7 
(TN) 
13 
Total 21 17 
 
Table 71: 2x2 contingency table for the ADNEX scores in the postmenopausal group 
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4.3.7.4. Sensitivity and Specificity  
 
In the postmenopausal group, the PMI showed the best sensitivity (90%), followed by 
GLCM (71%) when compared to our texture analysis using the wavelet technique 
(48%) and to the other widely used scoring system, RMI (40%) and the new scoring 
system, ADNEX (66%). In general, all these methods improved in sensitivity 
performance when compared to the premenopausal group (75% for the PMI, 14% for 
RMI and 50% for ADNEX: please refer to Table 65 for the premenopausal group). 
Sensitivity deceased slightly for GLCM: from 75% to 71%. The specificity of the 
PMI was the lowest (33%). The highest specificity was seen in the ADNEX score 
(76%), followed by the wavelet (72%), and then the GLCM (55%). When compared 
to the premenopausal group, a noticeable decrease in specificity was seen: for 
example, in the PMI, specificity decreased from 77% to 33%; in the GLCM, it 
decreased from 60% to 55%; in the RMI, from 95% to 64%; and for the ADNEX, 
from 80% to 76%.  A summary of these results is found in Table 72 for the 
postmenopausal group. 
Correlation Sensitivity Specificity PPV NPV Accuracy 
GLCM 71% (95% CI: 49-93%) 55% 47% 75% 59% 
Wavelet 48% (95% CI: too wide) 72% 62% 60% 60% 
RMI    40% (95%CI: 0-79%) 64% 55% 50% 52% 
PMI 90% (95% CI: 79-100%) 33% 61% 75% 64% 
ADNEX 66% (95% CI: 29-100%) 76% 77% 65% 71% 
Table 72: Summary of the sensitivity, specificity, PPV, NPV and accuracy of the Texture analysis feature wavelet 
compared to RMI, PMI and ADNEX in the postmenopausal group 
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In General, the ADNEX score was calculated for all masses, whether CA125 results 
were available or not. However, as mentioned by (Van Calster et al., 2014) in the 
study in which they developed the ADNEX model to differentiate between the 
different types of adnexal masses, CA125 was one of the strongest predictors, and 
they explained that deriving this model without the CA125 would decrease the 
discriminatory ability of the ADNEX. Therefore, it was decided to re-calculate the 
ADNEX score only for patients for whom CA125 results were available so that the 
difference could be appreciated.  
It was found that of the eighty-one eligible masses, sixteen had missing CA125 
results, divided equally between benign and malignant masses. Moreover, when 
dividing the population by menopausal status, six were in the premenopausal group 
and ten in the postmenopausal group. The ADNEX score was applied to sixty-five 
masses with available CA125 and resulted in 56% sensitivity, 81% specificity, 61% 
PPV, 77% NPV and 72% accuracy. A summary of the diagnostic performance of the 
ADNEX model for the total population as well as for pre- and postmenopausal groups 
is provided in Table 73. Surprisingly, the sensitivity of the ADNEX model decreased 
slightly when using only masses with available CA125: for example, in the total 
population, the ADNEX sensitivity deceased from 62% to 56%, and in the 
premenposausal group, from 50% to 40%. Lastly in the postmenopausal group, it 
decreased from 66% to 62%. However, the specificity, PPV, NPV and accuracy were 
similar to the ADNEX of all masses. 
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ADNEX with CA125 
available 
Sensitivity Specificity PPV NPV Accuracy 
Total population 56% (95% CI 29-83%) 81% 61% 77% 72% 
Premenopausal group 40% (95% CI 1-95%) 81% 38% 84% 74% 
Postmenopausal group 62% (95% CI 32-92%) 80% 77% 66% 70% 
 
Table 73: Summary of the sensitivity, specificity, PPV, NPV and accuracy of the ADNEX model with only 
CA125 available in all three groups of population. 
 
4.3.8. Combination of the two texture analysis 
features 
 
In order to improve the diagnostic performance, the two texture analysis features were 
combined, as confirmed by Singh and Singh (2002). Here, the same threshold values 
were used together to assess the diagnostic performance of the GLCM and the 
wavelet combined. Therefore, a threshold value of 245 was used for the GLCM and 
17191 for the wavelet simultaneously to indicate the risk of malignancy. This was 
applied to 145 masses, of which 29 were malignant by histology and 116 were benign. 
Seventeen of the 29 malignant masses had values higher than 245 for GLCM and 
17191 for the wavelet feature simultaneously: in other words, these were the true 
positive results, while 72 of the 116 benign masses were considered benign by texture 
analysis features combined, and represented true negative results. Please refer to 
Table 74 for a summary of these results. 
When dividing the total population into pre- and postmenopausal groups, eighty-nine 
masses were used for the analysis of both textural features together in the 
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premenopausal group, of which eight were malignant and eighty-one were benign. 
Four of the eight masses that were malignant by histology were malignant by texture 
analysis as well: therefore, these were the true positive results. Meanwhile, forty-eight 
masses that were benign by histology were considered benign by texture analysis and 
subsequently were regarded as true positive results. Please refer to Table 75 for a 
summary of these results. 
In the postmenopausal group, fifty-six masses were used for the analysis, of which 
twenty-one were malignant and thirty-five were benign. Thirteen of the twenty-one 
malignant masses were >245 in the GLCM feature and >17191 in the wavelet and 
therefore represent true positive results. Of the thirty-five benign masses, twenty-four 
were considered benign by texture analysis of both features together and represent 
true negative results. A summary of the data is shown in Table 76, below. 
 
Type of the test Malignant by histology Benign by histology 
GLCM >245 and wavelet 
>17191 
(TP) 
17 
(FP) 
44 
GLCM <245 and wavelet 
<17191 
(FN) 
12 
(TN) 
72 
Total 29 116 
 
Table 74: 2x2 contingency table for the combined two texture analysis features. 
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Type of the test Malignant by histology Benign by histology 
GLCM >279.5 and wavelet 
>18284 
(TP) 
4 
(FP) 
33 
GLCM <279.5  and wavelet 
<18284 
(FN) 
4 
(TN) 
48 
Total 8 81 
 
Table 75: 2x2 contingency table for the combined two texture analysis features in 
Premenopausal women 
 
 
Type of the test Malignant by histology Benign by histology 
GLCM >279.5  and wavelet 
>18284 
(TP) 
13 
(FP) 
11 
GLCM <279.5  and wavelet 
<18284 
(FN) 
8 
(TN) 
24 
Total 21 35 
 
Table 76: 2x2 contingency table for the combined two texture analysis features in postmenopausal women. 
 
4.3.4.1. Sensitivity and Specificity  
In the total population, the sensitivity was 58% when combining the two texture 
analysis features together and slightly higher in the premenopausal group (61%), 
while the postmenopausal group yielded the lowest sensitivity (50%). When 
comparing these findings to the GLCM and wavelet analysis separately, it became 
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apparent that sensitivity decreased in all three groups (total population, pre- and 
postmenopausal). In addition, the specificities were more or less similar to the 
analysis of the features separately, ranging from 59% to 69%. Please refer to Table 77 
for a summary of these results. 
 
Correlation Sensitivity Specificity PPV NPV Accuracy 
Combined texture 
features in total 
population 
58% (95% CI: 36-80%) 62% 27% 86% 61% 
In premenopausal 
50% (95% CI: 1-99%) 59% 11% 92% 58% 
In postmenopausal 
61% (95%CI: 35-87%) 69% 54% 75% 66% 
 
Table 77: Summary of the sensitivity, specificity, PPV, NPV and accuracy of the texture analysis features (GLCM 
and wavelet) combined. 
 
4.3.9. Logistic regression 
Further analysis was performed on the data using logistic regression to explore the 
relationship of the variables to the outcome (histology results or follow-up). Testing 
for correlation between the variables was carried out to observe which variables were 
collinear so that they would not be used simultaneously in the equation. It was found 
that GLCM and wavelet were collinear, as were age and menopausal status. The final 
equation included menopausal status, wavelet and the ratio between wavelet and 
GLCM. This model was showed to have good predictive capacity when tested using 
the Hosmer and Lemeshow test (p=.502). Table 78 illustrate the results of the model. 
Moreover, ROC analysis was performed to determine the ability of this model to 
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discriminate between benign and malignant masses and gave an AUC of 0.81, which 
has a good discriminatory ability. Please refer to Figure 69 for the ROC.  
 
Variable  Coefficient 
(ᵝ) 
S.E. P value Odds 
Ratio 
95% CI 
Menopausal 
status 
-1.834 .506 <0.05 .160 (.059 - .431) 
Wavelet .000 .000 <0.05 1.000 (1.000- 1.000) 
Ratio -.016 .007 0.032 .984 (.970 - .999) 
 
Table 78: Logistic regression model result 
 
 
Figure 68: ROC for logistic regression model. 
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4.4. Summary  
 (A)  GLCM 
 
Although initially the GLCM showed a significant difference when comparing the 
benign and the malignant masses, the ROC curve showed a poor discriminatory 
ability, with AUC=.668. Moreover, when dividing the study population into two 
groups (premenopausal and postmenopausal), the significant difference between the 
benign and the malignant masses was still seen in the premenopausal group using the 
GLCM feature for texture analysis. Here the ROC curve showed a fair ability to 
discriminate the benign from the malignant masses (AUC=.747), while in the 
postmenopausal group, no significant difference was found between the benign and 
the malignant masses using GLCM. 
GLCM showed a significant difference when comparing normal ovarian tissue with 
malignant tissue, with p <.05. 
When dividing the benign masses into subgroups such as teratomas, endometriomas 
and fibroids, it was found that GLCM could significantly differentiate benign 
suspicious masses from teratomas and endometriomas, but it was statistically 
insignificant when comparing them to fibroids. This could be explained by the fact 
that most of the benign suspicious masses were fibromas or adenofibromas, which 
closely resemble fibroids in texture. On the other hand, when comparing these benign 
sub-groups with the malignant masses in order to establish whether GLCM could be 
helpful in this matter, a significant difference was seen between the malignant masses 
and both endometriomas and fibroids, but it could not differentiate benign masses 
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from teratomas, which could also be explained by the fact that they have a very 
similar texture to malignant masses.  
 
(B) Wavelet 
 
Similar to GLCM, the wavelet function showed a statistically significant difference 
between the three mass types: benign, malignant and cysts. However, when 
generating a ROC curve, the wavelet function showed a poor ability to discriminate 
benign from malignant masses, with AUC=.630. Moreover, when dividing the study 
population into premenopausal and postmenopausal groups, unlike the GLCM, the 
wavelet function did not show a significant difference between the benign and the 
malignant masses. In the postmenopausal group, the wavelet function showed a 
significance difference between the benign and the malignant masses. However, when 
generating a ROC curve, it revealed a poor ability to discriminate between benign and 
malignant masses, with AUC=.683 
When looking at the difference between the benign subgroups, the wavelet function 
showed a significant difference between benign suspicious masses and teratomas, and 
between malignant masses and endometriomas. Unexpectedly, it could not 
differentiate between benign masses and endometriomas, although they have totally 
different texture features and can be easily distinguished visually. Similar to GLCM, 
the wavelet function could not differentiate benign from fibroid masses, as was 
expected. 
   
222 
 
However, when differentiating between normal ovarian tissue and malignant tissue, 
the wavelet function showed a significant difference, with p=.004. 
4.5. Discussion 
Ovarian cancer remains the leading cause of death among the gynaecological 
malignancies. To date, the nature of the mass – whether malignant or non-malignant – 
has to be confirmed by histology results, which means having a surgical procedure. 
Ultrasound imaging, on the other hand, is a non-invasive method for the diagnosis of 
ovarian cancer. Improvements in the diagnostic accuracy of the ultrasound will reduce 
the number of unnecessary surgeries. 
The aim of this study was to determine the ability of GLCM and wavelet features in 
characterising ovarian tissue, and in particular, to investigate the diagnostic ability of 
these features in discriminating cysts and benign and malignant masses. 
GLCM showed an excellent discriminatory ability to distinguish between malignant 
masses and cysts (AUC=.994) and between benign masses and cysts (AUC=.895), 
whilst for the wavelet feature it demonstrated a good ability of discrimination 
(AUC=.894 and AUC=.814 respectively). These findings are comparable to the 
results reported by (Hamid et al., 2011).   
In their study involving image texture analysis of transvaginal ultrasound in 
monitoring ovarian cancer, Hamid et al.  (2011) reported that the area under the ROC 
curve was .973 when comparing malignant masses with cysts and .889 when 
comparing normal tissue with cysts, and concluded that the GLCM feature can 
potentially be used to help in diagnosing ovarian cancer. Moreover, Hamid et al. 
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(2011) used 737 as a threshold value in GLCM, which led to an estimated sensitivity 
of 91% and specificity of 78%, while in our study, 86 was used as the threshold value, 
with an estimated sensitivity of 97% and specificity of 62%. The difference in the 
threshold values is obvious and led to an increase in our sensitivity to differentiate 
malignant masses from cysts, with a slight decrease in specificity.  
For the wavelet feature, Hamid and colleagues used 4,362 as the threshold value with 
both sensitivity and specificity set at 90%, while in the current study 10,484 was used 
as the threshold value, which led to similar sensitivity (90%) but decreased specificity 
(59%).  
In our study, we observed tissue characterisation using texture analysis by comparing 
normal ovarian tissue with solid areas of malignant masses. A significant difference 
was noticed when using both GLCM and wavelet features. These results are 
comparable to those of Hamid et al. (2011). Furthermore, it is worth mentioning that 
in our study, the technique for drawing the ROI on the ultrasound image was adopted 
from Hamid et al. (2011). He excluded anechoic areas from the ROI of complex 
masses after comparing this approach with icluding the whole mass in the ROI and 
found that there was a significant difference and that accuracy was improved when 
excluding the anechoic areas. 
Our results showed no significant difference between malignant and teratoma when 
using both GLCM and wavelet. This could be expained by the fact that teratoma 
usually conatians bone and teeth (solid area’s) that could resembel in texture to 
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malignant solid masses. However a significant difference was seen between malignant 
and fibroids using GLCM which could be useful clinically in the future. 
A diagnostic method should be positive for those with the disease (sensitivity) and 
negative for those without the disease (specificity). Our data analysis showed that the 
sensitivity of the GLCM feature using a threshold value of 245 as indicative of 
malignancy was 72%, which means that the ability of this texture feature to detect 
correctly those who have ovarian malignancy (true positive) is 72% and the remaining 
28% are false positive results. On review, the majority of the falsely categorised 
tumours were cystadenomas and fibromas, which are known to be difficult to 
characterise on ultrasound (Valentin, 2000, Valentin, 2004).  
Our sensitivity of GLCM is considered low: the  reason could be the fact that the 
appearance of many benign lesions overlaps with that of malignant diseases (Varras, 
2004). 
These sensitivity results are lower than those been published in earlier studies: for 
example, sensitivity was 92% in (Xian, 2010) study, which applied the GLCM texture 
feature to identify malignant and benign liver tumours on ultrasound images. This 
difference in sensitivity could be explained by the fact that texture analysis is more 
appropriate for the characterisation of regions exhibiting homogeneity in their 
structure, as discussed by Diamond et al. (2004) in their study of liver tissue, 
compared to the less homogenous ovarian masses in our study. 
Similarly, a higher sensitivity of 93%, specificity of 86% and AUC of .956 were 
achieved in a study published in 2007 by Michail and colleagues, in which they 
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studied the texture analysis of pre- and postmenopausal endometrial tissue via 
transvaginal ultrasound (Michail et al., 2007). 
For the wavelet feature, we used a threshold value of 17191 as indicative of 
malignancy, which led to 60% sensitivity: therefore, the ability of this texture feature 
to detect correctly ovarian masses (true positive) is 60%, and the remaining 40% are 
false positive results. 
Moreover, the ability of the wavelet feature to rule out those who do not have ovarian 
malignancy was 60%: this specificity means that 60% of the non-diseased women 
gave a true negative result. 
Predictive value is an important measure for diagnostic tests. Predictive values 
measure whether or not the individual actually has the disease. Positive predictive 
value (PPV) tells a postmenopausal woman how likely is it that she has an ovarian 
malignancy if she has an analysis of  >279 in the GLCM feature. In our analysis, PPV 
of GLCM in the postmenopausal group was 47%, which indicates that the probability 
that a woman with GLCM value of >279 actually has an ovarian malignancy is 47%. 
This probability limits unnecessary surgery to its half number without using the 
technique.  
Our GLCM PPV in the postmenopausal group (47%) is lower than the PPV that has 
been previously reported: 91.8% (Xian, 2010) and 99.7% (Acharya et al., 2013). 
Again, this could be as a result of thier studies are applied for other organs.On the 
other hand, a study conducted to evaluate the performance of pelvic mass index PMI 
(not a texture analysis feature) reported a lower PPV of 31.4% (Sinha A et al., 2015).  
   
226 
 
 These results could be also explained by the low number of women diagnosed with 
ovarian cancer (29.6%) among our study postmenopausal group (postmenopausal 
women who had complex masses by ultrasound and experienced surgical 
intervention), which is lower than previous studies, which documented a prevalence 
of 34% (Xian, 2010) but higher than the PMI study, which documented a prevalence 
of 16.7% (Sinha A et al., 2015). Nevertheless, the more sensitive the feature, the less 
likely it is that women with a GLCM of less than 245 will have ovarian malignancy, 
and so the greater the negative predictive value.  
Our analysis showed a NPV of 90% in the total population, which indicates that the 
probability that a women with a GLCM value of less than 245 does not have an 
ovarian malignancy is 90%. This finding is higher than the 37.5% described by 
Zimmer et al. (2003), but is close to the previous PMI study NPV of 96% (Sinha A et 
al., 2015) and lower than the 98% documented by (Xian, 2010). 
In a study by Vidya et al. (2015) using computer aided diagnosis in ultrasound to 
diagnose myocardial infarction (MI) using three different types of texture analysis, 
including GLCM, it was found that GLCM achieved an accuracy of 85%, sensitivity 
of 90% and specificity of 81%. Moreover, another recent study on breast morphologic 
features that focused on developing a computer-aided diagnosis (CAD) system based 
on texture features for distinguishing between benign and malignant breast cancers 
concluded that texture analysis can improve the ability to discriminate between 
benign and malignant breast lesions, with sensitivity of 96% (Moon et al., 2015). 
These studies yielded higher sensitivity and accuracy than our results, which showed 
a sensitivity of 72%, specificity of 60% and an accuracy of 60% for GLCM. The 
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reason for this difference could be explained by the larger samples used in their 
studies – 400 MI and 400 normal, compared to 116 benign and 29 malignant – which 
gave better results. However, collecting a similar number of images was not possible 
in our study due to the short period of recruitment approved by the ethics committee 
for this study (18 months) and the low prevalence of ovarian cancer in the population, 
as explained by Sinha A et al. ( 2015), who collected only 56 cancers compared to 
414 benign masses over a period of seven years, which makes it nearly impossible to 
reach this large number using only single centre data.  
Our study showed that GLCM had better performance than both the RMI and the 
ADNEX model when differentiating benign from malignant masses, even when 
applying them to pre- and postmenopausal groups separately. Although RMI should 
have improved performance when applied to the postmenopausal group, it still 
showed the lowest sensitivity (40%) among all the scoring systems applied. Our 
results showed a much lower performance of RMI (ranging from 40-14%) when 
compared with previous studies that validate the RMI. For example, the most recent 
systematic review and meta-analysis to investigate the diagnostic ability of several 
scoring systems calculated the pooled sensitivity and specificity of RMI at 72% and 
92% respectively (Kaijser et al., 2014). 
Amongst our patient cohort, the RMI had the highest specificity (87%); however, as 
reported by Myers and colleagues, studies on tests with high sensitivity usually report 
a lower specificity and vice versa (Myers ER. et al., 2006). 
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Similarly, our results demonstrate a lower sensitivity (62%) of the ADNEX model 
when compared to the original IOTA study, which concluded 94% sensitivity with 
almost equal specificity to our results, at 77% (Van Calster et al., 2014). 
The difference in sensitivity could be explained by Mol and colleagues in their study, 
in which they externally validated the prognostic models that were used to distinguish 
benign from malignant adnexal masses, concluding that the diagnostic performance of 
these models is not as good as that reported in the original publication (Mol et al., 
2001). 
Another obvious factor that contributes to this variety in performance could be the 
much smaller sample that was used in our analysis (81 masses, of which 29 were 
malignant and 52 were benign, with 35.8% prevalence), compared to the ADNEX 
study’s huge sample population of 5909 women, with 3980 benign and 1929 
malignant masses, with prevalence between 22%-66% in the study oncology centres 
(Van Calster et al., 2014). 
When applying PMI, our results agree with those of Sinha A et al. (2015) that PMI 
yields the highest sensitivity in our patient cohort in all three groups: 90%, 75% and 
90% for the total population, pre- and postmenopausal groups respectively. On the 
other hand, our results showed a lower specificity of PMI (ranging between 51-33%) 
than in their study (60%). 
Although results showed higher sensitivity of PMI (90%) compared to GLCM (75%), 
it has to be said that GLCM has the advantage of being objective, compared to the 
subjectivity of the PMI score, which is highly operator dependent. In addition, both 
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have the advantage over the RMI and the ADNEX in the fact that they are not 
dependent on the CA125. 
According to (Materka, 2004, Tesař et al., 2008), the GLCM feature is commonly 
used in 2D texture analysis of medical images. The results from this study 
demonstrated that in general, the GLCM has a better characterisation ability compared 
to the wavelet feature. This is in agreement with several previous studies: for 
example, Hamid et al. (2011), in their pilot study to investigate the use of texture 
analysis features in monitoring ovarian masses, concluded that GLCM had a higher 
performance than other texture features. This is in accordance with the statement by 
Tuceryan and Jain (1998) that GLCM generally outperforms other features. Likewise, 
in a study that focused on breast lesions, Garra et al. (1993) reported that GLCM is 
the most useful feature and stated that GLCM has long been a powerful tool for 
texture analysis. 
It was recommended in previous studies that combining texture features yields better 
performance compared to using features from a single category (Singh and Singh, 
2002, Michail et al., 2007). In our study, we applied this theory by combining GLCM 
with the wavelet feature to analyse the masses. Unexpectedly, this method did not 
yield better sensitivity nor specificity compared to using GLCM alone: in fact, it 
showed decreased performance in the total population as well as in both pre- and 
postmenopausal groups. This could be explained by the fact that the GLCM feature 
did not show a significant difference initially in differentiating between benign and 
malignant masses in the postmenopausal group, and therefore, when adding it to the 
wavelet feature analysis, the diagnostic performance of the combined features 
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decreased. The same concept is applied in the premenopausal group, where the 
performance of the test decreased when combining the GLCM with the wavelet 
feature; however, here the wavelet was the feature that gave the non-significant 
results initially when differentiating benign from malignant masses in the 
premenopausal group. 
Lastly, we explored the possibility of combining these two features in a different 
statistical way. This was applied by using them in a logistic regression model, which 
revealed that using the wavelet feature with the ratio of wavelet to GLCM along with 
the menopausal status as variables of the model gave a better discriminatory ability of 
AUC=0.8 and had a good predictive capacity when tested using the Hosmer and 
Lemeshow test (p=.502). 
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5. General discussion, Conclusion, 
Limitations and future studies 
5.1 General discussion and Conclusion 
 
Ovarian cancer accounts for about three percent of all cancers in women and is the 
fifth leading cause of cancer-related death among women in the United States. In 
2014, it is estimated that nearly 22,000 women will be diagnosed with ovarian cancer 
in the United States, and approximately 14,000 will die of the disease. (National 
Cancer Institute, 2014) 
In Europe, around 65,600 new cases of ovarian cancer were estimated to have been 
diagnosed in 2012. The UK incidence rate is the ninth highest in Europe. Worldwide, 
nearly 239,000 women were estimated to have been diagnosed with ovarian cancer in 
2012, with incidence rates varying across the world (Cancer Research, 2015). 
Ovarian cancer causes more deaths than any other cancer of the female reproductive 
system. This high mortality rate is because of the absence of early symptoms and a 
lack of effective screening tests. Consequently, ovarian cancer is often diagnosed at 
an advanced stage, after the disease has spread outside the ovary (National Cancer 
Institute, 2014).  
Among the various types of imaging modalities, ultrasound is considered the main 
imaging procedure for scanning ovarian masses. However, the main issue with 
ultrasound is that it is operator-dependent, and thus the accuracy and reproducibility 
of the diagnosis vary according to the experience of the operator. 
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In order to reduce the operator dependency, texture analysis, which is able to 
quantitatively characterise tissue through texture content, has been considered in this 
study. In medical imaging, texture analysis has been applied after proving to be 
valuable in characterising tissue such as liver, breast, prostate, carotid plaques and 
many others. 
As mentioned in Chapter 1, the aim of this study was to determine the ability of 
texture analysis features, namely GLCM and wavelet, as well as the new ASQ feature, 
in characterising ovarian tissue. To the best of the author’s knowledge, this study is 
the first to attempt to apply ASQ to ultrasound images of ovarian masses. 
5.1.1. ASQ  
 
Before applying ASQ to images of pelvic masses, it had to be tested in several 
aspects, since it has not previously been used in pelvic masses. Therefore, we tested 
the variability and reliability of ASQ on ultrasound images caused by random 
variation during image acquisition. It was found that the ASQ feature demonstrated 
excellent repeatability for ASQ software, with all transducers showing less than 0.4% 
variance from the mean, which indicates that ASQ software is able to produce reliable 
ASQ output measures. 
In this study, ASQ was applied to 45 pelvic masses on ultrasound images to 
investigate the ability of this method to distinguish between benign and malignant 
pelvic masses.  The preliminary results showed no significant difference between 
benign and malignant masses using the ASQ technique. For this reason, recruiting 
more patients was pointless and the study was terminated. This failure to discriminate 
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the benign from the malignant masses using ASQ could be because most of the 
masses in both groups had similar fibrotic nature, such as cystadenofibromas, fibroids 
and adenocarcinomas. Another reason could be the restricted ROI drawing, which did 
not allow us to include the whole mass in the image: instead, the ROI was drawn as a 
fan shape.  
In this study, two different techniques were adopted to draw the ROI. First, the whole 
mass was included in the ROI as much as possible. The second technique was to draw 
the ROI only on the solid area of the mass. Nevertheless, using different techniques 
did not contribute positively in distinguishing benign from malignant masses. 
ASQ works well on liver images and has proven to be beneficial in diagnosing 
various liver diseases (Brosky, 2009, Toyoda et al., 2009, Hung, 2010, Wang et al., 
2013, Ricci et al., 2013, Onodera, 2013). For this reason, we thought it might also 
work well on ovarian masses. 
Unfortunately, our study showed negative results: the quantitative ASQ analysis of B-
mode images demonstrated non-significant differences between benign and malignant 
tissue. This means that ASQ does not work on pelvic masses because both benign and 
malignant masses exhibit homogeneity and heterogeneity in the same way. This could 
be explained by the fact that liver is a smooth homogenous organ while ovary is in 
general normally heterogeneous due to the presence of follicles and the physiological 
changes that occur in it each cycle. 
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5.1.2. Texture analysis 
 
To carry out a good study, larger sample sizes should give more reliable results with 
greater precision and power; however, they also cost more time and money. 
Therefore, it is important to perform a sample size calculation before conducting a 
study to ensure a sufficiently large sample size to be able to draw meaningful 
conclusions, without wasting resources on sampling more than what really needed 
(Select Statistical, 2015). 
In this study, the calculation of sample size was based on the assumption that texture 
analysis may distinguish between benign and malignant masses, and after seeking 
statistical advice, it was concluded that with a 5% significance level and 80% power, 
a total of 200 women (100 participants in each arm) were required for the study to 
demonstrate a significant difference. Unfortunately, the total number of masses that 
were analysed in our study was 169, of which 140 were benign and 29 were malignant 
by histology results. 
It was understood that the number of malignant masses was too small; however, the 
recruitment of such masses was difficult for several reasons. First, most women with 
malignancy tend to be more ill than others with benign lesions, and therefore, the 
majority refused to participate in the study and have an additional internal scan. 
Second, some malignant diseases were disseminated and were thus excluded from the 
study because we were unable to view them on ultrasound images and analyse them. 
Third, the probability of ovarian cancer is higher in older postmenopausal women 
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(>70 years old) which makes it difficult to approach these women and ask for their 
participation in the study. 
Our study showed that the GLCM and wavelet texture analysis features are able to 
distinguish between benign and malignant masses with sensitivities of 72% and 60% 
respectively. The use of texture analysis in the diagnosis of ovarian tumours has some 
advantages: for example, the end results are more objective and reproducible 
compared to manual interpretation of ultrasound images, which can occasionally be 
affected by inter-observer variation. Another advantage is that since we use images 
acquired using the commonly available and affordable ultrasound modality, there is 
no additional cost for image acquisition. Moreover, the MaZda software that is used 
for texture analysis is available online free of charge and can be downloaded easily to 
any computer. The operator just has to run the software on the acquired B-mode 
ultrasound image and the software does all the processing and gives the output results 
after characterising the tissue. Hence, there is no need for trained experts to run the 
software. 
As proposed by Huynen et al. (1994), texture analysis may improve diagnostic 
accuracy by providing more reproducible results and information that is difficult for 
humans to comprehend. 
 This study demonstrated that texture analysis methods, particularly GLCM and 
wavelet features, are potentially able to discriminate between normal and pathological 
ovarian tissue. It is worth noting that the threshold value should be obtained by 
performing ROC curve analysis on a large sample size that is represented by the 
group studied before a threshold value can be set for clinical studies.  
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Our results showed a significant difference between malignant and fibroid using 
GLCM feature which can be useful clinically in the future, such as in some cases of 
degenerated fibroid that are difficult to diagnose visually by the operator. 
In our study, diagnostic performance of two texture analysis features namely GLCM 
and wavelet as well as the widely used scoring systems (RMI, PMI and ADNEX) 
were applied to the total sample population. The GLCM showed a higher sensitivity 
(72%) compared to two of the scoring systems applied (32% RMI and 62% ADNEX). 
In addition, analysis was carried out in the premenopausal and postmenopausal groups 
separately. Interestingly, GLCM and wavelet diagnostic performance was better in 
premenopausal compared with postmenopausal women (75% vs. 71% in GLCM and 
50% vs. 48% in wavelet), in contrast to the performance of RMI, PMI and ADNEX, 
which improved when applied to postmenopausal women (14% vs. 40% in RMI, 75% 
vs. 90% in PMI and 50% vs. 66% in ADNEX). This gives texture analysis an 
advantage over the other scoring systems when dealing with premenopausal women. 
GLCM and wavelet can also be useful tools to distinguish between malignant and 
cystic masses and between benign and cystic masses, since our results showed an 
excellent discriminatory ability of GLCM (AUC=.994; AUC=.895) and good ability 
in the wavelet feature (AUC=.894; AUC=.814) respectively. 
Another significant result was observed in our study when comparing normal ovarian 
tissue with solid areas of malignant masses when applying both GLCM and wavelet 
features, with p<.05 and p=.004 respectively. 
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Generally, our results demonstrate that GLCM has a better characterisation ability 
compared to the wavelet feature. 
Moreover, combining the two features of texture analysis the GLCM and the wavelet 
feature did not seem to give a better diagnostic performance. In fact, a decrease in 
performance was noticed; however, combining these two features in a different 
statistical way using a logistic regression model gave a better discriminatory ability. 
The developed logistic regression model produced using wavelet, the ratio of wavelet 
to GLCM, and the menopausal status as variables in the model resulted in AUC=0.8 
and a good predictive capacity when tested using the Hosmer and Lemeshow test 
(p=.502). 
The performance of the texture analysis methods is determined by measuring how 
they articulate the relationship between image elements (AL-KADI, 2009). Since the 
way in which a texture analysis method calculates the image parameters was not the 
primary objective of this study, we did not investigate the underlying factors which 
cause the difference in the performance of the GLCM and wavelet features. Lerski 
(2006) explained that the whole relationship of texture parameters to tissue structure 
is a very complex issue which is not fully understood. 
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5.2. Study limitations 
 
It is clear that in this study we analysed a relatively small sample of ovarian masses 
(29 malignant masses), as mentioned in the previous chapter. It is worth mentioning 
that at the beginning of the recruitment period (the whole first year, to be exact), the 
Gynaecology oncology clinic and the pelvic mass clinic from which we recruit 
participants were situated at different hospitals than the one where we scanned the 
patients using the Toshiba Aplio machine that has the ASQ feature. Thus, participants 
might not have been keen on taking part in a study for which they would have had to 
travel at their own expense to another hospital with payable parking to volunteer to 
have a scan for the study, which in turn resulted in a smaller number of participants 
than anticipated in this study. 
This, in addition to the limited duration of recruitment time that was approved by the 
ethical committee (18 months) and the fact that data were collected from a single 
centre, all contributed to our inability to achieve the sample size that was desired. 
Although texture analysis is a method applied to extract additional information from 
medical images that is difficult to apprehend by visual inspection, such analysis 
remains limited by the restricted resolution of the images. 
In the ASQ technique, the major limitation was the restriction in drawing the ROI in 
the ASQ software. It only allows ROI to be drawn in a fan shape, which made it 
difficult to include the whole pelvic mass of different shapes without including other 
tissue or omitting part of the mass.  
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5.3. Future work 
 
To assess the reproducibility of texture analysis features on ultrasound images of 
ovarian masses, a multicentre study should be carried out prospectively with a larger 
study sample to get more representative results and to confirm the clinical importance 
of this technique. 
Additionally, it might be beneficial to explore the possibility of combining texture 
analysis with Doppler flow assessment to achieve higher diagnostic performance in 
discriminating ovarian tissue as it might be the advantage of PMI method is that it 
includes Doppler information. 
Moreover, combining the GLCM and wavelet in other ways to achieve better results, 
such as the use of artificial neural networks, and combining GLCM/wavelet with 
scoring systems has the potential to improve the research, or using these features in a 
logistic regression model with a larger sample all could be used to improve this 
current work by applying it in future work. 
Lastly, ovarian cancer is classified into four stages based on the FIGO system. Future 
work may involve the classification of malignant tissue using texture analysis 
techniques at different stages similar to what has been done using the ADNEX model 
except with the advantage of being an objective rather than a subjective assessment.
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